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Abstract 
Microdialysis sampling has matured into a standard technique for sampling the 
rat brain in vivo. Microdialysis is beginning to be used for sampling from other 
tissues in laboratory animals. It has also been used in humans. The amount of 
material that enters or leaves a microdialysis probe is dependent upon many factors, 
some of which are presented in this dissertation. These factors include forced 
convection around the dialysis membrane, hindered diffusion through the membrane, 
and kinetic processes that occur in the tissue space. The aims of these studies were 
to identify factors that affect extraction efficiency in microdialysis systems and to 
develop develop methods to quantitate these factors. 
By setting up a specialized flow apparatus the effects of forced convection 
around a microdialysis membrane fiber were studied. From this same apparatus, 
values of the membrane permeability for hydroquinone, caffeine, theophylline, and 
theobromine were found for cuprophan, cellulose acetate and polyacrylonitrile 
membranes. A mathematical model was developed to determine the membrane 
permeability, and it fit the data well. 
The effects of inhibition of phenacetin and antipyrine metabolism in the liver 
and acetylcholine metabolism in the brain on the amount of each substance lost from 
the probe was studied. It was found through the development of a mechanistic model 
that micro vasculature exchange rates dominate metabolism rates in the liver. Inhibition 
of metabolism in the liver did not change the amount of material lost from the 
microdialysis probe during a local infusion. Acetylcholine is removed from the brain 
through only metabolic processes, thus inhibition affects the amount of material that 
is lost from the microdialysis probe after a local infusion of acetylcholine in the brain. 
A human study evaluated the usefulness of microdialysis for determining low 
levels of caffeine taken ad lib. This final study shows that microdialysis sampling 
although originally developed for brain studies in the rat, is finding more use in 
human studies. 
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Chapter 1 
Introduction: Methods used to Characterize Processes Affecting Microdialysis. 
1.1 Problem Statement 
The aims of the microdialysis studies described in this dissertation were two-
fold. The first goal was to identify the factors of the microdialysis system that affect 
microdialysis extraction efficiency in vitro and in vivo, primarily in rats. The 
microdialysis system consists of the dialysis probe and the environment in which the 
probe is placed. This goal was accomplished through the experimental studies 
described in Chapters 2, 4 and 5 of this dissertation. Briefly, Chapter 2 discusses the 
limiting role of the membrane in hydrodynamic situations. Chapters 4 and 5 discuss 
the implications of metabolic inhibition on the flux of material from the microdialysis 
probe in liver and brain. The second goal was to develop methods to quantitate, 
through empirical and theoretical approaches, the factors indentified after completion 
of the first goal. A model that describes the diffusivity of substances through the 
membrane while the membrane is placed in a flowing fluid is presented in Chapter 
2 and derived in Appendix 1. Chapter 3 develops a numerical model that predicts the 
concentration of substances as they exit the dialysis tubing under various conditions. 
1.2. Basic Principles of Microdialysis Sampling 
Much research in vivo in animals as well as in humans has focused on the 
collection of biological fluids, such as blood, urine, and feces to assess disease states 
or to determine the concentration of drugs or endogenous compounds. Although these 
routes of collection may give some indication as to the pathway that a compound may 
traverse, they are far removed from the site of action of the compound. These 
methods cannot be used to determine where a compound is concentrated or its local 
metabolism in a specific tissue site. To identify processes that occur at the site of 
action, such as local metabolism or transport rates, the use of other invasive and more 
destructive techniques becomes necessary. Techniques used to quantify metabolism 
include: liver perfusion, tissue slices, whole cell studies or the use of subcellular 
fractions such as liver microsomes. Although these techniques have greatly advanced 
the understanding of metabolic and transport processes, they do disrupt or destroy the 
normal physiological processes that are interconnected and interdependent upon each 
other such as blood flow and metabolism in the liver. 
Microdialysis is a sampling technique that involves the use of a hollow fiber 
dialysis membrane to separate low molecular weight compounds from larger 
compounds such as proteins at the site being sampled. This separation from the tissue 
space provides protein-free samples that can be directly analyzed without further 
clean-up procedures. The membrane length can vary from one to five mm for rat 
studies and up to 30 mm for human studies. The membrane lumen is perfused with 
a saline solution which allows diffusion of substances across the membrane into the 
dialysate perfusion fluid. Microdialysis was introduced as a sampling method for in 
vivo analyses almost thirty years ago and was used to sample the extracellular fluid 
(ECF) of brain tissue and blood plasma in dogs [Bito et al., 1966]. However, Urban 
Ungerstedt's research group at the Karolinska Institute in Stockholm, Sweden, is 
credited for developing and popularizing microdialysis sampling through the late 
1970's and early 1980's. Microdialysis has allowed researchers and clinicians to 
observe the chemical events that are directly related to the tissue that is sampled rather 
than in a biological space unrelated to, or removed from, the tissue of interest. 
1.2.1 Modes of Microdialysis Operation 
Microdialysis is utilized in two different operating modes as shown in Figure 
1. In both modes of operation, the dialysis fiber lumen is perfused with a solution that 
closely matches the ionic composition of the surrounding tissue space. This causes the 
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Ê ldialysate 
Figure 1. A linear microdialysis probe. [A] denotes the concentration of the 
analyte. 
mechanism of transport of molecules from the tissue space into the dialysis probe to 
be driven only by diffusion (concentration gradient) and not by osmotic pressure. 
Because transport into the dialysis fiber lumen is diffusive, there will be no net loss 
of fluid from the extracellular fluid space or the fiber lumen itself. This allows the 
fiber to behave as an artificial blood vessel in which low molecular weight substances 
(the analytes of interest) can be recovered from or delivered to the ECF space. 
1.2.1.1 Recoveiy 
The experiment that is most often performed using microdialysis sampling is 
called recovery. In a recovery experiment the analyte is removed from the 
extracellular fluid (ECF) space of the tissue by diffusion into the dialysis fiber lumen. 
It is important to note that microdialysis only samples analytes that are located in the 
ECF space and not the intracellular fluid space (ICF). The extraction fraction or 
recovery, R, which is the percentage of a substance that diffuses from one side of the 
membrane to the other, is described by the first equation shown in Figure 1. Most 
researchers use the term recovery to describe the relative recovery of the substance, 
which is defined in concentration terms as shown in Figure 1. The relative recovery 
value will decrease with increasing flow rates as shown in Figure 2 for hydroquinone. 
The term, mass recovery can also be used to describe the extraction efficiency of the 
microdialysis probe. Mass recovery will increase with increasing flow rates. This is 
because at higher flow rates the dialysis perfusion fluid in the hollow fiber becomes 
a sink and thus drives the movement of mass into the fiber lumen. Mass recovery is 
a difficult term to work with because in an in vivo situation the total amount of mass 
of a substance is unknown, thus the mass recovery would be difficult to calculate. 
Although the relative recovery may also be difficult to obtain in vivo, it can be 
obtained in vitro and is then applied in vivo. With mass recovery, the values will be 
different depending upon the volume of the standard in which the dialysis probe is 
placed. This is the reason for use of the relative recovery to describe the extraction 
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Figure 2. Hydroquinone recovery through a 3 mm PAN membrane in a stirred 
solution. 
efficiency of the microdialysis membrane fiber. Substances in the ECF space can pass 
through the fiber membrane by diffusion and be swept away by the perfusion fluid to 
be detected. In general during a recovery experiment, the concentration of the 
substance of interest is zero in the perfusion fluid that enters the microdialysis fiber 
lumen as shown in Figure 1, but in principle only needs to be less than the 
concentration in the sample ECF space in order for net diffusion into the probe to 
occur. 
1.2.1.2 Deliveiy 
When the transport of the analyte is in the opposite direction to that in the 
recovery experiment, the experiment is called delivery. In this mode, a known 
concentration of the analyte is included in the perfusion fluid. The analyte diffuses 
across the probe membrane into the ECF space, where it diffuses away from the 
probe, and is removed from the ECF by local metabolism or transport processes such 
as capillary permeation. An advantage of a delivery experiment is that a potentially 
toxic chemical can be delivered directly to the tissue space rather than through the 
circulatory system which may cause dysfunction of organs in the animal being studied. 
The delivery experiment can also be used to study local metabolism, which is 
discussed in Chapters four and five of this dissertation. 
1.2 J Mass Transfer Resistance in Microdialysis 
The percentage of a substance that enters or leaves the microdialysis probe is 
a complex function of a variety of factors of which only a few can be experimentally 
manipulated or measured. The driving force for mass transport in the microdialysis 
experiment is a concentration gradient between the outside tissue space and the 
dialysate perfusion fluid. Figure 3 shows how a compound must pass through three 
distinct regions, the extracellular fluid space of the tissue, the membrane, and the 
dialysate perfusion fluid itself prior to be carried away by the dialysate. The mass 
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Figure 3. Conceptual view of microdialysis transport resistances based on 
diffusion. 
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transfer resistance provided by each of these spaces can be better understood by 
considering each space as a resistance placed in a series configuration. In this case, 
the resistance is in series because the effects of each of the spaces is additive and the 
amount of substance that passes through is a function of these additive resistances: the 
resistance by the tissue ECF space, Rccf, the resistance given by the membrane, R^, 
and the resistance given by the dialysate, Rd. 
1.2.3.1 Tissue Resistance 
In the tissue space, the analyte undergoes a tortuous path around cells and 
blood vessels to reach the dialysis fiber membrane. This tortuous path increases the 
distance that the molecule must diffuse and thus reduces the diffusion coefficient 
through the use of a tortuosity factor that accounts for the increased path length. In 
brain tissue, this factor is usually considered to have a value of about 1.5 to 1.6 and 
differs between the various regions in the brain [Nicholson and Phillips, 1981]. The 
diffusion coefficient that is used to describe transport through the tissue space is 
generally the aqueous diffusion coefficient at 37°, Daq divided by the square of a 
tortuosity factor, thus giving an effective ECF diffusion coefficient described in 
Equation 1: 
- ^ <»> 
Iontophoretic injections of inert anions to produce a point source of substance away 
from an ion-selective electrode in order to determine the tortuosity of different brain 
regions has been reported [Nicholson, 1993]. This work verified Equation 1 for the 
use of these inert substances. For dopamine, a cation, use of Equation 1 to describe 
its in vivo diffusion coefficient was found to be incorrect. The in vivo diffusion 
coefficient for dopamine was found to be an order of magnitude lower than other 
anionic or neutral compounds of similar molecular weight and structure [Rice et al., 
1985]. It was suggested that the glycoaminoglycan content in tissue has a hindering 
affect on the in vivo diffusion coefficient of dopamine. This indicates that caution 
should be used when applying in vitro diffusion measurements to in vivo situations. 
The tissue resistance is a combination of the diffusion coefficient of the analyte 
in the ECF space, the volume fraction through which the analyte can pass, and the 
uptake and metabolism constants that may affect the concentration of the analyte. 
These uptake processes include capillary permeation into the local vascular space or 
reuptake of neurotransmitters in the brain. In general, it is assumed by most 
researchers in the microdialysis field that the major resistance to mass transport is 
provided by the lower tissue diffusion coefficients of substances. However, situations 
in which the kinetics of transport or metabolism in the tissue space are very rapid 
could alter this scenario such that the membrane resistance and the ECF resistance 
approach each other in their effects on regulating the mass transport to the inner fiber 
lumen. It is known from the mass transport literature that kinetic processes coupled 
with diffusion can influence the rate of mass transport tremendously [Cussler, 1984]. 
This problem will be further discussed in Chapter 3. 
1.2.3.2 Membrane Resistance 
From the perspective of the recovery experiment, after the molecule of interest 
has passed through the tissue space, it must pass through the dialysis membrane in 
order to be collected by the perfusion fluid. The dialysis membrane resistance is 
caused by the thickness and length of the membrane as well as the diffusivity of the 
analyte through the membrane. The most common membranes used in microdialysis 
include a proprietary polycarbonate membrane used by CMA/Microdialysis in their 
commercially available microdialysis probes, cellulose acetate, cuprophan, and 
polyacrylonitrile (PAN). These membranes have different chemical structures and 
variations in molecular weight cutoff. Charged small molecules seem to interact in 
different ways with each of these membranes despite having molecular weights far 
below the molecular weight cutoffs of these membranes. For instance, acetaminophen 
glucuronide (MW 350) is poorly extracted by PAN membranes despite the 29,000 
molecular weight cutoff designated to the PAN membrane. This is because PAN 
carries a negative charge due to the cyano groups; thus, hindered diffusion of polar 
or charged species could be expected with this membrane. This change in the 
diffusion rate from interaction with the membrane will result in an increased resistance 
due to the decrease in the value of the diffusivity. 
The membrane surface area and length are also known to influence the 
recovery [Johnson and Justice, 1983]. Since transport through the membrane is 
diffusion controlled, it is reasonable to expect the recovery to change as a function of 
the surface area of the probe as the total flux into the probe is dependent upon the 
surface area. Further work on the role of the membrane in microdialysis will be 
presented in Chapter 2 of this dissertation. 
1.2 .3.3 Dialysis Resistance 
The mass transfer resistance in the dialysate is due to the diffusion coefficient 
of the analyte in the perfusion fluid in the dialysis fiber lumen and to some extent the 
perfusion flow rate of the perfusion fluid. This resistance will be the least 
contributing factor to the overall resistance to mass transfer in either a recovery 
experiment or a delivery experiment. This is because the diffusion coefficient of any 
analyte in the aqueous perfusion fluid will be greater than in the membrane or the 
tissue because there will be no tortuosity or volume fraction effects in the dialysate. 
Higher flows of the perfusion fluid will create a greater sink in the dialysis fiber 
lumen, due to the formation of a thinner static fluid layer, thus preventing the 
possibilities of back-diffusion. An exception to the role of the dialysate resistance 
would be when the combination of membrane surface area and perfusion flow rate 
allow for 100 percent recovery or delivery of the analyte. In the recovery case, this 
would indicate an equilibrium has occurred, whereas in the delivery case it would 
indicate that the tissue has the ability to efficiently extract the analyte from the 
dialysis probe. In the 100 percent recovery case, it would be difficult to ascertain 
which particular kinetic rate in the tissue would most affect the dialysis experiment. 
For studies in which a perturbation is made to the tissue space, it is necessary to use 
flow conditions in which an observed change in the relative recovery can be assured. 
1.3 Controllable Conditions in the Microdialysis Experiment 
Microdialysis experiments are performed to help answer questions about 
specific molecules. The basic properties of the specific molecule such as its in vitro 
and in vivo diffsivity and its uptake cannot be altered by the researcher. The choice 
of the membrane that can be used for the microdialysis probe may be limited to that 
used by a commercial manufacturer's probe. Given this, the diffusion properties of 
the molecule and its interactions with the membrane are also fixed. The researcher 
can vary the flow rate of the perfusion fluid or the length of the dialysis membrane. 
It may be possible to vary the kinetic properties of the tissue through pharmacological 
means such as the use of uptake inhibitors for the neurotransmitter dopamine. 
1.4 Microdialysis Applications 
Microdialysis has become a standard technique in the field of neuroscience and 
has been used in blood-brain barrier studies, [de Lange et al., 1995] neurotransmitter 
and neuropeptide sampling [Robinson and Justice, 1991]. Microdialysis sampling 
strategies have also been developed for sampling from the extracellular fluid (ECF) 
matrix of other tissues such as the skin [Ault et al., 1992, 1994], liver [Scott et al., 
1990, 1993], kidney, heart [Van Wylen et al., 1993], muscle [Deguchi et al., 1991], 
and solid tumors [Palsmeier and Lunte, 1994a, 1994b]. Microdialysis sampling has 
been used in humans [StShle et al., 1991c, Lonnroth et al , 1987, Bolinder et a l , 1989] 
and has been approved for use in humans for determining levels of glucose in 
diabetics in Sweden. Microdialysis sampling has not only been used to gain 
information about the concentration of a substance in the ECF space of a tissue, but 
it has also been used to sample and obtain pharmacokinetic information from the 
blood [St&hle, 1993] and tissue of an animal [Lunte et a l , 1991, Wong 1993]. The 
technique has also found extensive promise in drug distribution studies [St&hle et a l , 
199la, 199lb, Ljungdahl-St&hle et a l , 1992, Van Belle et a l , 1995]. It is important 
to reiterate that microdialysis samples substances that have passed into the ECF space 
and not those in the intracellular space (ICF). However, microdialysis has tremendous 
promise as a sampling technique because it allows sampling of organs in their native 
environment which preserves the organ integrity and allows the animal to serve as its 
own control. Even though microdialysis sampling does allow sampling from an intact 
organ it is also important to note that the insertion of the microdialysis probe does 
cause some initial damage to the tissue. 
1.5 Calibration Methods and Issues 
In the neurosciences, microdialysis is often used to monitor events that can be 
reported in terms of percent variation from a control value. In these cases, the issue 
of in vivo calibration of the microdialysis probe is often avoided. It is assumed in 
these cases that the recovery remains constant despite a pharmacological challenge. 
However, if it is desired to quantitate the local concentration of a substance in the 
tissue space, then it becomes necessary to calibrate the microdialysis probe. The 
calibration methods used only obtain a value of the concentration of substances in the 
tissue space and do not aid in the understanding of the processes that can affect 
microdialysis transport. The initial use of models was to apply a mathematical 
function to in vitro calibration data and thus arrive at a predicted value of the local 
tissue concentration [Benveniste and Hiittemeier, 1990]. Kehr has extensively 
reviewed these calibration techniques, the various models used in microdialysis, and 
their utility [Kehr, 1993]. Since this thesis is not focused upon calibration, but rather 
parameters that affect microdialysis, only a brief review of calibration methods will 
be provided for readers not familiar with these techniques in microdialysis. 
1.5.1 In vitro Calibrations 
An initial method for calibration involved placement of the dialysis probe in 
a standard solution as a way of characterizing the membrane [Ungerstedt et al, 1982]. 
For brain tissue it has been shown that an in vitro calibration does not correlate well 
to the results obtained in vivo for various neurotransmitters and exogenous substances 
[Hsiao et al , 1990]. This method serves to correct for probe to probe differences in 
membrane length or heterogeneity in the membrane fiber [Johnson and Justice,!983]. 
1.5.2 Mass Transfer Coefficient Determinations 
Jacobson et al. presented an early in vivo calibration method based on mass 
transport in kidney dialysis and incorporated the use of mass transfer resistances 
[Jacobson et al. 1985]. The perfusion rate, Q, was varied to obtain an effective mass 
transfer coefficient, K, for the tissue and membrane as shown in Equation 2, where 
C is the concentration of the analyte in the dialysate, C0 is the concentration of the 
analyte in the tissue space and A is the surface area of the dialysis membrane. 
C/C = (2) 
A difficulty with this approach as with most of the in vivo calibration methods 
is that the method does not include any terms to describe the underlying physiology 
outside the microdialysis membrane. This was observed by Jacobson et al. as the 
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variation of the mass transfer coefficient changes for various amino acids in the brain. 
As an extension of Jacobson's work, Menacherry et al. presented the idea of 
using a low perfusion flow, which is limited by analytical considerations such as low 
sample volume, long collection times due to the 60 nl/min flow rate, and possible 
evaporation of the sample [Menacherry et al., 1992]. In this case the extraction 
efficiency or the recovery of the membrane approaches 100 percent and thus the 
concentration of the analyte in the dialysate is approximately that in the outside 
sample space. 
1.5.3 No-net Flux Determinations 
The no-net flux method attributed to LSnnroth [Lonnroth et al., 1987] and 
mathematically described by St&hle et al. [St&hle et al. 199Id] is a straight-forward 
method for determining an in vivo concentration and the in vivo recovery. This 
method requires that a steady-state of the analyte exists in the tissue space. 
Additionally, this method is based upon the assumption that mass transport processes 
in a microdialysis experiment are bi-directional. That is, that the flux of an analyte 
to and from the dialysis probe remains equal under the experimental conditions 
employed. 
The no-net-flux experiment involves perfusing the site or fluid of interest with 
varying concentrations of the analyte of interest. These concentrations should be 
above and below the expected ECF concentration. The difference between the outlet 
and inlet concentrations of the dialysate is plotted as a function of the inlet 
concentration of the dialysate. The x-intercept of the regressed line is considered the 
true concentration of the analyte in the sample space. The slope of the line is the 
recovery of the analyte of interest. An example of this particular method is depicted 
in Figure 4. This method has now become the most frequently used and "validated" 
method for determining the ECF concentration of an analyte of interest particularly 
in the brain [Justice, 1993]. If a steady-state is not achieved or the transport of the 
analyte of interest is not bi-directional, then a poorly regressed line would be 
expected. 
1.5.4 Internal Standards 
Using the same assumption that the flux of molecules is the same bi-
directionally, the internal standards approach attempts to perform an in vivo 
calibration with a calibrator other than the analyte species under investigation. These 
methods are assumed to correct for possible tissue differences in the probe or tissue 
space. Various internal standards that have been presented include 3H20, [Larsson, 
1991] antipyrine, [Yokel et al., 1991], AZT analogs [Wang et al., 1993], and various 
nucleosides [St&hle, 1994]. Although this technique may be useful for determining 
changes in the surrounding tissue space, it still does not address the fundamental rate 
processes that can affect the flux of a substance to the microdialysis probe. 
Additionally, questions still arise as to whether or not the calibrator interferes with 
any of the processes in vivo and thus inadvertently affects the results. For example, 
erroneous results may be possible with an internal standard that may bind or interact 
with the same transport protein that the studied analyte drug interacts with. To date, 
it seems as if every internal standard must be experimentally verified prior to use. 
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Concentration in Perfusate 
Figure 4. Lonnroth plot. Simulated data points are plotted here to illustrate this 
method of calibration. 
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1.6 Predictive Modeling in Microdialysis 
1.6.1 Introduction to Mathematical Model Building 
A mathematical model is a simplified construct that describes a part of reality 
by using mathematical symbols and is created for a specific purpose. There exist many 
reasons for creating mathematical models. Models can be used to predict certain 
outcomes of events that may be expensive or impractical to determine through 
experimentation. Models can also be used to aid the understanding of a particular 
process. 
Model building is a cyclical process that first begins with the formulation of 
a problem, which describes the information that is sought by the model creator. The 
next step involves outlining the model. This involves the determination of the input 
or independent variables, the output or dependent variables, and the variables or 
events that will be considered not to affect the model or that are too difficult to 
model. The third step involves deciding if the model is useful. In this case, it must 
be decided if the needed data for the model are available to make the predictions 
desired. Finally the model is tested against data or by using common sense. These 
steps can then be repeated if the data and the model do not agree or if the model 
creator wishes to incorporate some of the neglected variables back into the model. 
Further information on the model building process can be found in various textbooks 
[Bender, 1978, Box et al., 1978 and Rubinstein and Firstenberg, 1995]. 
1.6.1 Microdialysis Diffusion-based Models 
Benveniste first reported the use of a mechanistic model which incorporated 
the effects of volume fraction and tortuosity differences on the diffusion properties of 
substances in the tissue space for microdialysis experiments [Benveniste, 1989]. The 
goal of her mathematical model was to be able to use the model in conjunction with 
in vitro recovery experiments to determine the concentration of substances in the brain 
extracellular fluid space. She also presented in her review of brain microdialysis 
processes that can affect microdialysis sampling such as: substance interaction with 
the dialysis membrane, temperature, membrane surface area, composition of perfusion 
fluid, and drainage [Benveniste and Htittemeier, 1990]. 
In her development of a descriptive model for use in determining the recovery 
of a substance, Benveniste starts with the general equation to describe flux. This is 
important as it is the flux to the probe or away from the probe that will affect the 
extraction fraction of a substance from the tissue or the dialysis probe. Benveniste 
considered a diffusion only approach for substances to be transported between the 
interstitial space and the microdialysis probe. This was done only because it was 
claimed that a solution to the problem utilizing the uptake rate constants would be too 
difficult to solve, not because she did not understand the role of the microenvironment 
in which the dialysis probe resided. Using Fick's Law for a steady state concentration 
versus time profile, the flux to the microdialysis probe in tissue is described as: 
j = - 4 , (3) 
** X2 dr 
where <j>ecf describes the volume fraction of fluid in the ECF through which a molecule 
can diffuse and X is the tortuosity factor that describes the increased diffusion 
pathway in vivo due to the presence of cells and their impermeable membranes. It was 
assumed that the value of the volume fraction of the ECF space was about 0.2 and the 
tortuosity was 1.5 [Nicholson and Phillips, 1981]. The combination of the diffusion 
coefficient, the tortuosity coefficient and the volume fraction of the tissue ECF space 
gives an effective diffusion coefficient of a molecule through the ECF space. 
Equation 3 was solved and the results of the flux with those from an in vitro recovery 
experiment are used to determine the concentration of the substance in the ECF. One 
limitation of this model is that the parameters such as the volume fraction, diffusion 
coefficient in vivo and the tortuosity factor need to be determined for each individual 
substance. However the true physiological diffusion coefficients for many substances 
found in the brain have not been determined and are estimated from in vitro values 
at 37° C. Benveniste's final solution which relates the dialysate outflow, C0 to the 
concentration in the interstitial fluid, Cj is shown in Equation 4. 
Ct - [ * A 2 / < M R p r n v C ° ( 4 ) Recovery^^ 
K is a factor used to describe the differences between dialysis experiments performed 
in vitro and in vivo. K is assumed to be the same for all substances studied in the 
brain [Benveniste, 1989] and has a value of 0.7. 
Amberg and Lindefors [Amberg and Lindefors, 1989; Lindefors, et al. 1989] 
presented a more complete and complicated mathematical model to describe the 
microdialysis process in brain. Although this model did not include transport 
processes that may occur in the tissue, it did provide the reader with various important 
points to consider. Their work allowed for readers to understand some of the finer 
points in microdialysis including: 1) the idea that the recovery of a substance actually 
reaches a pseudo-steady state with time, 2) the relative distance that is affected by the 
microdialysis probe as a function of time and 3) the possibility of membrane 
interactions with molecules being dialyzed. The severe limitation of their work is in 
the presentation of the complex mathematics to solve for a concentration of a 
substance in the ECF space. The mathematics presented become a hinderance to 
understanding their work for many researchers utilizing microdialysis. 
1.6.2 Methods Based on Diffusive and Kinetic Processes 
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It is known from the chemical engineering mass transport literature that kinetic 
processes coupled with diffusion can greatly affect flux [Cussler, 1984]. Since the 
recovery of an analyte is a function of the flux of that analyte to and from the 
microdialysis probe, it makes sense that the role of kinetic processes should be 
included in a mechanistic model that would describe microdialysis. Although the 
modeling work presented by Benveniste, Amberg and Lindefors has advanced the 
understanding of the role of diffusion in microdialysis, their models did not 
incorporate the role of tissue reactions such as uptake and metabolism. Bungay et al. 
presented an improved model of the transport processes that affect the microdialysis 
experiment at steady state in the brain [Bungay et a l , 1990]. This improved model 
included linear terms for transport into and out of the microvasculature, uptake into 
and out of cells, and metabolism. This model predicted the recovery or delivery of 
a substance as well as the substance's concentration profile away from the 
microdialysis probe. At steady-state, the extraction fraction, which is a generalized 
term that describes the recovery or delivery ratios, can be obtained by using 
Equation 5. 
The extraction fraction, Ed is a function of the dialysis volumetric flow rate, Qd and 
the independent resistances of the dialysate, membrane and extracellular fluid space 
denoted by Rd, R,,, and Re. The formulas for the resistances are given by Bungay. 
The model of Bungay et al. has been further extended for use in transient 
situations in the brain by Morrison et al. [Morrison et al, 1991a, 1991b]. The same 
assumptions used in Bungay's model apply to Morrison's work. A complex analytical 
solution is obtained that must be evaluated numerically. The equations obtained are 
(5) 
not printed here because they will not aid in the understanding of microdialysis 
models. Interested readers are referred to Morrison's work for further details. 
The model of Morrison et al. may not be useful for use with microdialysis 
sampling in other tissues as it is currently formulated for several reasons. The first 
is an assumption which requires all kinetic processes to be linear. This assumption 
is necessary in order to achieve an analytical solution to the mass-balance equations. 
An analytical solution was desired by Morrison et al. so that the general microdialysis 
community could gain an understanding of the complex role that various parameters 
play in determining the recovery of an analyte. Because this assumption is used, 
substances which undergo active transport or have metabolism which is saturable 
under Michaelis-Menten kinetics cannot be solved using Morrison's model. However, 
an approximation of the effects of saturable metabolism could be obtained through the 
use of limiting cases of the Michaelis-Menten kinetics in the model. The linear 
kinetic assumption and the numerical integration that is used to evaluate the analytical 
solution, limit the model's use to compounds with recoveries under 70 percent. 
However, this is a reasonably safe assumption because recoveries would only exceed 
70 percent in the brain at very low flow rates (less than 0.5 (il/min). Another 
assumption incorporates the membrane and dialysis systems into the overall solution 
because it is assumed that the resistance to mass transport in the brain ECF is the 
greatest. These assumptions have not been validated for other tissue systems because 
the work of Morrison has only been applied to brain, where the transport of most 
substances to and from the microdialysis probe is believed to be relatively slow in the 
tissue as compared to the membrane and dialysate. In particular, the theory of 
Bungay predicts that as the overall sum of the transport and metabolic rate constants 
increases, the resistance in the ECF to mass transport decreases. The microvasculature 
permeability rate constant is relatively small in brain compared to other tissues 
because of the blood-brain barrier. In other tissues such as the liver, skin, or solid 
tumors it is expected that the microvasculature permeability will be larger. As the 
rates of the kinetic and metabolic processes increase, the tissue resistance will 
decrease and it is possible that the membrane and the tissue ECF resistances will 
approach each other. This indicates that the assumptions of collapsing the membrane 
and dialysate resistance into the solution of the concentration profile in the ECF may 
not be valid for other tissues such as the skin or liver where there is no barrier to drug 
permeation or cases in which the kinetic rate processes are rapid as in dopamine re-
uptake processes [Smith and Justice, 1994]. 
The same research group that developed Morrison's model also developed 
experiments to validate that model. This was performed by locally delivering sucrose 
[Dykstra et al., 1992] and AZT in the brain [Dykstra et al., 1993] over various time 
periods. The experimental results of the amount of substance lost from the local 
delivery and the concentration profile of these substances in the tissue space 
determined by quantitative autoradiography were compared to the model predictions. 
In both of these validation papers, the data fit the model predictions once the value 
of the volume fraction of the ECF space was adjusted from a value of 0.2 to 0.4. 
This adjustment was made because it was shown that edema had affected the 
microenvironment around the probe. 
The work by Dykstra et al. illustrates one of the difficulties of validation of 
microdialysis modeling. That is, there are only two dependent variables that are used 
in the model, the value of the concentration of the substance in the dialysate and the 
concentration profile away from the dialysis probe. This makes model testing difficult 
as the concentration profile away from the probe can only be verified through imaging 
methods such as autoradiography or possibly fluorescence imaging. Additionally the 
input variables such as the diffusion coefficient and kinetic rate constants for a 
compound that is being modeled are fixed and cannot be varied to stress the model. 
Microdialysis sampling in combination with a mathematical model is just 
beginning to be used to determine transport parameters in the brain as illustrated in 
Morrison and Dykstra's work. Microdialysis modeling has not been applied to tissues 
such as the liver or skin. There has been a recent adaptation of Bungay's model by 
Wallgren et al. [Wallgren et a l , 1995] to determine the local blood flow in muscle 
from the infusion of ethanol through the microdialysis probe. This model was tested 
using data obtained from isolated muscle tissue. This model is a modification of the 
work of Bungay et al. and has included a more comprehensive mathematical 
description of the flow of the dialysis perfusion fluid, which does not improve the 
model of Bungay. This is because the most uncertain factor in the model was the 
diffusivity of ethanol in the muscle. 
With an extended and general model, microdialysis could be used in attempts 
to determine transport and rate constants in these tissues. However, metabolism and 
transport processes in these systems are more complex and will require a more 
complex model that takes into account all three systems through which mass transport 
occurs, i.e., the tissue ECF, the membrane, and the dialysate. While the new model 
will be more complicated to solve, it will be applied for more general use in organs 
such as the skin or liver. In these organs, metabolism and transport across the 
capillaries is expected to occur at a faster rate than in the brain, thus reducing the 
resistance to mass transport in the tissue space and making the membrane and 
dialysate more limiting to mass transfer. 
1.7 Use of Microdialysis Mathematical Models for Use in Tissues Other than Brain 
As mentioned above, microdialysis has become a standard technique for use 
in sampling from the extracellular fluid of the brain. Extensive fundamental work by 
Professor Urban Ungerstedt's group at the Karolinska Institute in Stockholm, Drs. 
Paul Morrison and Peter Bungay at NIH, and Professor J. Justice's group at Emory 
University have provided the microdialysis community a greater understanding of the 
many factors that influence microdialysis sampling in vivo in brain tissue as well as 
the potential uses of microdialysis. The fundamental work that has been used for 
brain microdialysis can be applied to microdialysis sampling in other tissues. 
An exciting use of microdialysis sampling coupled with a mathematical model 
would be the estimation of uptake and metabolic rates is in the area of liver 
metabolism research. The liver is a highly complex organ and most experimental 
work that has focused upon liver research has been in vitro. In vitro studies of liver 
processes generally include: 1) microsomal studies to determine the role of the various 
cytochrome P450 isozyme's metabolism, 2) hepatocytes to determine the roles of other 
enzymes or 3) liver perfusion studies to determine the uptake of various compounds 
[Blom et al., 1982, Snell and Mullock, 1987]. 
Microsomes are prepared by isolation of the subcellular endoplasmic reticulum 
of the hepatocyte [Snell and Mullock, 1987]. Microsomal fractions of liver are 
advantageous because these subcellular fractions contain principally the cytochrome 
P450 mixed function oxidases and the UDP-glucuronyltransferases. The enzymes in 
these fractions can be induced and inhibited. Microsomal fractions have proven to be 
useful in testing the metabolism of in vivo marker compounds such as antipyrine and 
theophylline [Matthew, 1990a, 1990b]. Our present-day fundamental understanding 
of drug metabolism comes from work that has incorporated microsomes. 
The next step in complexity in drug metabolism utilizes the isolated hepatocyte 
in drug uptake, transport and metabolism studies [Cheney, 1988]. Here the isolated 
cell keeps the integrity of both the membrane bound enzymes such as the Cytochrome 
P450's and the cytosolic enzymes such as the sulfotransferases. Utilization of isolated 
rat hepatocytes has the advantage that the heterogeneity normally found in the intact 
liver is disrupted. This allows a comparison of metabolite kinetics to be made with 
the intact perfused liver [Pang et a l , 1985]. 
Perhaps the most widely used technique to study the liver is that of liver 
perfusion [Bartosek et a l , 1973]. This technique has been used widely to determine 
the rates at which substances are taken up by the liver [Goresky and Schwab, 1988], 
and the rates of metabolism of substances through the perfused liver. Without this 
technique, an understanding of basic hepatic pharmacology in the intact liver would 
have been difficult to obtain [Bass and Keiding, 1988]. 
There are few methods available to study the fate of drugs and other 
compounds in vivo in rat. Micro-light guides have been used to determine the 
fluorescence of NADH in the liver [Lemasters, 1986] and the metabolism of other 
fluorescent substances [Conway et al , 1982, 1984]. The utility of this technique is 
quite limited as it is only useful for drugs or compounds which fluoresce. There has 
been one paper that describes a method for collecting bile in an awake and freely 
moving rat [Kanz, 1992]. 
The present tools used to study drug metabolism and pharmacology in the liver 
will continue to be used, however, microdialysis can serve as an additional tool to 
study the liver in vivo. The rest of this dissertation focuses on some of the important 
processes that need to be considered when using microdialysis in tissues other than 
brain. The development of mathematical methods to describe and model the 
microdialysis experiment will provide understanding into the roles that the various 
mass transfer resistances provide in liver and brain. The development of the model 
is discussed in chapter three and examples of the model used with experiments in liver 
and brain are presented in chapters four and five. 
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Chapter 2 
Examination of Recoveiy Profiles for a Microdialysis System Under Hydrodynamic 
Conditions. 
2.1 Introduction 
Chapter 1 described the usefulness of microdialysis for separating larger 
biomolecules from the tissue extracellular fluid space. This makes the analysts1 job 
easier as there is no sample clean-up necessary prior to analysis. This has allowed 
the development of on-line sample detection systems for rapid and real time sampling 
for microdialysis [Church and Justice, 1987, Kehr and Ungerstedt, 1988, Newton and 
Justice, 1994, Chen and Lunte, 1995]. In addition, to sampling from a tissue space 
microdialysis has also been used to sample from fluids such as the bile [Scott and 
Lunte, 1993], blood [Steele et al., 1991] and fermentation broths [Marko-Varga et al., 
1993]. 
Despite the over 2200 papers cited in the literature that use microdialysis, 
[CMA/Microdialysis, 1994] there have been few fundamental studies describing how 
the membrane can affect microdialysis sampling. Johnson and Justice presented one 
of the first fundamental studies on the role of the membrane and studied the effects 
of the flow rate, length, and geometry on the relative recovery of a dialysis membrane 
[Johnson and Justice, 1983]. As would be expected from a technique that is based 
upon the flux of a substance into the membrane, the recovery increased with increased 
membrane length and decreased perfusion flow rates. Other methodological studies 
have been performed that have focused on the pressure through the dialysis membrane 
[Keipers and Korf, 1994] and the diffusion of substances away from the dialysis probe 
[Ruggeri et al., 1990]. The effects of protein binding on membranes that have been 
used to sample fermentation broths have been investigated [Buttler et al., 1995]. 
Since microdialysis sampling is used in various fluids and tissues that may have 
limiting effects on the membrane, it seems important to study the behavior of the 
membrane under controlled fluid flow conditions. 
2.1.1 Membrane Terminology 
A membrane can be considered to be a selective barrier between two phases. 
In microdialysis separations, the membrane is a barrier between the inner dialysate 
perfusion fluid flowing through the inner fiber lumen and the outside sample space. 
The microdialysis fiber is used to separate large biomolecules from the dialysis 
perfusion fluid which is similar to kidney dialysis separations. This feature of 
microdialysis allows the analyst to directly analyze the dialysate solution without any 
sample clean-up procedures. Typical fibers that are used for microdialysis are 
Cuprophan, a regenerated cellulose membrane, Cellulose acetate, PAN a 
polyacrylonitrile membrane, and a proprietary polycarbonate copolymer used for 
commercially available probes. Many of these fibers are actually asymmetric [Sakei, 
1994], which means they are a composite of two polymers consisting of a thin outer 
skin of approximately 0.5 (im and a thicker supporting porous underlayer of 
approximately 50-200 nm. This top layer or skin can often determine the transport 
rate through the membrane rather than the porous underlayer. These fibers also have 
different values for their molecular weight cutoff, which is a value used to define the 
retentive properties of the membrane in the kidney dialysis case. These molecular 
weight cutoff determinations are measured by performing solute rejection 
measurements [Mulder, 1991]. Cutoff is defined as the molecular weight at which 90 
percent of the solute in the sample is rejected by the membrane. Additionally 
membranes can have what is termed sharp cut-off or diffuse cut-off. An example of 
these two types of cut-offs is shown in Figure 1. Unfortunately it is not possible to 
define the characteristics of microdialysis membranes toward a particular analyte 
based on the molecular weight cutoff. Other factors also control the membrane 
separation process including fouling, adsorption, the shape of the solute and its 
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Figure 1. Comparison of membranes with diffuse and sharp cut-offs for solute 
rejection. 
interactions with the membrane (hindered diffusion). 
2.1.2 Microdialysis in a Fluid Space 
Since microdialysis is used to sample matrices besides brain tissue, such as the 
blood, bile, and fermentation liquids, it is important to determine how the membrane 
affects relative recovery in these situations. The recovery and delivery of an analyte 
in microdialysis is a mass transport controlled process. There are three regions where 
mass transport occurs in the microdialysis experiment which must be considered: the 
sample solution, the dialysis membrane, and the dialysate inside the membrane (i.e. 
the solution inside the fiber lumen). In general it has been suggested that the 
resistance to mass transport is greatest in the tissue space, with the membrane and 
dialysis fluid contributing a lesser resistance to the diffusion of an analyte [Hsiao et 
al, 1990]. Transport in the dialysate is generally considered unimportant relative to 
other regions when the perfusion rate is greater than 0.25 ^/min. 
Because the majority of microdialysis applications have focused on the brain, 
theoretical considerations have focused on this tissue. Recently, microdialysis has 
been used to sample from hydrodynamic systems such as blood and bile and in highly 
perfused tissues such as the liver. The effects of external fluid flow on the recovery 
of analytes through the microdialysis membrane are therefore relevant. In systems 
which include convective diffusion to the membrane, membrane resistance and any 
concentration boundary layer formed by fluid flow both on the outside and inside of 
the membrane will contribute to the recovery as shown in Figure 2. This boundary 
layer forms in conjunction with the hydrodynamic or Prandtl boundary layer. The 
Prandtl boundary layer is developed by the frictional drag of the fluid flowing near 
the membrane. As the Prandtl boundary layer forms, the concentration or diffusion 
boundary layer, grows in proportion with it. It is the diffusion layer that defines the 
concentration gradient next to the membrane. In applications involving hydrodynamic 
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Figure 2. Diffusion boundary layer formation due to fluid flow across a flat plate. 
fluids or highly perfused tissues, it would be expected that a diffusion layer forms 
around the membrane. This diffusion layer dictates the rate of recovery because its 
thickness defines the concentration gradient to the membrane. This chapter discusses 
the effect of controlled linear fluid velocity on the relative recovery of the analyte 
hydroquinone. The results obtained will be described using different theories from the 
mass transport literature. Hydroquinone was chosen as the initial analyte because its 
detection is amenable to electrochemical techniques, allowing ready determination of 
diffusion coefficients in various media by rotating disk voltammetry. 
2.2 Materials and Methods 
2.2.1 Chemicals 
Hydroquinone, caffeine, theophylline, theobromine, and phenacetin were purchased 
from Sigma (St. Louis, MO). All other chemicals were reagent grade or better. 
Ringer's solution contains 155 mM NaCl, 5.6 mM KC1 and 2.4 mM CaCl2. 
2.2.2 Microdialysis 
A combination dialysis fiber-sample flow system was designed for these 
experiments as shown in Figure 3. Three different dialysis membranes were used in 
this experiment: PAN (a polyacrylonitrile membrane with a molecular weight cutoff 
(MWCO) of 29,000) o.d. 340 \im, i.d. 240 ^im, Cuprophan (MWCO 12,000) o.d. 222 
^m, i.d. 200 |im, 
and cellulose acetate (MWCO 5,000) o.d. 250 nm, i.d. 232 \im. The PAN and 
Cuprophan membranes were gifts from Ivan Mefford at NIH and can be currently 
purchased from CGH Medical Inc. (Lakewood, CO). The cellulose acetate 
membranes were a gift from Bob Cross at the University of Kansas Medical School 
and can be purchased from Baxter Health Care (Chicago, IL). Pieces of fused silica 
(o.d. 147|im, i.d. 75^im Polymicro Technologies Incorporated, Phoenix, AZ) 
approximately 6 cm in length were inserted into each end of the dialysis fiber and 
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Figure 3. Set-up of microdialysis controlled velocity experiment. 
were affixed using UV curable epoxy (UVEXS Inc. Sunnyvale, CA). Connection of 
one end of the fused silica was made to a syringe needle by slipping a piece of PE-10 
tubing (o.d. 610 [im, i.d. 280 \im, Clay Adams, Parsippany, NJ) over the fused silica. 
A piece of PE-50 tubing (o.d. 965 ^m i.d. 580nm) was inserted over the PE-10 and 
was glued. With the aid of an 18 gauge needle, the other end of the probe was 
inserted into a 4 cm piece of Tygon tubing (o.d. 1/4", i.d. 1/8" Fisher Scientific) and 
positioned such that the dialysis fiber was centered in the tubing. 
The flow scheme used in these experiments is shown in Figure 3. A Harvard 
Apparatus 22 syringe pump (South Natick, MA) was used to pump the analyte across 
the dialysis membrane. A CMA/100 (CMA/BAS West Lafayette, IN) syringe pump 
was used to perfuse Ringer's solution through the dialysis fiber. The flow rate of the 
Harvard pump was adjusted between 10 fil/min and 5 ml/min to give the desired 
velocity of the analyte solution. For this experimental arrangement, the Reynolds 
number (Re) of the sample fluid ranged from 0.7-33.5. The Reynolds number being 
defined as the product of velocity and a characteristic length (in the case of a cylinder 
this is the diameter) divided by the kinematic viscosity (0.01 cm2/s in these 
experiments). A Reynolds number of less than 2000 is used as indication of laminar 
flow. The CMA/100 syringe pump was adjusted between 0.25 jil/min and 5 jil/min. 
This gives a Re number between 0.02 and 0.4 for the flow through the dialysis fiber. 
The system was allowed to equilibrate between each change in flow rate for 5 
minutes. Samples were collected for 5 minutes at each of the perfusion rates and were 
diluted with 95 \i\ of Ringer's solution to prevent evaporation effects. The percent 
recovery is defined as the ratio of the dialysate concentration to the concentration 
outside of the dialysis membrane. The sample solution consisted of 150 jig/ml 
hydroquinone in Ringer's solution. Three samples were collected at each sample flow 
rate and perfusion flow rate. For clarity, the flow of solution through the dialysis 
fiber will be termed perfusate flow, and the flow of solution around the dialysis fiber 
will be termed sample flow. 
2.2.3 Liquid Chromatographic Analyses 
The concentration of the dialysate was determined by LC-EC. An ODS-
Hypersil 4.6 mm x 15 cm column (packed in-house) was used to achieve separation. 
The mobile phase was 0.05 M sodium phosphate buffer, pH 2.5, with 10 % (v/v) 
acetonitrile. A 20 \i\ Rheodyne injection loop was used. The amperometric detector 
was a BAS LC-4C (BioAnalytical Systems, West Lafayette, IN). A glassy carbon 
electrode was used at a potential of +800 mV vs. Ag/AgCl. The retention time for 
hydroquinone under these conditions was 3.4 minutes, and the void volume eluted at 
1.7 minutes. The system was calibrated in the range of 0.5 ng/mL to 75 ^ig/mL 
hydroquinone and was linear within this range. 
The methylxanthines were analyzed by using LC with UV detection. The 
ODS-Hypersil column was used with a mobile phase of 0.05 M sodium phosphate 
buffer, pH 2.5 with 15% (v/v) acetonitrile. The Shimadzu UV detector was set to 275 
nm. 
2.2.4 Rotating Disk Electrochemistry 
The diffusion coefficient for hydroquinone in the Ringer's solution was 
determined using a rotating disk electrode (Pine Instruments Co., Grove City, PA). 
The rotation rate was varied between 200 and 2000 rpm. The potential was scanned 
between +100 and +900 mV vs. Ag/AgCl. The limiting current was plotted versus 
the square root of the frequency which gives the familiar Levich plot for determining 
diffusion coefficients [Bard and Faulkner, 1980]. The diffusion coefficient for 
hydroquinone was found to be 0.85 x 10"5cm2/s in Ringer's solution. This agrees with 
literature values for hydroquinone in other ionic media [Kolthoff and Orlemann, 
1941], 
2.2.5 Determination of the Membrane Permeability 
The membrane permeability can be determined by using the following 
equation: (See Appendix 1 for the derivation.) 
[ C - C J ln(R/R.) L 0 0UtJ = Q 0 ' ' - ln(R/R.) (1) 
C„lt 2nLDM„K out mem 
where C0 is the concentration in the bulk (jig/ml), Cout is the concentration in the 
dialysate (^g/ml), R0 is the outer radius of the fiber (cm), Rj is the inner radius of the 
fiber (cm), L is the length of the fiber (cm), Dmcm is the diffusion coefficient in the 
membrane (cm2/s), K is the partition coefficient between the membrane and aqueous 
solution and Q is the flow rate through the fiber (cm3/s). The permeability can be 
defined as the product of the diffusion coefficient and partition coefficient, (DmemK). 
For the permeability experiments, the flow of the sample was set at 3.0 ml/min, which 
is sufficient to reduce the diffusion boundary layer around the membrane. Although 
the chosen flow rate does not have any particular physiological significance, this flow 
rate lies on the plateau portion of the recovery curve for the membranes studied 
(Figure 4). A flow rate of 3.0 ml/min gives a linear velocity of 0.7 cm/s. A typical 
blood velocity through the main veins of a dog which have an inner diameter of 2.4 
mm (close to our tube which is 3 mm) is 1.48 cm/s [Lightfoot, 1974]. This high flow 
rate allows the assumption of a steady-state process which is necessary in order to use 
the above equation. 
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Figure 4. Normalized percent recoveries versus sample flow velocity. The inset 
shows the effect of velocity on boundary layer thickness. 
2.2.6 Determination of Membrane Partition Coefficients 
A 50 |ig/ml solution of phenacetin was prepared for use in an equilibrium 
study with the cellulose acetate dialysis fibers. Membrane fibers were placed into a 
tared 5 ml vial to approximately one half of the volumetric capacity of the vial. The 
weight of the fibers was recorded and 3 mis of the phenacetin solution were added to 
the vial. The weight was recorded again after the addition of the phenacetin. The vial 
was placed in a sonic bath to remove air bubbles that had formed. Additional 
membrane fibers were added until the vial was full. The weight was recorded a final 
time. Control samples of 3 mis of phenacetin were also prepared. All solutions were 
stored in the dark to prevent the photo-oxidation of phenacetin. After preparation of 
all the solutions, 15 jxl were removed for LC analysis. This procedure was repeated 
24 and 48 hours after the initial sample preparation. 
2.3 Results and Discussion 
2.3.1 Recoveiy Experiments 
A plot of the normalized percent recoveries for each membrane versus the 
linear velocity of the sample solution is shown in Figure 4. The normalization is 
calculated by dividing each recovery obtained for a particular membrane by the 
highest recovery obtained for that membrane. The linear velocity of the solution is 
determined by dividing the flow rate of the solution by the cross-sectional area of the 
tube through which the solution passes. This calculation provides the average fluid 
flow through a tube. Since the Reynolds numbers for the flow experiments are much 
less than 2000, the flow is considered laminar. The recovery is affected by the 
change in velocity only at very low linear velocities. As shown in Figure 4 the 
percent recovery increases with increased velocity until a plateau value is reached. 
Linear velocity, rather than flow rate, is the critical factor as identical curves are 
obtained using Tygon tubing of different internal diameter and flow rates to achieve 
equivalent linear velocities as shown in Figure 5. 
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Figure 5. Hydroquinone recovery through a PAN membrane using two different 
probe diameters. 
Although the sample solution flows around a cylindrical microdialysis tube, 
its flow pattern can be described more simply by approximating it as flow across a 
flat plate. This simplification is accurate here because of the low Reynolds numbers 
for flow on the sample side (0.7 < Re < 33). Levich has shown that the complex flow 
separation and reversal which are characteristic of flow over curved surfaces exist 
only at Reynolds numbers greater than 20 [Levich, 1962]. Because all but the highest 
flow experiments had a sample side Re < 20, the flat plate approximation is used in 
this study. 
For flow across a flat plate, the diffusion layer thickness has been shown to 
be proportional to the inverse of the square root of the velocity [Levich, 1962], Here, 
the flat surface length has been taken to be half the circumference of the dialysis 
membrane. A plot of the diffusion layer thickness is shown in the inset of Figure 4. 
As the linear velocity increases the diffusion layer formed around the membrane 
decreases, making the concentration gradient in the boundary layer steeper. The rate 
of mass transfer is increased according to Fick's law of diffusion. At a limiting 
velocity, the diffusion layer around the membrane has become so thin that any further 
increase in linear velocity does not affect its thickness. In such a case, diffusion 
through the membrane becomes the limiting factor in mass transport. This limiting 
condition is shown in Figure 4, where the percent recovery, which is a function of the 
mass transfer rate, remains constant at higher sample solution velocities. 
The flux of a solute can be expressed as: 
N - k(Cin*rfiKt Clmlk) (2) 
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where k is the rate constant for mass transfer from the membrane/solution interface 
to the bulk solution. To further characterize the recovery data in terms of a boundary 
layer being formed around the membrane and to determine the limiting factor in the 
recovery data, boundary layer theory can be used. From boundary layer theory the 
mass transfer rate can be determined as [Cussler, 1984]: 
where, k is the mass transfer rate (cm/s), D is the diffusion coefficient (cm2/s), L is 
the length of the membrane (cm), v is the kinematic viscosity (cm2/s), and v° is the 
maximum velocity of the fluid (cm/s). 
From the above equation, a plot of percent recovery (or mass transfer rate) 
versus the square root of the velocity, v°, should be a straight line in cases in which 
a diffusion layer exists. Figure 7 shows the percent recovery for a cuprophan 
membrane as a function of the square root of the velocity, v° ( l /2). As the fluid 
velocity approaches zero, Equation 3 can no longer be used as there is no convection 
in the system. At zero sample velocity, the mass transfer rate constant is described 
in the purely diffusional case by 
(3) 
k = D/h (4) 
where h is the diffusion layer thickness which would include the sample fluid and the 
membrane. Thus, the percent recovery approaches a nonzero value at zero sample 
velocity. 
Figure 6 shows the percent recovery for a cellulose acetate membrane plotted 
versus the square root of the velocity. This plot exhibits three regions corresponding 
to whether mass transport through the sample solution or through the membrane is 
most important in determining the sample recovery. The first region occurs at low 
linear velocities where the diffusion layer is large. This region shows a linear 
dependence of recovery on the square root of sample velocity. In this region mass 
transport is limited by diffusion through the sample diffusion layer and not diffusion 
through the membrane. In the second region, the diffusion layer is rapidly decreasing 
and the concentration gradient to the membrane is increasing. The relation of recovery 
to sample velocity is nonlinear in this transitional region. As the sample diffusion 
layer decreases, mass transport through the membrane becomes more important 
relative to transport through the sample. In this transitional region, recovery is 
controlled by both sample transport and membrane transport. The third region is the 
plateau at high sample velocity, in which recovery is independent of sample velocity. 
In this region the sample diffusion layer has decreased to the point that mass transport 
is primarily controlled by diffusion through the membrane. 
2.3.2 Mass Transfer Coefficient Determinations 
In Figure 7, the mass transport coefficients for a PAN membrane are plotted 
according to the method of Jacobson as described in Chapter 1 [Jacobson et al., 1985]. 
Mass transfer coefficients can be obtained from these plots as the slope is equal to the 
product of the mass transfer coefficient and the surface area. The calculated mass 
transfer coefficients are presented in Table 1. As can be seen, the slopes for linear 
velocities greater than 0.211 cm/s are essentially overlapping, indicating that the 
membrane resistance controls mass transport rather than the solution resistance. As 
mentioned above the terminal veins of a dog have a blood velocity of 1.3 cm/s and 
the large veins of a dog have a blood velocity of 3.6 cm/s 
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Figure 7. Permeability plots of hydroquinone through PAN, cellulose acetate 
and cuprophan membranes. 
[Lightfoot, 1974]. Since 0.211 cm/s is much lower than these physiologically relevant 
velocities, the membrane is the limiting factor in mass transport in these systems at 
velocities greater than 0.211 cm/s and not diffusion through the sample. 
Table I. Mass-transfer coefficients at different flow velocities. 
Flow Rate Linear Velocity 106 slope 104 k 
(nl/min) (cm/s) (cmVs) (cm/s) 
7500 1.58 7.54 2.53 
5000 1.05 7.65 2.57 
1000 0.212 7.55 2.53 
250 0.053 7.20 2.42 
100 0.021 6.93 2.32 
25 0.005 5.79 1.94 
10 0.002 5.31 1.78 
0 0.0 5.32 1.78 
233 Permeability Determinations 
The permeability of the membranes have been determined according to 
Equation 2 from the slopes of the plots shown in Figure 8. The permeability of 
hydroquinone through the membranes used is shown in Table II. These values are all 
lower than the free solution diffusion coefficient for hydroquinone, which was 
determined to be 0.85 x 10"5 cm2/s. This is further evidence that the membrane limits 
mass transport in a hydrodynamic situation. The permeability varies greatly between 
1/Perfusion Rate (min/pL) 
Figure 8. Plot of the determination of the mass-transfer coefficients for 
hydroquinone at various flow rates around a PAN fiber. 
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Table II. Membrane permeability of hydroquinone in dialysis fibers. 
Membrane Slope Regression Permeability 
(cm2/s) 
PAN 1.282 0.99 1.72*10'6 
Cuprophan 1.365 0.99 5.33*10"7 
Cellulose Acetate 1.801 0.99 2.97* 10'7 
Table III. Permeabilities of methylxanthine compounds in PAN membrane. 
Analyte Permeability 
(cm2/s) 
Theophylline 1.37* 10"6 
Theobromine 1.18* 10"6 
Caffeine 0.97* 10"6 
the membranes because of the different chemistry and porosity of the various fibers. 
Because the permeabilities differ through these membranes, the rate of mass transport 
through these membranes will be different. Ultimately it is the permeability and the 
surface area of the dialysis membrane that affects the amount of material recovered 
in a hydrodynamic microdialysis experiment. This was determined experimentally for 
three similar methylxanthines, theobromine, theophylline, and caffeine for a PAN 
membrane as shown in Table III. From Table III it can be seen that the permeabilities 
vary for the three methylxanthines. This is interesting as theophylline and 
theobromine have the same molecular formula and thus the same molecular weight 
and caffeine has only an extra methyl group. Additional observations on the 
variability of diffusion properties for set of neutral, cationic and anionic compounds 
has been described by Zhou and Lunte [Zhou and Lunte, 1995]. 
It may be expected that the sample velocity needed to decrease the diffusion 
layer such that diffusion through the membrane is limiting would vary among the 
different membranes. However, the recovery data shown in Figure 4 indicates that 
the difference in the permeabilities as well as the differences in the outer radius of the 
membranes do not cause a significant difference in the hydrodynamic behavior. 
Essentially, the permeability affects the value of the probe recovery but not the 
recovery's dependence on sample flow. This means that in physiologically relevant 
experiments using microdialysis sampling in a hydrodynamic system such as sampling 
intravenously, the membrane is the limiting factor in mass transport and that an in 
vitro determination of recovery in a stirred solution at 37°C should be valid in vivo. 
2.3.4 Permeation Through the Membrane 
Because the membrane permeability is defined as the product, DneaK, an 
approximate value of the partition coefficient, K, in Equation 1 would be desirable. 
An approximate value of K would then allow for calculation of Dmem. The 
approximate volume percent of the PAN and Cuprophan membranes has been 
experimentally determined as 57 and 65 percent [Collins and Ramirez, 1979]. This 
indicates that for the PAN membrane that the value of K for hydroquinone is 
approximately one as the value of the Dmem can be determined as the product of 
<LeniD.q- However, the use of the volume fraction of space does not explain the order 
of magnitude difference between the Cuprophan and Cellulose Acetate membranes. 
Initial experiments using hydroquinone with only a few membrane fibers indicated 
that K must be one as there seemed to be little uptake of material. However, to test 
this further, more membrane fibers were used as described above in the methods 
section. 
Because of the difficulties in determining the true volume of the these 
membranes, an approach was used based on weight differences. Volume measurements 
of membranes are performed by wetting the membrane and determining the amount 
of water taken up by the membrane. This is performed by shaking or drying excess 
water off the hollow fiber. One can imagine the experimental error that would be 
incorporated into these measurements due to the uncertainties in shaking and drying. 
Therefore only the dry weights were used in these experiments. For these experiments 
phenacetin was used for convenience (current in vivo experiments were utilizing 
phenacetin) with cellulose acetate membranes. The results for three different samples 
are shown in Table IV. The concentration of phenacetin in the sample vials was 
lower than the control vials immediately after contact with the cellulose acetate 
membrane and this initial drop did not change over the 48 hour period. Permeation 
into these membranes was expected to exhibit equilibrium behavior and the initial 
decrease was unexpected. This immediate drop in concentration seems indicative of 
an adsorption phenomenon rather than an equilibrium. However, the data indicate that 
the same mass of phenacetin was taken up by each membrane despite the differences 
in the weight of the membranes in the vials. Phenacetin is a hydrophobic molecule 
so it is possible that it adsorbed to the membrane. It should be noted that 0.1 g of 
membrane would be enough membrane to make more than 500 five mm dialysis 
probes. Therefore, the effect of possible adsorption onto the membrane on the results 
of a microdialysis study is unknown. 
Table IV. Uptake of phenacetin into cellulose acetate membranes. 
weight (mg) uptake (|imol/g) 
0 hours 24 hours 48 hours 
0.174 1.02 0.98 0.83 
0.266 0.68 0.74 0.66 
0.328 0.62 0.59 0.51 
To confirm these findings it would be useful to test a few model compounds 
with the membranes that are used in microdialysis experiments. Additional 
experiments such as the possible determination of a Langmuir isotherm should be 
determined for a selected class of compounds which the author would suggest below. 
The following because of their acid/base and steric effects (MW) are useful readily 
available compounds and can be easily quantitated by LC-UV methods: dopamine, 
DOPAC, acetaminophen, and acetaminophen glucuronide (available from Sigma). 
Another useful data gathering exercise would be to determine the membrane 
diffusion coefficients for the various compounds mentioned above and compare that 
with their in vitro solution diffusion coefficients. The author suggests that these 
experiments continue to determine if any of the compounds used routinely in 
microdialysis sampling exhibit any permeation into the membrane. These experiments 
would be useful in continued development of membrane materials for microdialysis 
as well as for various biosensor applications that utilize the same membranes used in 
microdialysis experiments. 
2.4 Conclusions 
It has been shown that the mass transport to a microdialysis membrane is 
affected by the velocity of the fluid flowing around the membrane. This fluid flow 
will cause a diffusion boundary layer to form which will affect the rate of mass 
transport to the dialysis membrane. As the linear velocity of the fluid increases the 
diffusion layer collapses, thus causing mass transport to be limited by the membrane 
rather than the sample solution. These observations are important because they 
indicate that an in vitro calibration may be performed for applications which involve 
a flowing solution such as the blood or bile. 
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Chapter 3 
Development and Analysis of Mechanistic Models to Describe the Extraction 
Efficiency in Microdialysis Experiments. 
3.1 Development of Models to Describe Microdialysis Experiments 
This chapter presents methods that will be used to describe mathematically 
the fundamental processes that affect microdialysis experiments. Two approaches will 
be used to model microdialysis experiments: analytical and numerical. Analytical 
methods are used when a general description about a particular process is desired. An 
analytical model will describe why a response is affected by the input variables in a 
particular manner. An example would include the exponential expression that is used 
to describe radioactive decay, C(t)=C0e("lrt). The output concentration at a specific 
time, C(t), is related to the input variables which includes the initial concentration, C0, 
the decay rate, k, and time. Numerical methods on the other hand give a specific 
answer to a complex set of equations. Numerical methods become necessary when 
the equations used to describe a physical process become too complex to be solved 
by analytical methods. For the microdialysis sampling case, the equations become 
complex due to the system of partial differential equations that is necessary to 
describe the physical process of microdialysis. Other examples of complex terms 
include time-varying or spatially-varying parameters or non-linear kinetic terms such 
as Michaelis-Menten kinetics or Langmuir isotherms. 
Mathematical modeling of physical processes can aid microdialysis research 
in a number of ways [Box et al., 1978]. First, modeling forces the researcher to 
identify the variables and parameters that affect the system being studied. Second, it 
provides a means of making progress through basic understanding of the system. For 
example the interaction of the various parameters that influence microdialysis 
sampling such as diffusion coefficients and kinetic rate constants can be predicted. 
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Third, the gain in understanding may suggest further experiments thus providing a 
way to confirm and if necessary to improve the model. In the words of the famous 
analytical chemist, I.M. Kolthoff, the approach is "to allow theory to guide, but 
experiments to decide" [Christian, 1995]. Fourth, mechanistic models that have been 
tested can provide a basis for extrapolation of values near the boundary conditions. 
This type of extrapolation is questionable when used with empirical models based on 
polynomial fits of the data. Fifth, a mechanistic model can be used to estimate 
parameters. Sixth, a mechanistic model is more parsimonious than models obtained 
empirically. A parsimonious model would predict the experimental results using as 
few variables as possible. In the radioactive decay model mentioned above, the 
mechanistic model using the exponential would be more parsimonious than a 
polynomial fit of the decay data. 
Chapter 1 provided introductory details about modeling the three different mass 
transport systems in microdialysis. Assumptions about these processes can be made 
such that simplified analytical expressions can be obtained. These analytical 
expressions will provide a basic insight into how the diffusion coefficient and kinetic 
rate constant parameters will affect microdialysis sampling. After presentation of the 
analytical methods, the development of the numerical methods used to model 
microdialysis sampling will be presented. A discussion of the assumptions and 
limitations of the numerical model will be presented. 
3.2 Analytical methods 
An important aspect of modeling is to facilitate understanding and enhance 
prediction capabilities. A simplified approach to modeling the microdialysis sampling 
process is derived in Appendix 2. Only the equations which are pertinent to this 
chapter are presented here. 
3.2.1 Analytical assumptions 
Several assumptions are necessary to model the microdialysis sampling process 
through the use of analytical methods. The derivation in Appendix 2 uses the 
following assumptions. 1) The microdialysis probe is assumed to be a cylinder with 
a defined outer radius, r0 as shown in Figure 1. Although the linear probe geometry 
is shown here, a cannula design can also be used. 2) At r0, a constant amount of 
material is released from the cylinder, Cmlx. 3) The substances emanating from the 
cylinder diffuse only in the radial direction, r, and not in the axial direction, z. This 
is because the length is assumed to be greater than the radius to force the solution into 
cylindrical terms. For most microdialysis experiments this is true except for probes 
with membrane lengths of 1 mm or less. For shorter probes, it becomes necessary to 
use a spherical geometry approach. 4) The analyte moves through the tissue by 
diffusion, concentration gradient driven mass transport, but not convection, fluid flow 
(pressure) driven mass transport. 5) Kinetic processes such as metabolism or uptake 
terms are included as one lumped kinetic term. These terms are also considered to 
be first order. This is because these processes are additive and thus need to be 
summed. These uptake processes are assumed to occur homogeneously in the tissue 
space. For the simple case that will be considered, that of delivery, these processes 
are assumed to only be uptake processes and not generation processes. 6) The 
diffusion coefficient is constant throughout the tissue medium. This ignores the 
possibility of the molecule diffusing through cell membranes and having a different 
affinity through the cell membrane. 7) A value for the volume fraction, <j>ecf is not 
included. Although this term is necessary to describe the physical process of diffusion 
and reaction through a tissue medium, it only serves to reduce the parameters by the 
fraction number. For example the diffusion coefficient, Decf, would just be reduced 
to <|)ecfDecf. 8) The system is at a steady-state. 
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3.2.2 Analytical Solution 
By using the assumptions given above and solving the appropriate mass 
balance, Equation 1 is obtained. 
Because the probe is assumed to be a cylinder the (1/r) dependence is necessary for 
the diffusion part of the expression [Cussler, 1984]. Through expansion of the 
derivative, it is noticed that the equation fits that for a generalized Bessel function 
solution that can be found in mathematics textbooks [Mickley, et al., 1957]. The 
Bessel function is a series function that is used to solve some types of differential 
equations. The value of these functions for specific arguments can be found by 
looking them up in mathematical handbooks [Abramowitz and Stegun, 1964], by 
calculation through a numerical method using Fortran or some other programming 
language, [Press et al.,1992] or by using a common spreadsheet program such as 
Microsoft Excel. Bessel functions appear to be exponential in nature with increasing 
values of the argument as shown in Figure 2. 
Equation 1 is solved using the following boundary conditions. 1) Cecf = 0 as 
r—>oo. 2) C=Cmtx at r=r0, where Cmix is the concentration at the outer radius, r0. The 
solution of Equation 1 gives Equation 2, which can be used to describe the 
concentration profile away from the probe. 
This concentration profile is dependent upon the diffusion of the substance away from 
(1) 
(2) 
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o 
m ^ H S B j • Q Q 
• 
Q • • 
Argument fir the Bessel function 
Figure 2. Values for arguments using the Bessel functions I0, K0, and 
the cylinder, DECF, and consumption of the substance in the tissue space, k. 
Figure 3 shows the values obtained by using Equation 2 for various values of 
the kinetic rate constant, k, and for a fixed diffusion coefficient of 7.5MO"6 cm2/s. 
From this simplified equation it can be seen that the concentration profile away from 
the cylinder will become steeper with increasing values of the kinetic processes. This 
is expected when diffusion is combined with reaction [Cussler, 1984]. These steeper 
values will in turn reflect an increased flux from the probe. 
Flux is defmed as the amount of material removed from the dialysis membrane 
per unit area and per unit time. The general expression for flux is J = - D dC/dr. For 
the case of a cylinder this is found by taking the derivative of Equation 2 which gives 
J = JDECFk C^axi^ 
A ECF / 
/ IN D
 0 
ECF 
(3) 
As the values of the kinetic rate constant increases or the diffusion coefficient 
decreases, K, and K0 will approach a value of one. In these cases the value of the 
flux, J, will approach the square root of the product of the diffusion coefficient, the 
kinetic rate constant. For the diffusion coefficient value considered above of 7.5*10"* 
cm2/s the limiting cases described above would occur when the kinetic rate constant 
exceeds 10 min'1. Whether this is faster than biological rates found in vivo is 
unknown. 
3.2 J Addition of Membrane Diffusion 
Diffusion through the membrane can be added to modify the derivation. The 
microdialysis literature states that only the tissue plays a role in limiting the flux of 
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Figure 3. Predicted tissue concentrations for the simple analytical model 
for various values of kinetic rate constants. 
a substance through the microdialysis membrane [Morrison et. al., 1991, Hsiao et al., 
1991]. In the brain tissue this assumption has been shown to be valid for 
acetaminophen and a few acid metabolites of dopamine, DOPAC and homovanillic 
acid [Hsiao et al., 1991]. However, for other tissues such as liver or even other 
compounds in the brain such as the neurotransmitter dopamine [Smith and Justice, 
1994] this assumption may not be valid. In these cases, the membrane may become 
more limiting. Solving for a mass balance that includes diffusion through the 
membrane as well as through the tissue yields the equation that describes the flux of 
a substance at the outer radius of the cylinder. 
Ci 
(Dji0) + K l n ( r 0 / r i ) 
_1_ (4) 
r . • o 
In Equation 4, Dm is the effective membrane diffusion coefficient for the analyte, r0 
is the outer radius, and r{ is the inner radius of the cylinder. In this expression, K, is 
defined as shown in Equation 5. 
r ^ — ^ ^ k / P E C F I 0 ) (5) 
One useful practice with analytically derived equations is to evaluate the 
equation at the limits of the equation. For thin membranes, as r0 approaches r; as in 
the case for a Cuprophan membrane (r0 = 1 0 6 jim, rt= 100 |im), the value of r0/rs 
approaches 1 and thus the natural logarithm approaches zero (for this particular 
Cuprophan membrane, the value of ln(r0/ri) is 0.058). In this case, the flux through 
the tissue becomes the predominant factor in determining the flux from the probe. For 
thicker membranes such as PAN or the CMA/polycarbonate the value of rjxi will be 
greater than one, and the natural logarithm of rjT-, will be about 0.35, for the PAN 
which has r0 = 170, r( = 120. In this case the membrane may provide a greater 
resistance to the mass transport which could influence studies used to determine which 
tissue processes are dominant in microdialysis sampling. For low values of the kinetic 
rate constants, values of the concentration obtained using Equation 4 will approach 
the values for the ECF space only approximation in Equation 3. 
The approximate value for the delivery of a substance can be calculated by 
considering the dialysate flow to be fast enough that the amount lost from the inner 
fiber lumen is small. This approximate value will depend on the membrane type and 
length, but practical experience suggests that perfusion flows greater than 5|il/min 
could be used. In general, perfusion flows greater than 5 jil/min will give delivery 
values of 10 percent or less, indicating that less than 10 percent is lost from the probe. 
Figure 4a shows that for thicker walled membranes, the membrane resistance affects 
the delivery as the kinetic rate constant, k,approaches 1.0 min'1. In situations which 
have rapid kinetic processes, the membrane resistance and the tissue resistance will 
both contribute to the amount of material extracted from the probe. Figure 4b shows 
that for thinner walled membranes, the rate constant in the tissue needs to increase to 
10 min'1 before the membrane resistance has an effect on mass transport. This finding 
indicates that if microdialysis is to be used for determining the values of different 
parameters such as the in vivo diffusion coefficient or the kinetic rate constants, then 
a thinner walled membrane with a lower mass transport resistance should be used. 
3.3 Numerical Methods 
The use of the analytical method described above can be a practical tool for 
understanding and predicting how microdialysis experiments may behave in vivo. In 
order to evaluate the transient behavior of the probe and to begin inclusion of the flow 
regime it is necessary to use numerical methods. Because these equations form the 
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Figure 4. Analytical model predictions for a microdialysis experiment 
with a perfusion speed of 5 jil/min for the membrane dimensions given. 
bulk of this dissertation, they will be derived here. The following sections derive the 
necessary mass-balances used for this model. As the mathematical model forms the 
body of this work, it has not been placed into an appendix. Readers who are not 
interested in the mathematical development are encouraged to read through the 
assumptions needed to develop the model as well as the limitations of the model. 
3.3.1 Numerical Method Assumptions 
Many of the assumptions that were made for the analytical solution still hold 
here and are only briefly described again. 1) The microdialysis probe is a cylinder 
and is assumed to have intimate contact with the surrounding tissue. No liquid layer, 
fibrotic layer or interferences with other substances such as protein adsorption onto 
the outer membrane are considered. 2) The concentration at the outside of the probe 
is not a constant, but rather a function of the three mass-transfer resistances 
encountered by a molecule. 3) Only diffusion away from the cylinder in the radial 
direction is taken into account. Axial diffusion, although physically possible in a 
microdialysis experiment, is assumed to be negligible as the length of the cylinder is 
greater than the radial diameter of the cylinder. Moreover, the inclusion of an axial 
diffusion component would add another complexity to an already complex analysis. 
4) Mass transport by diffusion only is considered, i.e., convective processes are not 
ncluded in the model development. 5) Metabolism and uptake terms are separated 
so that they can be modified by the user of the model. 6) The diffusion coefficient 
remains constant throughout the tissue space. 7) A volume fraction and tortuosity 
through which diffusion and reaction occur must be considered. Diffusion for some 
substances is generally considered to be through the ECF space only which reduces 
the effective diffusion coefficient to <t»NfDecf, where <J>ecf is the volume fraction in the 
ECF space. The diffusion through the tissue is tissue specific. In the brain most 
substances do not cross cell membranes through passive diffusion [Cooper et al., 
1991], whereas in the liver uptake occurs because the hepatocyte is highly fenestrated 
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thus facilitating the uptake of substrates by diffusion through the cell membrane 
[Goresky and Schwab, 1988]. 8) The system is allowed to behave transiently. 
Assumptions that are needed in addition to the modification of the simplified version 
are as follows. 9) The blood capillaries are considered to be evenly spaced in the 
tissue space. This allows for the microvasculature efflux term to be constant at all 
radial points. 10) Metabolic processes are equally spaced. 11) Metabolic and 
microvasculature uptake processes are considered only to be first order or linear, i.e. 
saturable metabolism is not considered. For systems in which the concentration of 
substrate is well below the Michaelis constant, K^, this is valid. Since for most cases 
this assumption will not be true in general, the inclusion of saturable metabolism or 
higher order terms would need to be considered. However, the inclusion of saturable 
metabolism in the numerical model will require extensive computation effort. A later 
section discusses how saturable metabolism affects microdialysis sampling. 12) 
Because the model is already somewhat parameter laden, binding to plasma or cellular 
proteins is not included in the model. These processes however, can be included into 
the FORTRAN code provided in Appendix 4. For many of the compounds used in 
microdialysis, separate experiments would be necessary to determine the extent of 
binding to proteins. 
3.3.2 Solution of the Numerical Equations 
3.3.2.1 Tissue Space 
A partial differential equation (Equation 6) is obtained after solving the mass 
- X*4>icf*l».tC.cf t> - ( r , Z, t) 
+<J».cf * <t>eCfKpCecf z> t) +kgeDCg0n (X, t ) 
(6) 
balance [Bird, et al., 1960] in the tissue space for the diffusion and reaction processes. 
This equation is found from Morrison's model [Morrison et al., 1991] and thus the 
term names are kept the same. This equation states that the change in concentration 
in the extracellular fluid space, Cecf with respect to time is a function of the following 
parameters: <J)ecf, the volume fraction of the ECF space typically considered to be 0.2 
for most tissues; <j>icf, the volume fraction of the intracellular space which is defined 
for this model as (l-<|>ecf); Decf, the in vivo diffusion coefficient of the substance, and 
the various rate processes in the tissue such as kime„ the intracellular rate constant; 
kcmet, the extracellular rate constant; kpe, the plasma to extracellular fluid space 
exchange rate across the microvasculature; k^ the extracellular to plasma space 
exchange rate; and kgen a generation rate constant associated with the concentration of 
the species that is being generated, Cgen. K„ is a partition coefficient that describes 
the intracellular, Cicf, and extracellular concentrations, C^, of the dialyzed substances 
and is defined as Cicf/Cecf. K„ is set as 1 in the mathematical model described here. 
This value can be adjusted when more is known about the nature of the uptake of 
substances in the ECF space. Further experimentation such as the use of 
autoradiography [Dykstra et al., 1992, 1993] or fluorescence microscopy would be 
needed for verify the assumption of unity for K„ for each analyte modeled. 
The following boundary and initial conditions are needed for the ECF space. 
The initial condition for recovery is that at t = 0; Ce(all r) = Cknown, where Ctnown is 
either zero for a pharmacokinetics experiment or the known concentration value for 
an endogenous species. The initial condition for a delivery is at t=0, Cd=CentCT, where 
Center is the concentration of the substance in the entering perfusate. The boundary 
conditions are: 1) r = oo, C= Cx, where C*, is calculated by an analytical equation 
described in Appendix 3 for the pharmacokinetic recovery experiment, or is zero for 
a delivery experiment. 2) r=rout; Ce(r0) = Cm(r0). 
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Figure 5. Diagram of the control volume used for the membrane with inner 
radius, Rj, and length, L. 
3.3.2 Membrane mass balance 
The mass balance through the membrane is depicted in Figure 5. The 
assumptions that apply to the membrane mass balance are: 1) Mass transport through 
the membrane occurs by diffusion. The diffusion coefficient describing this mass 
transport assumes that diffusion occurs through the water space in the membrane 
[Sakei, 1994], 2) Diffusion only occurs in the radial direction and not in the axial 
direction giving an axial average of the concentration through the membrane at all 
radial points. 3) No reaction processes occur in the membrane. Unlike Morrison's 
model, in this work, the role of the membrane is accounted for in the solution of the 
equations. The differential equation describing the change in the membrane 
concentration as a function of time is shown in Equation 7. 
^H = D 1 A 
dt
 m
r dx 
rdCm 
dr 
(7) 
The initial condition used to solve the membrane mass balance is: at t=0, Cm = 0, 
where Cm is the concentration of the analyte in the membrane. Two boundary 
conditions are necessary and include at r = R0 , Cm = Ce(r0) and at r = Rj , Cm = 
C(average)d (z,t). The boundary conditions state that when the dialysis experiment 
begins the membrane is free of material. At the outer radius, the value of the 
concentration of the membrane is equal to that in the ECF space at the interfacial 
point. Similarly for the dialysate the inner membrane radius is averaged as having a 
value equal to the average concentration of the dialysate leaving the probe. These 
boundary conditions greatly simplify the mathematics in that they assume that the 
concentration values are an axial average. This allows the problem to be 1-
dimensional in nature rather than two dimensional. However, these assumptions of 
the 1-D nature may break down at slow flow rates or with long probes, which will 
have a large variation in the concentration in the axial direction. 
3.3.3 Dialysate mass balance 
Finally, the third system which must be considered is the perfusion of fluid 
through the dialysis fiber lumen. In this case, the fluid flows through the fiber lumen 
at a set perfusion rate generally between 0.5 and 2.0 nl/min. The fluid itself is 
actually taken as one piece and the concentration at individual points are averaged as 
done by Bungay et al. [Bungay, 1990]. It is assumed that the membrane is short 
enough that the fluid can be considered to be well-stirred or at least moving fast 
enough that back diffusion into the tissue space does not occur. 
Figure 6 depicts the mass balance control volume for the dialysate. In the 
steady-state balance for a delivery experiment, analyte enters the system through 
convection (flowing fluid) through the lumen and leaves the system by convection and 
diffusion through the membrane in an axial increment defined as Az. Note that the 
system is radial and thus diffusion occurs at all points across the membrane. The 
steady-state mass-balance is described and derived by the following sets of equations 
using the following assumption: 1) Diffusion occurs only in a radial direction and not 
in the vertical (z) direction. 
O ^ - 2*R D g g k l f i i f ! = 8C<* - o (8) *RiD*—a? Wc 
This partial differential equation requires an initial condition and 2 boundary 
conditions in order to be solved. The initial condition is that at t=0, Cd= C^ , where 
Cj,, is the concentration of the substance that enters the dialysis probe. The boundary 
conditions are 1) at z = 0,the inlet to the probe, Cd = C^, and 2) a condition exists 
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Figure 6. Control volume used for the determinations of the mass-balance 
equations for the dialysate. 
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such that the flux across the membrane is proportional to the concentration difference 
between the membrane and the dialysate [Bungay et al., 1990], This boundary 
condition is described by Cussler as: 
where k = a mass transfer coefficient (mass/time); C u = the concentration at the 
interface; and C, = the concentration in bulk solution. Flux for diffusion across the 
membrane is described in Equation 10 [Crank, 1975] 
The right hand side of Equation 9 can be approximated by using a mass transfer 
coefficient approach [Cussler, 1984, pg. 300]. This approach is based on the 
assumption of simple mass transport through a hypothetical film [Cussler, 1984], in 
this case the dialysate. This is described as 
where k is the mass transport coefficient, cm/s, L is the length through which mass 
is being transported (the radial distance in dialysate), cm, and D is the diffusion 
coefficient of the substance through the hypothetical film, cm2/s. Transformed into 
the dialysate case the length of the path, L, simply becomes the inner radius of the 
fiber lumen, r{. The inner radius is chosen rather than the diameter of the membrane 
N = k(Cu -CJ (9) 
(10) 
(11) 
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because there exists an equality of flux such that there is no change in mass 
concentration across the midline of the dialysate perfusion fluid. By using this 
dC
m
(i,z, t) 
dr 
D
d
[C
m
(x
it
z, t) - ~C
d
(z, t) 3 
r i 
(12) 
approximation Equation 9 is transformed into Equation 12 and is used in the finite 
difference solution of these equations. The assumption of the hypothetical film works 
well as incorporation of another mass transfer expression for laminar flow found after 
development gave similar answers as outputs from the model. This alternative mass-
transfer correlation is described by as [Cussler, 1984, p.230]: 
where d is the cylinder diameter and v° is the average velocity in the cylinder. 
3.4 Solving the system of equations for microdialysis 
Complex partial differential equations can be solved by a variety of methods. 
These methods include: finite difference methods [Carnahan et al., 1969 and Chapra 
and Canale, 1986], method of lines [Schiesser, 1991], and finite element methods 
[Chapra and Canale, 1986] The method of lines suffers from the inability to couple 
several different equations together. For the microdialysis case, the role of the 
membrane resistance would have to be excluded in the solution process. The finite 
element method is typically used for complex geometries. For a simple geometry the 
finite difference method can be easily described in terms of FORTRAN code and is 
the method that was chosen to solve the microdialysis equations. 
(13) 
Differential equations solved by finite difference methods can be described 
either explicitly or implicitly [Carnahan et al., 1969]. The solution begins by defining 
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a grid for the system to be solved. An example of a grid for the microdialysis 
equations can be seen in Figure 7. In this case, the vertical (z) direction is considered 
negligible and is averaged. The finite difference method is derived from a Taylor's 
series expansion of the function. It assumes that in the direction of change in the 
function is a very small increment and that the function remains continuous in that 
increment. A Taylor's forward series expansion can be defined as: 
fui+1) = f ( X l ) + f ' i x j h + + . . . d 4 ) 
where h stands for the incremental step taken along the function curve. In the 
Taylor's series, if h is chosen to be small enough the higher order terms can be 
truncated [Chapra and Canale, 1986]. Equation 18 then can be solved for the 
derivative. For the partial differential equation describing the mass-balance in the 
ECF of the microdialysis experiment the finite difference equation is described in 
Equation 15 for diffusion and the rate constants. 
Ci.J+l ~ Cl.j - J. Dacf( Ci*l,j+l~Cl-l,j*l + _ Ci*l, J*1 " 2C1, j+1 + Cl-1, ) 
At Vacf r { 2Ar (Ar)2 j ( 1 5 ) 
~ kmetKnCli - kalCit - kieK^Cii - kepCi, j*i + kpeCp + kgeJCliCli ^ 
where, Cu+1 is the concentration at the (i)th position in radial space volume element 
and the (j+1 th) time point, i.e. the next incremental time point. In this equation a 
forward divided difference is used for the time derivative and a centered divided 
difference is used for the first partial in the equation. In this case the equation is 
written implicitly. Implicit finite difference equations require that all the radial steps 
be solved at one time. An explicit solution would require that only the next time 
point at a particular point in space be solved. Although the explicit finite difference 
method is well-described in the field of electrochemistry [Feldberg, 1969, Maloy, 
1986, Bartlett and Pratt, 1993], it is not practical for solving the microdialysis 
equations. 
The principal shortcoming of the explicit finite difference method is that for 
stability the solution diffusion coefficient, DAt/(Ar)2, X needs to be less than 0.5 
[Carnahan et al., 1969]. The explicit finite-difference approximattion also has stability 
problems when the concentration changes in certain volume elements are rapid. 
Unlike electrochemical events which occur on the millisecond or lower time scale, 
microdialysis is bounded by the sampling interval time. Although interfaces such as 
capillary electrophoresis allow for shorter sampling intervals due to the nanoliter 
volumes necessary, the sampling performed in this thesis was on the order of minutes. 
In order for X to be less than 0.5 in the microdialysis equations, the value used for At 
must be very small or the value used for Ar needs to be large. For a diffusion 
coefficient of S^IO"6 cm2/s and a five minute time period, At, the value of Ar would 
have to be 547 microns or larger in order to satisfy the stability requirement. This 
value is larger than the membrane wall thickness which indicates that it is not 
suitable. Use of a small At greatly increases the computational time to solve the 
equations. Therefore the use of an implicit method is a better choice for solving the 
microdialysis equations. 
Equation 15 describes the ECF mass-balance in terms of an implicit finite 
difference equation. The implicit finite difference method varies from the explicit 
method in that in the explicit method the solution is solved by marching forward from 
space point to space point and from time point to time point. In the implicit scheme, 
all the space points are solved simultaneously thus requiring the use of linear equation 
solvers. The system of equations that must be solved for is unique in that a 
tridiagonal matrix is formed which can be readily solved using the Thomas algorithm 
[Carnahan, et al., 1969] on the matrix set shown in Equation 16, where A,B,C are 
coefficients derived from rearrangement of the finite difference equation in terms of 
the space points i-l,i,i+l and also include the boundary conditions. 
B C R1 CI 
A B C R2 C2 
A B C R3 C3 
A B C R4 C4 
A B C R5 C5 
A B C R6 C6 
A B C R7 C7 
A B R8 C8 
(16) 
3.5 Specifics Needed for the FORTRAN code 
Solution of the dialysate concentration and concentration profile from the 
dialysis membrane out into the ECF space begins by determining what the far field 
concentration is in the ECF space. The far-field concentration (oo) for a 
pharmacokinetics experiment is determined by using Equation 17, which is derived 
Ce~ ( t ) = kpeC0
e (-it) k
x
 C 
+ k ep *met X) e«ip+kmt) t (kx k - A ) 
(17) 
in Appendix 3. In Equation 16, the far-field concentration in the ECF fluid space 
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after an i.v. infusion is a function of the initial concentration, C0 in the plasma, the 
elimination rate from the plasma, X, and the transport and metabolism rates in the 
tissue space which have been defined above. Note that for a delivery experiment this 
far-field concentration is usually set to a value of zero. 
The program begins by setting a percentage guess of the far-field concentration 
as the outflow dialysis concentration. Typically this guess is less than one percent of 
the far-field concentration for a recovery experiment. For the delivery experiment the 
guess is based on an incremental one percent loss from the dialysate. By using this 
value the program then utilizes the analytical solution of the dialysate concentration 
to determine the flux into or out of the fiber lumen. The program then solves for the 
membrane concentrations based on the boundary condition that the flux is based on 
a concentration difference between the membrane and the dialysate as shown in 
Equation 18. At the membrane/dialysate interface and the membrane/ECF interface 
a condition holds that the flux across these two boundaries is equal and is shown 
below: 
D dCm _ Pd(Cm\Ri - Cd) ndCa efC. 
D»~dF T , D»~dE ~ e~dx (18) 
The program compares these two flux values and determines whether or not they meet 
a minimum tolerance (1 percent) and if not, the program increases the percentage of 
the guess and continues until the answer is obtained through relaxation.[Press et al., 
1992]. A copy of the FORTRAN code is attached in Appendix 4 of this document. 
A feature used to save computational time and space is the inclusion of a 
logarithmic step increase originally described by Feldberg [Feldberg, 1981]. This 
logarithmic step increase was necessary as these equations were solved using 
Microsoft FORTRAN, which seemed to have a memory limitation that would not 
allow the arrays to be greater than 700. Because the Taylor's series approximation is 
assumed in the finite difference approximation, small values of Ar are necessary to 
achieve an answer closer to the 'true' value. For large values of the far-field radius, 
the number of radial spaces could exceed 700. The logarithmic approximation used 
in the solution of these equations is shown in Equation 19 
A r = A r 0 e p ( i _ 1 ) P^O.5 (19) 
where i is the space step and P is a tolerance. The logarithmic approximation allows 
the values Ar to stay small near the membrane, where the greatest rate of change in 
the concentration will occur. Feldberg found that for most cases this equation worked 
fairly well for f}< 0.5. For the microdialysis model, P = 0.005. In Figure 8, the 
effects of various tolerances is depicted. Table 1 shows the differences in the outflow 
concentrations and calculated deliveries for the various values of P that were shown 
in Figure 8. There is a 2.0% absolute error difference in the predicted dialysate 
percent delivery using p=0.005 versus P=0.0. Although a lower beta will give a 
lower error this has to be weighed with the memory that can be lost with the 
computer as well as the computational time involved with the calculation. In the 
program the default Ar is the difference between the inner and outer membrane 
divided by 10. Since the model will be used in conjunction with analytical data 
obtained in vivo it is suspected that the data obtained would not have an error 
associated with it of less than 2.0 %. 
The program initially had a time instability with the early data points. This 
was solved through the Use of the subroutine RAMP described in the FORTRAN code 
in Appendix 4. RAMP is used to get numerical values into the concentration vectors. 
This gives more accuracy in the first time step as then the values don't go from a zero 
value to another value. 
3.6 Adaptations to the Original Program 
The solutions to the equations above fit well with similar solutions from the 
program of Morrison. There are a few advantages of using the complete numerical 
approach. The first is that the analytical approach of Morrison reduces the role of the 
membrane in the equation solution. With the finite difference approach the 
membrane's diffusivity is always included in every microdialysis calculation. The 
present program can be modified to include different types of microdialysis 
experiments such as euthanasia or metabolite recovery after a delivery of a parent 
compound. In a euthanasia situation, it could be envisioned that k^, the 
microvacsculature permeability rate constant falls to zero. In a recovery of 
metabolites from a local delivery, the boundary conditions near the dialysis probe 
would require modification. 
3.6.1 Euthanasia of the Animal 
For the effect of euthanasia, the initial condition must be modified. In this 
case, the initial concentration of the substance being dialyzed is no longer zero or a 
fixed concentration, but rather the concentration gradient of that substance prior to 
death. This change in the initial condition is easily incorporated into the main 
program. The parts of the program that are different than the main program entitled 
'DIALYSIS .FOR' are shown in Appendix 5 for the program 'DEADDIAL.FOR'. With 
this the outflow concentration of the dialysate can be modelled over time and its 
decay can be approximated. 
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Figure 8. Effect of the tolerance P on the predicted concentration 
profile from the mathematical model 'DIALYSIS.FOR'. 
Table 1. Error associated with the value of (3 in the exponential step function. 
Beta # Steps predicted [outflow] % Delivery % Error % Error [outflow] 
0.0 462 7.822 21.77 - -
0.0005 417 7.817 21.82 0.22 0.063 
0.005 248 7.779 22.21 2.02 0.56 
0.05 75 7.469 25.30 16.21 4.51 
0.2 35 6.883 31.16 43.17 12.01 
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3.6.2 Metabolite formation 
An interesting use of the microdialysis model would be to use it in conjunction 
with metabolite studies and thus determine the concentration of metabolites that could 
be generated. This is especially useful in conjunction with the experiments, which are 
described in Chapter 4 indicating that at least in the liver, blood flow dominates the 
kinetic processes in vivo. This means that from a single recovery or delivery 
experiment the value of the rate constants are non-parsimonious, that is the values 
could be a combination of a variety of values. However, the value of the metabolic 
formation for specific metabolites may be obtainable. Here the initial concentration 
will be a function of the metabolic rate constant in the tissue space. The file 
DATAFILE.DAT needs to be modified and the program runs under METAB.FOR. 
An example of the output is shown in Figure 9. 
3.6.3 Non-linear kinetics in microdialysis 
Biological reactions that involve metabolism or receptor uptake are described 
by the use of non-linear kinetics. For enzyme metabolism, this is termed Michaelis-
Menten kinetics. Since microdialysis samples from tissue which will contain 
enzymes, it is possible that these kinetic rates are not linear as assumed above for the 
development of this microdialysis model. In these cases the diffusion and kinetic rates 
can be expressed in a concise manner as shown in Equation 20 
where kcat is the turnover number for the enzyme, and n is the Hill coefficient which 
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Figure 9. Predicted metabolite concentration profile after local infusion of a 
parent substance using 'METAB .FOR' 
can have a non-integer value of 1 or greater. Equation 20 assumes that the amount 
of enzyme is constant. Considering the case for when material is delivered, the 
highest concentration of material will be nearest to the dialysis probe. If this 
concentration is greater than one tenth of the value of the Michaelis constant, Km, then 
the kinetics in that region would be non-linear. However, further away from the 
probe, the kinetics would approach the linear limit as the concentration decreases 
away from the probe. The argument for the recovery case is the opposite, the kinetics 
near the probe will approach the linear limit whereas at a distance from the probe, the 
kinetics would be non-linear. 
The non-linear term was added to the analytical equation derived at the 
beginning of this chapter, Equation 1, and a solution was obtained for the kinetic rate 
constants depicted in Figure 10. The inset shows that the concentration profile near 
the dialysis probe matches that of the linear limit shown, 0.5 m i n H o w e v e r , further 
away from the probe, the concentration profile approaches the other limit of 1.0 min"1. 
The flux out of the probe will depend upon the concentration profile near the probe, 
thus it will be approximated by the lower limit of 0.5 min"1. Therefore, using the 
numerical model described above with the linear kinetic terms at the lower limit will 
best approximate the non-linear terms without further extensive computation. 
However, the non-linearities may affect the recovery and delivery terms. This 
indicates that when Michaelis-Menten kinetics describe the rates in the tissue, the 
values of in vivo recoveries may not match in vivo deliveries. 
3.7 Strengths and limitations of the model 
The mathematical model derived here has several advantages and 
disadvantages. Several of these points have already been mentioned by Morrison et 
al. [Morrison et al., 1991]. If the kinetic rate values are known along with the in vivo 
diffusion coefficient, then the model can be used in lieu of a calibration method such 
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Figure 10. Predicted concentration profile away from a hypothetical 
cylindrical probe using linear and Michaelis-Menten kinetics. 
as the Lonnroth no-net-flux method. However in many cases the values of the in vivo 
diffusion coefficient are not known and therefore the value must be scaled from in 
vitro values. Rice et al.[Rice et al., 1986] have pointed out that this can lead to a 
discrepancy in the diffusion coefficient of an order of magnitude for cationic 
substances such as dopamine and norepinephrine. 
This model does allow the researcher to determine which factors, such as the 
kinetic rate constants, the diffusion coefficient, or the membrane, will affect the 
microdialysis values the most. However model confirmation with experimental data 
will be limiting for this microdialysis model. This is because the only value that is 
measured in the microdialysis experiment is the outflow concentration. This outflow 
concentration profile is dependent on the tissue concentration profile around the 
dialysis probe which is unknown unless special techniques are employed such as the 
use of autoradiography [Dykstra et al., 1992,1993]. Therefore matching model output 
with experimental data is a poor way to confirm the model as any combination of 
diffusion coefficients or reaction rate constants could produce the model output. For 
this reason, the use of the model in metabolic recoveries is useful as the metabolism 
values will be the same for the parent and metabolite generation. 
An essential part of model-building is model discrimination and parameter 
estimation [Box and Hunter, 1962, 1965]. These concepts also illustrate more of the 
limitations with the microdialysis model. Model discrimination is difficult because 
multiple mechanistic models have not been created. Additionally the problems of 
confirmation with only one experimental output readily measurable (outflow 
concentration) make it difficult to try to improve the microdialysis model. Since the 
microdialysis model has not be truly confirmed through experimental data, parameter 
estimation may not provide the 'true' results for the kinetic rate constants and in vivo 
diffusion coefficients. Additionally if parameter estimation is a goal of the 
microdialysis model, then sensitivity analyses will be necessary [Seinfeld and Lapidus, 
1974, Koda et al., 1979]. Sensitivity analyses are necessary to determine the amount 
of error that would be obtained in the output as a result of error in the parameter 
estimation. For analytical diffusion-reaction models, there are set methods available 
to determine the sensitivity of the model to errors [Koda et al., 1979]. However for 
the microdialysis model described here, the sensitivity analysis may need to be 
performed one variable at a time due to the coupling of the non-linear equations. It 
may be possible to apply statistical methods such as partial least squares regression 
(PLS) to the microdialysis model to obtain a sensitivity analysis. However intuitively, 
it should be realized that errors in the value of the perfusion fluid flow rate and the 
volume fraction of the ECF will affect the output of the microdialysis model the most. 
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Chapter 4 
Liver microdialysis: Identification of processes that contribute to the flux from the 
probe using model compounds phenacetin, antipyrine, and acetaminophen. 
4.1 Introduction 
The liver is a highly complex organ that is devoted to many special tasks 
including endocrine production, gluconeogenesis and metabolism of xenobiotics. 
Metabolism in any specific site in the liver is difficult to study as the blood flow 
pattern through the organ creates metabolic zones which differ in oxygen tension and 
drug metabolism ability [Thurman and Kauffman, 1985, Pang et al. 1994]. In addition 
to the metabolic complexity the liver is difficult to study in vivo due to its anatomical 
attachment. For example, in the brain it is easier to locate the same position from one 
experiment to the next with the use of a stereotaxic unit. Because of the structure of 
the brain, the implantation point of the microdialysis probe can be verified by 
comparison with an atlas. Since a stereotaxic atlas for the liver does not exist, 
placement of a probe in the same area from one experiment to the next is difficult to 
achieve. In vitro techniques such as the use of microsomal fractions, isolated 
hepatocytes, and perfused liver preparations, which were discussed in Chapter 1, have 
been developed to study the liver and its function. Although the use of these in vitro 
techniques can provide useful information concerning metabolism and uptake of drugs, 
they disturb the physiology of the animal. These techniques also by their means of 
disrupting the physiology, also disrupt processes which may be interconnected such 
as the blood flow rate and the uptake of compounds into the hepatocytes. A 
technique which can be used in vivo and not disrupt the normal physiology of an 
animal is desirable to study drug effects quantitatively in the liver. 
This chapter presents experiments that were performed to determine how 
metabolism and uptake rates affect the flux of a substance from the microdialysis 
probe. In particular, the change in the flux (amount of a substance delivered) of 
specific compounds from the microdialysis probe after selective inhibition experiments 
was studied. If the flux of the microdialysis probe changes in animals with inhibited 
metabolism, then the mathematical model developed in Chapter 3 could be applied to 
approximate the values of the rate constants that were inhibited. In the liver, it is 
expected that the major contributions to the microdialysis flux include the permeability 
of the substance across the sinusoids, kep (in the model), and the metabolism, km of 
the substance. If the flux does change with the inhibition of metabolism, then 
microdialysis in conjunction with a mathematical model could provide an alternate 
method to determine kinetic rate constant values as compared to difficult isolated 
perfused liver studies [Gores et al., 1986]. 
4.1.2 Inhibition Studies 
Phenacetin and antipyrine were chosen to study the effect of inhibition on the 
microdialysis flux. These test drugs were chosen for several reasons. 1) They have 
been well-characterized in vivo in rat liver and there exits a large body of knowledge 
concerning these drugs. 2) Both of these compounds are metabolized through the 
cytochrome P450 isozymes, which will allow for easier inhibition than substances that 
undergo conjugation such as acetaminophen. The cytochrome P450 enzyme system 
can be inhibited through entities such as suicide substrates which block the binding 
and electron transport system of the cytochrome. Generally for enzymes that 
conjugate compounds, the best way to block those enzymes is to include a substrate 
that rapidly utilizes most of the co-factor necessary for the conjugation reaction rather 
than through inhibition of the enzyme [Hanzlik, 1991]. 3) Phenacetin is a high-
clearance drug and antipyrine is a low-clearance compound. In metabolic terms this 
means that the metabolic rates associated with phenacetin are more rapid than that for 
antipyrine. A high clearance compound is defined as a compound which is removed 
more than 70 percent from a first pass through an isolated perfused liver preparation. 
A low clearance compound is defined as one in which less than 30 percent is 
extracted after first pass metabolism [Gibaldi and Perrier, 1982]. Phenacetin is o-
deethylated in the rat by CYP 1A2 [Seasardic, 1990a,1990b] and antipyrine is 
oxidized by three different rat P450's. Figures 1 and 2 depict the metabolic pathways 
for phenacetin and antipyrine. 
An animal can be made cytochrome P450 deficient by using cobalt 
protoporphyrin IX [Drummond and Kappas, 1982, Spaethe and Jallow, 1989; 
Muhuberac et al., 1989]. Cobalt Protoporphyrin IX (CoProto IX) represses 8 -
aminolevulinate synthase, which is the rate limiting enzyme of heme biosynthesis. 
CoProto IX also potently induces microsomal heme oxygenase, which is the rate 
limiting enzyme of heme catabolism. These two effects cause the cytochrome P450 
levels to decrease in the liver. Cobalt chloride can also be used for this purpose, but 
has some disadvantages. Cobalt chloride produces a short lived suppression of the 
heme oxygenase levels (48-72 hours versus the protoporphyrin's 2-10 days), and it 
causes an increase in the levels of hepatic glutathione, an enhancement of 
acetaminophen glucuronidation, and a suppression of acetaminophen sulfation. Cobalt 
Protoporphyrin IX was used for some initial experiments in this chapter. A problem 
with this compound was that it caused the rats to lose weight and hair. It was then 
decided that although the CoProto IX was documented in the primary literature as a 
means to make an animal P4S0 deficient, it would be more appropriate on ethical and 
scientific grounds to use a different inhibitor. 
The antidepressant drug fluvoxamine was found to be a CYP 1A2 inhibitor 
[Brosted, 1993] and could be used as a means of inhibiting phenacetin metabolism. 
Fluvoxamine was given as a systemic dose for some experiments. In other 
experiments, it was co-perfused with phenacetin. Initially no change was observed 
and disagreements from the manufacturer proved that it would be difficult to obtain 
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enough to continue the studies with this drug. 
Since CoProtoIX could not be used to inhibit cytochrome P450 because of the 
ethical considerations and fluvoxamine became unavailable, the suicide substrate 1-
aminobenzotriazole (1-ABT) was chosen. 1-ABT is a suicide substrate for CYP 1A2 
[Mico et al, 1987,1988]. A suicide substrate is a substance that binds irreversibly to 
the cytochrome thus causing it to lose activity [Ortiz de Montellano, 1983]. 1-ABT 
has the advantage that the effect is short term because heme synthesis replaces the 
destroyed heme which causes the content of the active CYP 1A2 to increase after 48 
hours. 
4.1.3 Metabolite Studies 
For metabolite studies phenacetin and acetaminophen were used. Again these 
compounds were chosen because of the extensive body of knowledge in the literature 
and because the metabolic rates for these compounds are greater than the antipyrine 
metabolic rate [Houston, 1994], 
4.2 Materials and Methods 
4.2.1 Materials 
A CMA-10 microdialysis probe with a 4 mm polycarbonate membrane, 
(CMA/Microdialysis AB Stockholm, Sweden or CMA/Microdialysis Acton, MA) with 
20 cm of FEP inlet tubing and 3 cm of FEP outlet tubing was used and was prepared 
according to the instructions given by the manufacturer. Briefly this initial 
preparation involves rinsing and flushing the probe with ethanol to remove the 
glycerol used in the manufacturing process. After the flushing period, the probe is 
ready for use. 
Phenacetin, antipyrine, acetaminophen, acetaminophen glucuronide, 1-
aminobenzotriazole, and cobalt protoporphyrin IX were obtained from Sigma 
(St.Louis, MO). Acetaminophen sulfate was a gift from the McNeil Consumer 
Products Company (Ft. Washington, PA) Fluvoxamine was a gift from Docent Leif 
Bertilsson at the Department of Clinical Pharmacology, Huddinge University Hospital, 
Huddinge, Sweden. Halothane and Ringer's solution were obtained from 
Apoteksbolaget at the Huddinge University Hospital, Huddinge, Sweden. Ketamine 
and Xylazine were obtained from the local animal care facility at the University of 
Kansas. Sprague-Dawley rats were obtained from ALAB (Sollentuna, Sweden) and 
were allowed at least 24 hours to accommodate to the animal facility prior to use. 
Sprague-Dawley rats used at the University of Kansas were obtained from a local 
breeding colony. 
4.2.2. Ethical Statements 
All animal experimental procedures were approved by the local ethical 
committee at the Huddinge University Hospital and the local IUCUC at the University 
of Kansas. 
4.2.3 In Vitro Experiments 
In vitro samples were obtained by placing the dialysis probe in an in vitro 
stand attached to a CMA 102 syringe pump (CMA/Microdialysis AB Stockholm, 
Sweden). The probe is placed in a 2.0 ml microcentrifuge tube which contained 
Ringer's solution and was perfused with the drug of interest at a concentration of 5 
|iM at flow rates of 0.5, 1.0 and 2.0 nl/min. 10 nl of dialysate was collected for LC 
analysis. These studies were performed to check probes removed from the package 
and to assess the performance of re-used probes. 
4.2.4 In vivo Experiments 
Surgical procedure: Male Sprague-Dawley rats weighing 220-280 grams were 
used. The rat was anesthetized using Halothane and was placed on its back with its 
tail facing the operator. For pharmacokinetic studies the left jugular vein was exposed 
by making an incision just above the animal's collar bone. In young rats, the jugular 
vein is clearly visible whereas in the heavier animals, fat tissue was removed through 
blunt dissection in order to locate the jugular vein. 
The liver was exposed by making an incision perpendicular to the midline of 
the animal approximately one cm from the xyphoid process. The lower lobe (right) 
is then secured to the abdominal wall by preparing a suture through the skin on the 
left side of the incision and then by gently inserting the suture needle through the 
edge of the lobe (left side of the operator) and tightening it. On the right side of the 
incision, a second suture is passed through the abdominal wall to secure the 
microdialysis probe. A 23 gauge needle is used to gently pierce the outside of the 
liver tissue so that the dialysis probe can be inserted into the tissue. A small amount 
of blood will emerge from this puncture and the dialysis probe is then inserted 
carefully through this hole toward the animal's head and parallel to the midline of the 
animal. Note that the 23 gauge needle is only used to pierce the outside of the tissue 
and is not used to create a channel for the indwelling probe. 
The FEP tubing connected to the syringe pump is then taped to the animal's 
body to prevent the probe from causing damage to the liver through movement. The 
cannula is secured to the skin by a third suture. This allows the probe to move with 
the animal's respiration. This is illustrated in Figure 3. This prevents the probe from 
moving excessively during the experiment. Normally this procedure does not cause 
any bruising around the dialysis probe. However on some animals a bruise was 
observed and thus that animal was not used and was euthanized. Finally a large piece 
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Figure 3. Implantation of CMA-10 probe into liver tissue. 
of tape is used to cover the incision and to prevent the liver from becoming 
dehydrated. 
The microdialysis probe was perfused with a 5 |iM phenacetin Ringer's 
solution at a rate of 0.5 nl/min or 1.0 jil/min for the delivery studies and 2.0 nl/min 
for the pharmacokinetic studies. Dialysates were collected for 50 minutes (two 25 jtl 
samples) for the 0.5 nl/min experiments and 45 minutes (three 15 fxl samples) for the 
1.0 |il/min experiments to allow for equilibration. These dialysates were analyzed, but 
were not included in the calculation of the amount lost. 
When pharmacokinetic experiments were performed after delivery of the drug, 
the probe was allowed to flush for 45 minutes prior to i.v. injection of the drug. With 
phenacetin, the animal was dosed at 5 mg/kg with a solution that contained 75/25 
(v/v%) Ringer's solution/propylene glycol. A propylene glycol solution which 
contained 10 mg/ml was used to make the dilution with the Ringer solution. This was 
necessary as phenacetin has a water solubility of approximately 1 mg/1.3 ml H 20 
[Merck Index]. Although phenacetin does dissolve in ethanol, this is not 
recommended as even small amounts of ethanol given i.v. to a rat will cause the blood 
alcohol concentration to reach intoxicating levels. For this reason propylene glycol 
is used as it is safe to inject i.v. and is converted to lactic acid in vivo. 
Pharmacokinetic samples were collected using a perfusion rate of 2.0 (il/min in order 
to obtain the early time points on the kinetic curve. 
1-ABT was dissolved in a saline solution. Animals were dosed at a level of 
50 mg/kg with a 25 mg/ml solution of 1-ABT. This is approximately ten times the 
molar concentrations used for phenacetin and gave complete inhibition. One hour was 
allowed to pass before delivery samples were obtained or pharmacokinetic studies 
were begun. 
In the metabolite studies, blanks without the phenacetin or acetaminophen in 
the Ringer's solution were necessary to identify possible interferences. After 
collection of Ringer's blanks at 1 fil/min, an electronic syringe selector is used to 
switch to the sample syringe containing the substance to be perfused to prevent the 
introduction of air bubbles. 
4.2.5 LC Analyses 
A CMA/250 LC pump connected to a CMA/260 degasser (CMA Microdialysis 
AB, Stockholm, Sweden) was used with a Knauer fixed-wavelength UV photometer 
(Knauer, Germany). A Phenomenex C-8 spherex 3 |im column (150 mm x 2.0 
mm(i.d.)) (Torrence,CA) was used at a flow rate of 0.22 ml/min. Mobile phase 
conditions for the compounds studied were: phenacetin - 70/30 (v/v%) 0.05 M 
NaH2P04 pH 2.7/acetonitrile, antipyrine - 75/25 (v/v%) 0.05 M NaH2P04 pH 
2.7/acetonitrile with 4 ml/liter tri-ethylamine, and acetaminophen and its metabolites 
acetaminophen sulfate and acetaminophen glucuronide - 97/3 (v/v%) 0.05 M NaH2P04 
pH 2.7/acetonitrile. An underfill injection of 7 |xl from the 10 jxl samples was 
performed manually with a Cheney adapter attached to a Hamilton HPLC syringe to 
provide greater reproducibility. 
4.3 Results and Discussion 
Microdialysis is an invasive technique. Upon insertion of a dialysis probe 
there will be damage to the local tissue site [Ungerstedt, 1991, Davies and Lunte, 
1995]. This damage may include disruption of cell membranes and rupturing of 
capillaries. The disruption of cell membranes will release cellular components such 
as NADPH. This response can be observed in the blanks that are obtained prior to 
the collection of samples. The cellular species are usually hydrophilic and in a typical 
chromatogram for acetaminophen it can be seen that there is a large amount of 
material that elutes with or after the void response, which is an indication of a 
hydrophilic material. The level of this void response decreases over time which is an 
indication that the liver is beginning to stabilize after the initial trauma associated with 
the insertion of the microdialysis probe. The void responses are shown in Figure 4 
for post-surgical samples collected at 15 minutes (A), 30 minutes (B) and 45 minutes 
(C). 
4.3.1 Inhibition Studies 
Figure 5 shows the pharmacokinetic curves for control, cobalt protoporphyrin 
IX, fluvoxamine and 1-ABT treated animals. The half-lives and clearance values 
obtained from the CoProto IX and fluvoxamine inhibited animals were not different 
when compared to control values. The combination of poor inhibition of phenacetin 
and the difficulties with obtaining and using these two compounds provided a basis 
for rejecting their use in further experiments. 
Figure 5 shows that 1-ABT increased the half-life of phenacetin clearance and 
Table I shows the pharmacokinetic parameters of the control animals and 1-ABT 
treated animals. A 90 percent inhibition of the phenacetin metabolism was obtained 
using 1-ABT. The percent inhibition of the phenacetin by 1-ABT was determined by 
using the method reported by Mico et al.[Mico et al. 1988]. Note that 1-ABT is a 
potent inhibitor as an accidental dose of only 5 mg/kg gave a two-fold increase in the 
elimination half-life of phenacetin. These experiments were performed in separate rats 
because it is difficult to maintain rats on halothane for longer than four hours. This 
is partly due to congestion that builds up in the animal's airway that causes the animal 
to have difficulty breathing. Atropine can be used to relieve the muscle spasms that 
may occur, but this does not always save the animal's life. The delivery experiments 
in conjunction with the clearance measurements require at least seven hours of 
anesthesia. This same problem occurs with the 1-ABT treated animals. Indeed, it 
may be argued that a better experimental design would have been to collect 
108 
Table I. Phenacetin pharmacokinetics in control and 1-ABT treated animals 
t1/2 (min) Vd (liter) Clearance (1/min) 
Controls 35.4 2.73 0.053 
30.7 1.53 0.034 
41.3 1.64 0.028 
43.2 1.44 0.023 
Average 37.7 1.84 0.034 
Std. Dev. 5.71 0.60 0.013 
1-ABT treated 177.4 11.7 0.0046 
349.0 1.00 0.0020 
264.0 1.70 0.0044 
Average 263.7 1.29 0.0037 
Std. Dev. 85.8 0.36 0.0015 
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Figure 4. Chromatograms of blanks obtained from rat liver at 15, 30 and 45 
minutes post-surgery. 
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Figure 5. Pharmacokinetic curves of phenacetin in control and treated animals as 
indicated in the figure legend. 
the control samples and then dose the animal with 1-ABT and collect the inhibited 
samples, however, this would have required at least six hours of sample collection 
thus the same problem with the halothane would have occurred. The delivery results 
for the inhibition of phenacetin and antipyrine are shown in Tables II and III. 
Table II shows that there was no statistical difference between mean value for 
the delivery from the control animals and the 1-ABT treated animals with phenacetin. 
An ANOVA was performed to see where the most variation in the results occurred 
and it was determined that in the control animals there was significant animal to 
animal variation. With the treated animals this variation decreased and there was 
more variation from sample to sample. This can easily be attributed to operator 
experience with the surgical technique. In microdialysis it is of utmost importance 
to perform surgeries carefully as the results obtained from the experiments themselves 
can be related to the quality of the surgery performed. For example, a sloppy surgery 
will cause more damage to the tissue area in which the probe is inserted. The control 
animal experiments were performed first, shortly after the author had been trained to 
perform the surgical procedures necessary to insert the probe. For this reason eight 
animals were used. An example of the sample to sample variation in the phenacetin 
controls and 1-ABT treated phenacetin animals is shown in Figure 6 for all the animal 
experiments. 
•4 * 
Initial scanning of the antipyrine results suggests an increase in the delivery 
values after 1-ABT treatment. To determine if the 1-ABT treatment had an affect on 
the delivery, the t distribution was applied to determine the probability of the results 
obtained. Using the t distribution as an approximation to the randomized distribution 
described by Box et al. [Box et al., 1978] the null hypothesis of no difference between 
the means was determined. The t value obtained can be used to find the tail 
probability for these observations which was 42 percent, which indicates that these 
Table II. Phenacetin delivery to control and treated animals. 
Controls 
Average (%) Std. Dev. n 
63.2 2.4 5 
77.3 0.9 5 
69.5 4.5 5 
74.8 4.7 4 
72.9 4.4 5 
74.3 2.4 4 
64.1 1.0 5 
68.0 4.1 5 
1-ABT 
Average(%) Std. Dev. n 
70.3 2.2 5 
69.3 3.0 6 
69.2 1.7 6 
71.7 3.4 6 
73.4 2.0 6 
Controls 1-ABT 
Average (Delivery) 70.5 70.8 
Std. Dev. (Average) 5.2 1.7 
Pooled Variance 11.5 6.6 
Grand Average 70.3 70.8 
Between Animal Variance 26.8 3.1 
F Ratio 2.3 0.5 
F Distribution 0.04 0.76 
* n denotes the number of dialysate samples taken to formulate the average. 
Table III. Antipyrine delivery statistics for control and treated animals. 
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Controls 1-ABT 
Average (%) Std. Dev. n Average (%) Std. Dev. n 
55.9 4.3 4 54.6 1.6 6 
54.9 3.1 5 49.5 1.9 6 
42.1 4.3 5 55.5 1.4 5 
44.8 6.5 5 
42.6 8.1 5 
37.8 4.8 5 
Control 1-ABT 
Average (Delivery) 46.35 53.25 
Std. Dev. (Average) 7.35 3.23 
t (null hypothesis) 0.198 
t distribution probability 42 % k 
* n denotes the number of dialysate samples taken to formulate the average. 
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Figure 6. Delivery of phenacetin at 0.5 jil/min to control and 1-ABT treated rats. 
means are similar and that 1 -ABT is without effect. It is not known why the control 
animals have lower values. These lower values (last two) were measured using a new 
probe from CMA. However, this fact alone does not exclude that data from the set 
as there were no experiments performed to test this hypothesis. 
4.3.2 Euthanasia Studies 
On several occasions after the collection of samples from control animals, the 
animal was euthanized using an overdose of halothane and then collection of the 
samples was continued. These values never approached a steady state convergence. 
Phenacetin seems to be reproducible, however, a steady-state value was not obtained 
indicating that the processes that allow for a 70 percent extraction of the phenacetin 
from the dialysis probe have ceased and that possibly only diffusion is driving the flux 
away from the probe. This is shown in Figure 7. The antipyrine data show more 
scatter. However in one case, the animal expired after the injection of 1-ABT and 
those results show a steady-state of approximately 20 percent delivery of antipyrine 
to the rat. 
To verify that the liver wasn't being freely stirred, experiments were performed 
in the blood and the liver with two CMA-10 probes that were characterized as having 
similar delivery properties. The blood probe delivered more antipyrine than the liver 
probe as shown in Figure 8. Based on tortuosity and diffusion differences between 
the blood and the liver, it would be expected that the blood would extract more from 
the microdialysis probe. Figure 8 also depicts one of the many problems associated 
with microdialysis, i.e., probe to probe characterization. Although the surgical 
placement of a cannula type commercial probe into the liver is perhaps more difficult 
than that of using a linear probe design, the utilization of the same probe allowed for 
a more direct determination between the liver and the blood. However, upon death, 
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Figure 8. Antipyrine delivery (0.5 ^l/min) to a normal rat using CMA-10 probes 
in the jugular vein and liver. The animal was euthanized at 170 minutes. 
both values approached the same value, which could be an indication that around the 
blood probe, the antipyrine was diffusing through the vein. 
The euthanasia studies do not match the mathematical modeling in that if 
metabolism continues, the probe should reach a steady-state shortly after euthanasia 
if the metabolism rates are as high as those reported in the literature. This is not due 
to the fact that the animal is dead, as the isolated perfused liver is obtained from a 
dead animal, liver slices have reported metabolic activity [Worboys, et al., 1995], and 
microsomes and hepatocytes remain viable after collection. A possible explanation 
to the rapid decline without convergence to steady-state is the high delivery values 
obtained are due to convection around the probe due to the animal's respiration. If 
there is convection around the probe, then the membrane rather than the tissue 
becomes the limit to mass transfer [Stenken et al., 1993]. This hypothesis is partially 
supported by the fact that in vitro characterization of the dialysis probes at room 
temperatures of 23° C at 0.5 nl/min, give a delivery value close to 70 percent for 
phenacetin and antipyrine. The phenacetin in vitro delivery value matches its in vivo 
value. The in vitro value obtained for antipyrine does not match its in vivo value. 
It is possible that antipyrine has a diffusion coefficient in vivo that is reduced to a 
greater extent than for phenacetin. A lower in vivo diffusion coefficient due to 
hindered diffusion or possible protein interactions would cause lower in vivo delivery 
values. For phenacetin, the increased temperature, combined with a possible 
convective flow around the fiber due to the animal's respiration, may offset the 
delivery lowering effects of tortuous diffusion pathway and increased resistance in the 
tissue space. 
Using estimated values from the literature for phenacetin and antipyrine, the 
mathematical model developed in Chapter 3 was applied to understand the inhibition 
results. Table IV shows the values used in the phenacetin simulation. Values for the 
metabolism were scaled by using values for antipyrine and phenacetin obtained from 
the literature [Houston, 1994]. The microsomal clearance values of phenacetin and 
antipyrine reported by Houston are 33 and 3.6 |il/min/mg microsomal protein. Houston 
reports that about 500 mg of microsomal protein is obtained from a rat of standard 
weight (250 g). Assuming that the density of liver tissue is about 1.5 the value for 
phenacetin approaches 1.8 min'1. The value for the permeability of compounds across 
the sinusoidal space was taken to be 2.0 min '1 [Ichikawa et al., 1992], Additionally 
it should be noted that the metabolic rate reported for antipyrine would be close to the 
inhibited rate of phenacetin. This is because phenacetin's metabolic rate is reduced by 
90 percent upon inhibition by 1-ABT. 
From Table V it is seen that values for the delivery do not change significantly 
with the reduction of capillary permeation for phenacetin because of the metabolic rate 
of phenacetin is high. For antipyrine, a reduction in the capillary permeation rate does 
affect its delivery. This is because the flux is affected by the addition of each kinetic 
process. Since the blood exchange rate is much greater than the metabolism rate, the 
changes in metabolism will not cause an effect in the levels of the flux from the 
probe. Additionally as was discussed in Chapter 3, as the kinetics increase the 
membrane becomes more limiting to mass transport, thus causing the flux to decrease 
little with changes in kinetic rate constant values. It should be noted that modeling 
results shown in this table do not match the experimental results. This may be due 
to several factors. The model does not account for convection and it is possible that 
convection around the probe due to the animal's respiration may occur. A second 
possible source of error may be in the model formulation. The capillaries may 
provide an additional sink volume that was not included in the original model 
formulation. 
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Table IV. Values used for Model Analysis of Phenacetin and Antipyrine 
Inner Radius (cm) 0.020 
Outer Radius (cm) 0.025 
Diffusion Coefficient Dialysate (cm2/s) 7.5*10 6 
Diffusion Coefficient Membrane(cm2/s) 7.0 * 10"6 
Diffusion Coefficient Extracellular Fluid (cm2/s) 5.0*10"6 
Volume Fraction of ECF 0.3 
Volume Fraction of the Membrane 0.6 
Rate of Metabolism (intracellular) (min1) 1.8 
Rate of ECF/Plasma exchange (min1) 2.0 
Membrane Length (mm) 4.0 
Flow Rate of Dialysate (|il/min) 0.5 
Table V. Model predicted delivery values for phenacetin and antipyrine 
k =2.0 ep k ^ l . O k =0.5 ep k =0.001 ep 
Phenacetin 52.8 52.6 51.0 50.3 
Antipyrine 46.5 42.8 39.9 34.9 
4.3.3. Portal Vein Ligation 
Portal vein ligation in conjunction with microdialysis has proven to be difficult 
at the present time. Successful implementation will require an improved microsurgical 
technique. A change in delivery is expected, but the extent cannot be predicted easily 
except through modelling. The portal vein supplies 75 percent of the blood to the 
liver. Therefore, a reduction of the blood flow by 75 percent would be expected. If, 
however, the capillaries still provide good sink conditions with the lowered blood 
flow, then delivery will not change. A starting point for the surgery can be found in 
Brand et al. and Um et al. [Brand et al., 1995; Um et al., 1994]. 
4.3.4 Metabolite Studies 
Other authors have reported the formation and collection of metabolites from 
microdialysis experiments in rat liver. Scott and Lunte [Scott and Lunte, 1993] 
reported obtaining over 20 nM phenyl-glucuronide after an infusion of 500 nM phenol 
of which 181 |iM was lost across the probe. Van Belle et al. [Van Belle, 1995] 
observed a 18 percent oxidative conversion of carbamazipine at a 2 |il/min flow rate 
after a local infusion. 
Acetaminophen and phenacetin were used to determine the amount that could 
be obtained after a local infusion. In the acetaminophen case, only the sulfate was 
quantitated in the perfusion fluid. This is due to the location of the phenol 
sulfotransferases in the cytosolic space, whereas the glucuronyltransferases are located 
on the endoplasmic reticulum along with the cytochromes [Mulder, 1990]. It would 
be expected to obtain a greater amount of sulfated conjugates as the sulfates can be 
formed in the cytosol and diffuse or be transported out of the cell into the 
microenvironoment sampled by the microdialysis probe. Whereas for the glucuronide, 
the glucuronyltransferases are located in the vicinity of the bile ducts and thus the 
metabolite, if it is formed, would be shunted into the bile more efficiently than be 
transported back into the extracellular space. In vitro delivery values at 1 nl/min for 
acetaminophen, acetaminophen sulfate and acetaminophen glucuronide were 47%, 
42%, and 28%. Because of the lower delivery value for acetaminophen glucuronide, 
this compound would be extracted at a lower level than a sulfate conjugate. 
Table VI shows the formation of acetaminophen sulfate after the infusion of 
various denoted concentrations of acetaminophen. The metabolite data obtained is in 
contrast to the observations by Scott and Lunte [Scott and Lunte, 1993], who reported 
collection of phenol-glucuronide after a local infusion of 500 nM phenol. No 
acetaminophen glucuronide formation was observed after the local infusion of 
acetaminophen in these experiments. The microdialysis data presented here is 
supported by phenacetin and acetaminophen data from Smith and Timbrell [Smith and 
Timbrell, 1974], Smith and Griffiths [Smith and Griffiths, 1976], and Pang et al. 
[Pang et al., 1985], At the low concentrations of acetaminophen, 10 nM, 
approximately 9 percent of the amount removed from the probe was converted into 
the sulfate metabolite. Formation of a glucuronide conjugate was not observed. This 
is expected as a typical K^ value of the phenol sulfotransferase is given by Pang 
[Pang, 1990] as 10 jiM and the Km for the glucuronyltransferase is reported as 200 
fiM. The amount removed from the probe is well below both of these values at the 
11 and 110 jxM concentrations infused. A shift between sulfate conjugation and 
glucuronidation would be expected for the values between 10 and 50 |iM for the 
acetaminophen as modeled by Morris and Pang for the isolated perfused liver [Morris 
and Pang, 1987], Experimental results from Koster et al. exhibit the same behavior 
for phenol and other phenolic compounds [Koster et al., 1981]. As the concentration 
of acetaminophen was increased, a decrease in the percent of the acetaminophen 
sulfate was observed. This indicates that a process affecting the recovery of the 
acetaminophen sulfate across the microdialysis probe was perturbed. This may be 
Table VI. Metabolite recovery from a local infusion of acetaminophen. 
[APAP] pM [APAP] pM [APAP] pM % of APAP-S04 
probe lost (± std.dev) gained (± std.dev) gained from loss 
11.9 3.73±0.46 0.04±0.026 10.82 
11.9 3.43±0.07 0.22±0.12 6.25 
11.0 1.75±0.21 0.16±0.02 9.53 
119 35.6±4.9 2.34±0.03 6.59 
119 27.4±2.0 1.56±0.06 5.69 
110 18.9±1.5 1.03±0.15 5.44 
238 61.4±6.0 3.54±0.14 5.77 
238 52.14±5.2 2.88±0.2 5.54 
220 49.8±4.4 1.57±0.55 3.17 
Table VII. Phenacetin (59 pM) delivery to a rat. Recovery of the metabolites 
acetaminophen and acetaminophen sulfate. 
[APAP-S04] pM 
gained 
[APAP] pM 
gained 
[Phenacetin] pM % metabolites 
gained from loss 
0.38 1.06 43.6 3.3 
0.79 1.58 35.4 6.7 
1.29 1.42 30.3 8.9 
0.99 1.59 31.3 8.3 
1.21 1.51 29.9 9.1 
1.06 1.89 33.5 8.7 
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saturation of the sulfotransferase or an inhibition of the active transport of 
acetaminophen sulfate out of the hepatocyte [Goresky et al.,1992]. 
After a local infusion of phenacetin the metabolites acetaminophen and 
acetaminophen sulfate were collected into the dialysate. The results of these 
experiments are described in Table VII. The K,,, value reported for the high affinity 
site for phenacetin based on microsomal studies is approximately 5 nM [Boobis et al., 
1981]. Based on Michaelis constant values and maximum rate arguments, the 
formation of the sulfate seems reasonable as the sulfotransferases are known to be 
high affinity and low capacity enzymes whereas the glucuronyltransferases are low 
affinity and high capacity enzymes. This means that at low concentrations of the 
substrate the sulfotransferase will more readily convert the acetaminophen than the 
glucuronyltransferase. 
Part of the problem with comparing these studies with studies in the isolated 
perfused liver is that it is not known to what extent the metabolite is lost across the 
tissue microvasculature. Van Belle et al. [Van Belle et al., 1995] discussed that 
microdialysis can be used in conjunction or as an alternative to the isolated perfused 
liver for metabolite conversion studies. However, in their experiments, they did not 
secure or verify the placement of the probe. In the dialysis experiment, part of the 
drug will be completely removed from the area through the sinusoids whereas another 
part may be taken up by the cells. It is unknown how 'good' a sink the microdialysis 
probe provides in contrast to the sinusoids in the isolated perfused liver. 
4.4 Summary 
From these studies it is seen that for microdialysis sampling applied in the 
liver, metabolism does not contribute greatly to the flux from the microdialysis probe. 
This was shown by the lack of change in the delivery after inhibition of cytochrome 
P450 enzymes with the suicide substrate 1-ABT. Experiments with euthanized 
animals show that the blood flow is a large contributing factor to the amount of 
material removed from a microdialysis probe. The role of convection in microdialysis 
liver sampling is suggested as an additional factor that may attribute to the large flux 
values obtained in these experiments. In vitro delivery experiments suggest that the 
membrane may also contribute to the overall flux of phenacetin and antipyrine as the 
in vitro deliveries closely matched those in vivo. 
Metabolic recovery after a local infusion of a parent compound may provide 
a way of utilizing the mathematical model formulated to determine metabolic rate 
constants. However, this procedure will be compound specific and will depend upon 
the transport properties of the dialysis probes. 
A possible avenue of study would be the induction of the cytochrome P450 
enzymes followed by an inhibition of the enzymes to determine if the increase of drug 
metabolizing enzymes would affect the flux. Sesardic et al. [Sesardic et al., 1990] 
have reported that CYP 1A2, the phenacetin o-deethylase, is highly inducible by using 
3-methylcholanthrene. They reported a 30 fold increase in activity in microsomes 
(CYP 1A2 makes up about 4-6 percent of the overall cytochrome P450 pool). 
However, they also report a great variability in the induction from animal to animal. 
Hepatic transport is an area that has undergone extensive work. There is 
tremendous complexity of transport and uptake for cationic as well as anionic drugs 
and their transport influence by protein binding [Meijer, 1987, Meijer and van der 
Sluijs, 1987]. Additionally the role of changes in metabolism as well as liver blood 
flow [Reichen et al., 1988, Buters et al., 1993] may be assessed by using 
microdialysis in animals induced with cirrhosis. 
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The effect of acetylcholinesterase inhibition on the flux of 14C-acetylcholine in 
microdialysis deliveiy experiments. 
5.1 Introduction 
Chapter 4 showed that for two model compounds, phenacetin and antipyrine, 
in the liver, metabolic rates did not affect the flux of these substances from a local 
delivery. This indicated that processes such as the microvasculature uptake rates, (k^ 
in the model described in Chapter 3) contribute significantly to the overall sum of the 
kinetic processes in the liver. Since metabolism did not affect the delivery of 
compounds to the liver, a second tissue and analyte were explored to show that in 
specific cases metabolism will affect the flux in microdialysis experiments. 
Acetylcholine esterase (AChE) is one of the most efficient enzymes known in 
terms of its catalytic efficiency, kCit. AChE has a kc„ of 14,000 sec"1, which means 
that it can convert 14,000 molecules of acetylcholine (ACh) into acetate and choline 
per molecule of AChE per second [Fersht, 1985], Acetylcholine is unique as a 
neurotransmitter in that the only process that removes it from the extracellular fluid 
space is the degradation through AChE, unlike dopamine that can be taken back into 
the neuron through reuptake processes [Cooper et al., 1991]. 
Like most enzymes, AChE is heterogenous in its expression in the mammalian 
brain [Ogane et al., 1992]. There are several types of AchE that have been isolated 
from mammalian brain. The predominant forms in the mammalian brain include the 
globular tetrameric form, G4, and the monomeric G, form. The G4 form in the 
membrane accounts for approximately 70 percent of the activity of AChE in 
membrane extracts and is known to be extracellular in nature, i.e, it faces the 
extracellular space, which is the space that is sampled by microdialysis techniques. 
Therefore, this enzyme/substrate system serves as an ideal candidate for studying the 
effects of kinetic inhibition in microdialysis. 
AChE can be inhibited by two different classes of inhibitors typically named 
reversible or irreversible [Taylor, 1990]. Reversible inhibitors, which include 
physostigmine and neostigmine, inhibit the acetylcholinesterase enzyme through 
carbamoylation. The enzyme is then reactivated through hydrolysis of this 
carbamoylate bond. Irreversible AChE inhibitors, which include agricultural 
insecticides and chemical-warfare nerve gas agents, phosphorylate AChE. This is a 
stable process, which causes the enzyme to be inactive. 
In this study, microdialysis probes were placed in the striatum of a rat to study 
the effects of inhibition on the loss of 14C-acetylcholine through the microdialysis 
probe. Neostigmine was included in the perfusate in a cross-over design. This cross-
over design allowed the comparison of ACh loss before and after pharmacological 
challenge with neostigmine. 
5.2 Materials and Methods 
CMA-12 microdialysis probes (CMA Microdialysis AB, Stockholm, Sweden) 
with a 4 mm membrane were used for all experiments. Probes were prepared 
according to the manufacturer's instructions which briefly state that probes need to 
rinsed with ethanol prior to use to remove the glycerol that is used in the 
manufacturing process. After rinsing, the probes were ready for use. 
14C-acetylcholine chloride (50-60 mCi/mmol) was purchased from Amersham 
(Solna, Sweden) and was dissolved in Ringer's solution (Apoteksbolaget, Huddinge 
University Hospital, Huddinge, Sweden) to 2 pM prior to infusion. Neostigmine 
bromide was obtained from Apoteksbolaget, Huddinge University Hospital and was 
prepared to a concentration of 100 nM prior to infusion with 2 nM acetylcholine. 
Male Sprague-Dawley rats (225-275 g) were anesthetized with halothane and 
were maintained at 37° C through the use of a CMA-150 heating pad. Five rats were 
used. Each rat was placed in a Kopf stereotaxic frame, with the incisor bar set 3.3 mm 
below the interaural line. The skull was exposed and then trephined using a 1 mm 
diameter drill bit. The microdialysis probe was slowly inserted 0.2 mm anterior and 
2.7 mm lateral to bregma, to a depth of 6 mm below the dura. These experiments 
were approved by the Animal Ethical Committee of the Huddinge University Hospital. 
After insertion, the probe was allowed to flush at 1.0 (il/min for one hour prior 
to the beginning of sampling. After one hour, four 15 minute samples were collected 
into scintillation vials and stored at ambient temperature until analysis, which occurred 
after the completion of the experiment (approximately 3.5 hours). After the control 
samples were obtained, cross-over to the syringe which contained 100 |aM 
neostigmine and 2 nM Cu-acetylcholine occurred. The use of the syringe selector 
prevents the introduction of air bubbles into the microdialysis probe. To allow for the 
dead volume in the tubing, the probe was allowed to continue flushing for 15 minutes 
prior to the collection of the neostigmine inhibited samples. The dead volume of the 
tubing used and the probe together approaches 10 nl and would require at least 10 
minutes for the dead volume to clear at a 1.0 nl/min perfusion flow. Samples, which 
included neostigmine, were collected for another hour and then the perfusion fluid was 
switched back to the perfusion fluid which contained only ACh. 
The 15 |il dialysate samples were mixed with 3 ml Optisolv scintillation fluid 
(DuPont) prior to counting. Standards were prepared by pipetting 15 from the 
solutions that were perfused through the microdialysis probes. Samples and standards 
were analyzed using liquid scintillation counting. Deliveries were calculated by using 
the count ratio of (CountsstM-Countssamp|e)/Counts5lan, where Counts5tan and Countssampl(. 
stand for the counts obtained for the standard and the sample respectively. 
5.3 Results and Discussion 
The percent of the 14C-acetylcholine delivered is shown in Table 1. The same 
probe was used in rats number 4 and 5. The high delivery values obtained may 
indicate that this probe had a small micro-tear in the membrane, which would have 
caused a set amount of material to leak from the probe thus making the results appear 
higher when compared with the 15 pi standards. 
Because the data are somewhat scattered due to animal-to-animal and sample-
to-sample variation, the data were normalized to changes from the control values 
obtained within the first hour of sampling. These percent control values were 
calculated by taking the highest delivery percent from the initial ACh infusion and 
dividing the four samples by this value. This gives a value that is below 100 percent 
of control, but takes into account the sample-to-sample variation. This same 
procedure was performed for the perfusion that included neostigmine and the cross-
back to acetylcholine. The bar graph depicting these values is shown in Figure 1. 
Table 2 shows the average percent lost, the standard deviation of the average and the 
probabilities that the treatments are the same based on a randomized t distribution. 
By visual inspection it is clear that the cross-over back to the ACh after 
infusion with 100 pM neostigmine did not reach the original control value. However, 
the cross-over is statistically different from the neostigmine infusion and the controls. 
About a 30 percent reduction in the delivery was obtained through the use of infusion 
of neostigmine through the probe. The lack of greater increase after the cross back 
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Table I. Percent delivered of 14C-acetylcholine ± standard deviation for ACh and 
ACh/neostigmine treatments. 
ACH ACH/NEO ACH 
Rat 1 13.0 ± 1.0 7.6 ± 2.1 11.0 ± 3.4 
Rat 2 17.4 ±1.6 13.0 ± 1.7 15.0 ± 0.9 
Rat 3 20.0 ±1.9 15.5 ± 0.7 17.0 ± 1.3 
Rat 4 40.8 ± 2.3 26.8 ± 0.9 36.5 ± 0.9 
Rat 5 43.2 ± 0.8 24.6 ± 1.4 27.2 ± 0.8 
Table II. Percent loss of ACh expressed < 
tailed t probability for the null hypothesis. 
as a control, standard deviation, and one 
Group ACH (1) ACH/NEO (2) ACH(3) 
Average 94.9 62.8 76.9 
Standard deviation 2.7 7.6 8.7 
Combination t, tail area probability 
Group 1/2 1.0*10"5 
Group 2/3 0.012 
Group 1/3 0.0011 
ACH NEO ACH 
Figure 1. Acetylcholine delivery as a percent of control values, before, 
during and after neostigmine (NEO) treatment. 
to the ACh perfusion fluid may be due to the presence of excess neostigmine in the 
area surrounding the probe. Additionally reversible inhibitors of AChE are known to 
have an effect that last approximately 3-4 hours in vivo [Taylor, 1990], The area that 
is affected by the neostigmine relative to the acetylcholine is unknown. This is 
because the in vivo diffusion coefficient of neostigmine and the uptake rates are 
unknown compared to those for acetylcholine. Therefore neostigmine's effect at 
distances away from the probe may be different than those for acetylcholine and thus 
may affect the results of the cross-over back to acetylcholine. 
Neostigmine has been previously reported to give a lower inhibition than 
physostigmine and unstable sample-to-sample results when used in concentrations 
greater than 50 pM [Messamore et al., 1993], Although some sample-to-sample 
variation was observed in these studies, neostigmine consistently gave a reduction in 
the microdialysis delivery of ACh. 
Figure 2 shows a theoretical approximation of how 50 and 90 percent 
inhibition to AChE may affect the delivery of acetylcholine in vivo after introduction 
of an inhibitor using the data from Table III. The legend shows what may be 
expected for inhibitions of 50 and 90 percent of a rate constant denoted as 1.0 min"1. 
The pl50 of neostigmine on AChE is 8, which means that inhibition is 50 percent at 
10"8 M or 10 nM [Cohen and Oosterbaan, 1963]. This value was exceeded assuming 
a 15 percent delivery of 100 pM neostigmine through the dialysis probe. 
Figure 2 shows that for a 90 percent inhibition, a steady-state value should be 
reached after about 45 minutes. This was not observed experimentally in vivo. 
However, this drop to steady-state values only occurs over a 1 percent range of a 
predicted delivery value. If this did occur experimentally the phenomenon was 
probably lost in the experimental uncertainty. 
Table 3. Parameters used for acetylcholine simulation 
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0.025 OUTER RADIUS OF THE MEMBRANE {cm} (ROUT) 
0.020 INNER RADIUS OF THE MEMBRANE {cm} (RIN) 
7.5e-6 DIFFUSION COEFFICIENT (DDIAL) 
7.0E-6 MEMBRANE DIFFUSION COEFFICIENT (DMEM) 
3.33e-6 ECF DIFFUSION COEFFICIENT (INCLUDES TORT) (DECF) 
0.2 Volume Fraction (PHI) 
0.6 Volume Fraction of the membrane (PHIM) 
1.0 Metabolism Rate Constant {min-1} ECF (RMETAB) 
0.0 Metabolism Rate Constant {min-1} ICF (RICF) 
0.0 Plasma to ECF exchange (min-1) (XKPLEC) 
0.0 ECF to Plasma exchange (min-1) (XKECPL) 
0.0 Production in the ICF (GICF) 
0.0 Production in the ECF (GECF) 
1.0 Ratio keix/kiex (XKPI) 
100.0 Total simulated time (min) (TIME) 
10.0 Number of time steps (TMSTEP) 
0.0 Plasma Cone (CPLAS) 
0.4 Length of the membrane (cm) (XLEN) 
1.0 Dialysis Flow Rate in nL/min (QDIAL) 
10.0 Perfusion Fluid Concentration (CPERF) 
0.0 Plasma decay constant ( xlam ) 
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Figure 2. Model of acetylcholine delivery before and after various levels of 
inhibition of AChE. 
5.4 Summary 
This chapter shows that a reduction in the microdialysis flux can be obtained 
though a local inhibition of metabolism achieved by delivery of an enzyme inhibitor 
through the microdialysis probe. However, although a reduction in the delivery of 
l4C-acetylcholine was observed, it is unknown if full inhibition of AChE was 
achieved. It may be possible to titrate the reduction in delivery through the use of 
varying combinations of concentrations of neostigmine and acetylcholine. It is 
unknown how much neostigmine was lost through the microdialysis probe. Assuming 
that its diffusion coefficient and uptake rate parameters are similar to acetylcholine 
then, the same percentage would be lost as acetylcholine. For these experiments this 
would be about 15 percent. This 15 ^M loss of neostigmine would then be diluted 
in the tissue microenvironmental space. The microdialysis model can make 
approximate predictions about how far a molecule can diffuse through the 
microenvironment after diffusion through the microdialysis probe However, these 
predictions would have to be confirmed in order to make further conclusions about 
the extent inhibition of AChE by neostigmine. For these reasons, it may be difficult 
to determine a metabolic rate for the uptake of neostigmine in vivo. 
These results show that after a pharmacological challenge, such as the 
inhibition of an enzyme, the mass-transport dynamics to and from the probe may be 
changed and these changes need to be considered when interpreting microdialysis 
data. Fortunately for the inhibition case, the ACh levels in the brain not only rise, but 
the transport of ACh from the ECF space is lowered, therefore a decrease in the loss 
of ACh from the dialysate is expected. However, if it were possible to induce AChE, 
then the local levels of ACh in the ECF space would also change along with the probe 
dynamics due to a greater heterogenous rate constant. Dialysis data from this type of 
experiment should also be interpreted with caution. It should be noted that these 
scenarios would not only hold true for microdialysis sampling, but for all in vivo 
sampling. 
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Determination of sub-cutaneous caffeine levels in a humans after voluntaiy caffeine 
ingestion. 
6.1 Introduction 
The chapter discusses the last experiment performed while working as a 
visiting scientist at the Karolinksa Institute in Stockholm. The experiment performed 
here does not directly relate to the mathematical model, but serves as a means to give 
the reader a flavor for some of the possible human uses of microdialysis. In humans, 
microdialysis probes are easily implanted into the subcutaneous fat. In this particular 
study, the dialysis catheter was used to study the dynamic changes of the caffeine 
levels as well as to see if the probe could be used to quantitate low levels of caffeine. 
This was a pilot study to determine if there is a certain level to which individuals dose 
themselves with caffeine. 
Caffeine is one of the most widely used substances in the world. The human 
use and effects of caffeine have been widely studied [Starvic, 1992]. In Sweden the 
average daily ingestion of caffeine is 425 mg per day whereas in the United States the 
value is 211 mg per day [Spiller, 1984]. A consumption of over 250 mg per day of 
caffeine has been termed caffeineism [Somani and Gupta, 1988]. The reinforcing 
ability of caffeine has been debated and discussed in the literature [Griffiths and 
Woodson, 1988], Studies have shown that physical dependence potentiates the 
reinforcing effects of caffeine [Griffiths et al., 1986]. Additional questions about the 
mode of action of caffeine and why it affects individuals differently has been called 
into question as well. Caffeine has several pharmacological effects. Effects that may 
be produced at physiological levels of caffeine obtained through ingestion from food 
or beverages include blockade of adenosine receptors and inhibition of cyclic-AMP 
phosphodiesterase[Fredholm, 1980]. These effects and the dose at which they are 
obtained has been questioned [Nehlig and Debry, 1994]. Additional questions can be 
raised as to the inter-individual variability of caffeine metabolism [Caraco et al. 1990]. 
The purpose of this study was to use microdialysis sampling to follow the 
levels of caffeine in the subcutaneous fat of a human at regular time intervals while 
the subject participated in normal daily activities. Microdialysis sampling provides 
protein-free samples from the ECF space that can be directly analyzed without sample 
preparation. This is a distinct advantage over blood sampling methods which require 
sample clean-up prior to analysis. The author was chosen as a test subject because 
of her low ingestion of caffeine as compared to the native Swedes with whom she 
worked with for 10 months. Microdialysis sampling has been used in a previous 
study to determine the disposition of caffeine to male subjects after the ingestion of 
an oral dose of caffeine [St&hle et al., 1991]. In those studies, caffeine was given in 
doses of 300 to 400 mg, which gave rather large dialysate outflow concentrations (20-
80 pM). In this study the feasibility of determining levels throughout the day was 
investigated and if fluctuations and low levels could be obtained through the use of 
microdialysis sampling. This initial study may become part of a larger study to 
determine if there is a certain blood level to which individuals dose themselves 
between low level drinkers and higher level drinkers. This has not been addressed in 
the literature, as generally heavy-drinkers of caffeinated beverages are used [Griffiths 
et al., 1986] in caffeine related dosing studies, which ignores inter-individual 
variability in caffeine metabolism. 
6.2 Materials and Methods 
6.2.1 Microdialysis 
A CMA Human dialysis catheter (CMA/Microdialysis AB, Stockholm, Sweden) was 
implanted 6 cm above the umbilical line after the application of a local anesthetic. 
The probe was perfused at a rate of 0.5 nl/min with a 0.9% saline solution by an 
infusion step-pump. All procedures were approved by the local ethical committee. 
The probe was implanted at 13:00 on day 1 prior to sampling the following morning. 
This allows any initial damage caused by the probe implantation to clear. Although 
sampling was to begin on day 2, difficulties with the LC system (the chromatography 
was still being optimized) and the absent-mindedness of the author (5 days and 
counting to departure from the country) caused several key time points to be missed 
throughout the day. On day 3, the analyses began. Samples were obtained every 30 
minutes, if a deviation occurred in the sample changing time due to different 
circumstances this was noted in the lab book and 30 minute samples would continue 
from that time on. Dialysates were analyzed without any further sample clean-up or 
dilution. All dialysates were injected onto the LC column no more than 10 minutes 
after obtaining the sample. The afternoon of the first day was used to allow 
equilibration of the probe to occur. The second day was used to optimize the 
experimental procedures and thus the data is not presented as it was not collected 
continuously throughout the day. Although microdialysis is a continuous sampling 
technique, only discrete time point samples are obtained. For simplicity, the data are 
plotted as the single time point concentration outflow. It should be noted that each 
of these discrete dialysate samples contains the average caffeine concentration during 
the sampling interval. 
6.2.2 Caffeine Consumption Procedure 
The subject was allowed to ingest caffeine ad lib. The subject's normal coffee 
drinking behavior consisted of generally drinking only one cup of coffee at the 8:45 
break and a half cup at the 14:45 break. On this day, out of curiosity's sake, a Coke 
Light® was consumed with lunch (12 noon), along with the normal cups of coffee. 
6.2.3 LC Analyses 
Caffeine was analyzed using liquid chromatography with UV detection. The 
system consisted of a Phenomenex C-8 column with a mobile phase of 0.05 M sodium 
acetate pH 5.0 and 15 % acetonitrile. The pump was a CMA-250 delivery system 
(CMA Microdialysis AB, Stockholm, Sweden) with a CMA/260 degasser. The flow 
rate was 180 pl/min. The detection was performed using a fixed wavelength UV 
detector from Knauer (Germany). The system was calibrated between the ranges of 
0.5 pM and 10 pM and was linear. The detection limit based on a S/N of 3 was 0.1 
pM. Caffeine eluted in 5 minutes and no interfering peaks were present in the 
human dialysate. A 1 ml aliquot of the caffeinated beverage consumed was saved for 
analysis of the dose. Caffeinated beverages were diluted 100 fold with 0.9% saline 
and injected onto the LC without any further sample clean-up. 
6.3 Results and discussion 
The main advantage of using microdialysis sampling versus blood sampling 
for drug disposition studies is that microdialysis sampling provides a clean sample. 
An example of this is shown in the chromatograms in Figure 1. Figure 1A is the 
chromatogram from a 7:30 am dialysate sample from the subject. Figure IB is the 
18:30 sample from the same subject after ingestion of caffeine throughout the day. 
The peak that elutes at approximately 3.50 minutes appears to be a metabolite of 
caffeine as it does not show up in the standards obtained from the beverages that were 
used to obtain the dose of caffeine as shown in Figure 2. This peak may be 
paraxanthine, which is caffeine's major metabolite that appears in the blood (Rail, 
1990). 
Figure 3 depicts the levels of caffeine obtained throughout the day. Prior to 
ingestion of the caffeine, a morning level of caffeine of approximately 1 pM is 
present. For the caffeine ingested in the morning coffee break the caffeine level 
rapidly rises and is detectable in the first sample obtained after ingestion of caffeine. 
Although caffeine was ingested with the noon meal the levels obtained do not seem 
to rise as much as the other two ingestion periods. The sharp rises in the caffeine 
concentrations after the morning and afternoon coffee breaks are most likely due to 
an increased absorption of caffeine because of an empty stomach. The maximum 
concentration obtained was 8.8 nM after ingestion of caffeine at the afternoon coffee 
break. 
From this study it seems feasible to use microdialysis sampling to study the 
variation in caffeine after habitual ingestion even when caffeine is present in low 
levels. If microdialysis could be used in other studies of caffeine such as an 
alternative to the caffeine test used to determine the metabolic activity of CYP 1A2, 
which converts caffeine to paraxanthine, [Kalow and Tang, 1993] is unknown, but 
may be worthwhile to study. 
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Figure 1. Chromatograms of human dialysate from 7:30 (left) and 18:30 (right). Caffeine elutes at 5.05 minutes. 
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Figure 2. Chromatograms of human dialysate and samples of the beverages ingested. Caffeine elutes after 5 minutes. —i 
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Figure 3. Caffeine concentration in human dialysate samples at the indicated 
discrete time points. The dose and the duration of time used to ingest the 
indicated dose are denoted by the boxes at 8:45, 12:00, and 14:45. 
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Summary 
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The basic underlying principle the describes transport of substances to and 
from the microdialysis probe is diffusion. During a recovery experiment, material 
diffuses across the dialysis membrane into the inner fiber lumen in order to be 
sampled in microdialysis. The dialysis probe can also be used as a local infusion 
device in which analytes or enzyme inhibitors can be delivered. Although diffusion 
into the microdialysis probe may be a straight-forward concept, there are other factors 
that can affect diffusion to the microdialysis probe. These other factors will affect the 
separation efficiency of the microdialysis process. 
Diffusive behavior of substances can be altered by a number of different 
processes including forced convection, homogeneous or heterogeneous reactions, 
tortuous pathways, solute-boundary interactions, and solute-solvent interactions. All 
of these processes should be considered when interpreting microdialysis data or any 
data obtained from an in vivo sensor that may include diffusion of an analyte through 
a membrane. 
During microdialysis sampling, convection in tissues is ignored because it is 
assumed that diffusion is the dominant mass-transport process in tissues [Benveniste 
and Hiittemeier, 1990], Chapter 2 has shown that at very low fluid velocities the flux 
of material to a microdialysis membrane changes as the velocity of the fluid is 
increased. For three different microdialysis membranes that are commonly used in our 
laboratory, a linear velocity of 0.025 cm/s or greater would cause the membrane to 
be the limit to diffusion when placed in a fluid sample. It is unknown what the 
values for linear fluid velocities in tissues would reach. For the brain, convection may 
not be a problem since the probe is secured to the skull in microdialysis experiments. 
However for use in other tissues such as liver or muscle of rats, the convection may 
affect the recovery of a substance. In microdialysis experiments in muscle and liver, 
both tissues may be subject to movement, particularly in animals that are freely-
moving. For liver, the question that should be considered is to what extent does the 
respiration of the liver play in the membrane separation. For muscle, a different 
question would be to what extent does local muscle contraction play in the recovery 
of substances. 
Chapters 4 and 5 discussed how inhibition of metabolism affects the flux from 
the microdialysis probe. This is because diffusion through the membrane is defined 
by diffusion and reaction processes that occur in the tissue, which was discussed in 
Chapter 3. With reaction terms, the diffusive flux is increased, which results in a 
greater loss of material from the microdialysis probe. However, the kinetic processes 
that occur in a tissue are additive. If one kinetic term is much greater than another, 
then it is possible that the diffusive flux will not change significantly when the smaller 
term is removed through inhibition. This was shown in Chapter 4 from the 
experimental results and by using the model developed in Chapter 3. In the liver, 
inhibition of metabolism does not change the flux from the microdialysis probe. This 
can be attributed to one or two factors. The first is that the capillary permeability 
exchange rates are large enough that an inhibition would not significantly change the 
flux from the probe. This is supported by experiments that observed a drop in the 
flux of phenacetin and antipyrine after euthanasia of the animal. The second is that 
respiration of the animal cause some fluid convection around the membrane, which 
causes the membrane to be a limiting factor to mass-transport. The second factor is 
not completely supported by experimental evidence since the in vitro deliveries of 
antipyrine and phenacetin were the same, but in vivo deliveries were significantly 
different. The differences between the in vivo deliveries of antipyrine and phenacetin 
suggests that the tissue and not respiration affected the flux from the dialysis probe. 
In Chapter 5, acetylcholine was used for inhibition studies because there exists 
only one kinetic reaction that removes it from the ECF. In this study, when 
metabolism was inhibited, a decrease was observed in the microdialysis flux of 
acetylcholine. These results and the results obtained from Chapter 4 indicate the 
importance of understanding the underlying physiology of the microdialysis process. 
Many researchers use microdialysis without appreciating how pharmacological 
changes affect the amount of analyte that is obtained. For brain studies, it seems 
relevant to proceed with caution when comparing results obtained from control and 
pharmacologically treated animals that obtain tissue concentrations by using in vitro 
calibrations, since tissue dynamics affect the flux to and from a microdialysis probe. 
In the liver, pharmacological studies will be easier to interpret since the 
microvasculature exchange rates dominate other kinetic rates in this tissue. 
Although metabolism did not change the microdialysis flux, metabolites could 
be obtained in the dialysate after a local infusion in the liver. These types of 
experiments provide an alternate route to study metabolism with microdialysis. By 
perfusing the probe with varying concentrations of acetaminophen, it was found in 
Chapter 4 that saturable metabolism could be observed. This was seen as a decrease 
in the total percentage conversion of the parent compound, acetaminophen, into its 
metabolite acetaminophen sulfate. Additional studies with other substrates would be 
necessary to determine the feasibility of using microdialysis sampling as an alternative 
to liver perfusion studies for metabolite determination. 
The results and the modeling presented in this dissertation show that diffusion 
coupled with microdialysis sampling can be affected by the various factors presented 
above. The factors presented are not meant to be the only factors that could affect 
microdialysis sampling. Other non-linear processes such as protein-binding and 
variation of diffusion coefficients through cells will also affect the microdialysis flux. 
However, as was described in Chapter 3, models are made to be as parsimonious as 
possible. Inclusion of every possible interaction that could occur in a microdialysis 
experiment only leads to a model that would be parameter laden. Many of the 
parameters that are used in the model presented here are derived from other sources 
and have not been verified experimentally in vivo. 
Benveniste, H.; Huttemeier, C. Microdialysis-Theory and Application. ProgNeurobiol. 
1990, 35, 195-215. 
Appendix 1. Development of the membrane peimeability equations for 
microdialysis. 
The mathematical relationship used to determine the permeability of the 
microdialysis probe membrane, 
Equation 1, is developed in this 
appendix. When the 
microdialysis probe is used as 
described in this paper, analyte 
diffuses from the surrounding 
fluid, across the probe 
membrane and into the flowing 
perfusion fluid, as shown 
schematically in Figure 1. For 
the mass balance around the 
probe membrane, a membrane 
with inner radius, Rj, and outer 
radius, R0, is immersed in a 
solution containing a fixed 
concentration, C0, of the analyte 
of interest at high flow rate, so that the resistance of the external boundary layer is 
negligible. C'0 and C'j are the concentrations of the analyte in the probe membrane 
at the inner and outer radii due to the partition coefficient, K, in Equation Al-1. 
Because the concentration at the inner radius is dependent on the partition coefficient, 
C'0 can be greater or less than the solution concentration C0. The perfusion fluid 
flows through the probe at a fixed flow rate, Q. At the probe inlet, the analyte 
concentration in the perfusate, C^, and is equal to zero in these experiments. At the 
probe outlet, the analyte concentration is CL. The length of the probe exposed to the 
Q 
i 
L 
C=c0 
\ 1 \ c=cL 
1 
I 2 
r=R0 
i 
Figure 1. Schematic of the steady-state assumption. 
System 1 is the fluid in the probe lumen and system 
2 is the membrane. 
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dialysate fluid is L. 
Analyte mass transport in the probe can be modelled mathematically by 
considering two "systems". System I consists of the flowing fluid within the probe. 
System II consists of the polymeric dialysis membrane that forms the wall of the 
probe. A mass balance around the membrane wall can be described as 
0 = JA\r At - JA\r^rM J = -DmmdC'\dr (A1.1) 
Dividing equation Al by ArAt and taking the limit yields the following equation: 
0 = -(d/drX-D^dC'/drVnrL) (AI,2) 
Assuming no change with small changes in L and that Dmm is constant, Equation Al-
2 may be written as 
0 = - (d/dr) (r (dC 'idr)) (A1-3) 
Integration of Equation A1-3 two times yields 
0 = C' + Cj lnr + C2 (A1.4) 
This equation is subject to the following boundary conditions: at r = R„, C-KC0 (C0 
is the concentration outside of the probe); at r =R„ C-KC L (CL is a function of the 
length and the concentration inside the probe). 
In this case, K, the membrane partition coefficient is defined as 
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K = C'J C0 = C//CL (A1-5> 
By using the above boundary conditions the constants C, and C2 may be obtained and 
are as follows: 
c, = K(CL - (A1*6) 
K(C0 - CL)lnR0 KC (A1.7) 
2 " ]n(R0jRj) 
By using the boundary condition for R„, Equation A4 becomes 
K(C0 - CL). s (A1.8) 
Note that CL will vary with distance along the length of the probe. 
The second system, the dialysate mass balance around a unit surface area, dA, 
on the inside of the probe (dA=27tRidx) can be described as 
(A1.9) 
0=QC\x-QC\x + Xx^JHA 
By using the definition for flux from Equation Al-1, dividing by Ax, and taking 
limits, the mass balance becomes 
(A1.10) 
0 = -Q(dC/dx) + 2%RlDmen{dC'ldf) 
Taking the derivative of Equation Al-8 and substituting into Equation Al-10 yields 
Equation Al-11 upon rearrangement and integration becomes 
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dC _ 2*DmemK (C C ) (A l . l l ) 
dx QMRJRy 0 0 
1 - K D ^ K (A1.12) 
MC0-CL) = PJC + C2t P 
QHRJR,) 
Equation Al-12 is subject to the entrance boundary condition, C=0 at x=0, and 
becomes 
C, 
— = 1 - exp 
C. 
(A1.13) 
QHR0IRi) 
Rearrangement of equation Al-13 gives Equation 1 in the text of Chapter 2. 
Evaluation of this equation at the probe outlet (x=L) relates the external bulk fluid 
concentration , C0, the probe outlet concentration, CL, and the geometry of the probe 
to the unknown permeability, DmemK. The membrane permeability can then be 
determined experimentally by measuring CL at various values of the perfusion flow 
rate, Q. The slope of the linear regression of ln(l-(CL/C0)) vs 1/Q is proportional to 
the membrane permeability. 
Several assumptions have been made in developing this equation: (1) The 
system is at steady state. (2) The analyte concentration just outside the probe (at r = 
R0 ) is equal to the analyte concentration in the bulk external fluid. (3)Analyte 
transport across the probe membrane occurs by Fickian diffusion. (4) There are no 
radial gradients in concentration in the perfusion fluid (i.e., the fluid in the probe is 
well-stirred). The assumption that the system is at steady state (i.e., dCoutle/dt=0) has 
been substantiated by experimental observation within 5 min of operation. 
Assumption 2 is equivalent to assuming that there is no resistance to analyte mass 
transfer outside the probe. This is a reasonable assumption when the probe is 
immersed in a well-stirred liquid, as in these experiments, but may not apply to 
experiments performed in more resistant media such as tissue or agar. Assumption 
3 is valid when hydrostatic and osmotic pressure gradients across the probe membrane 
are minimal, so that no significant convective mass transport occurs. Assumption 4 
is likely the weakest of the four since radial concentration gradients will exist under 
the laminar flow conditions of these experiments. However, this assumption 
simplifies the mathematical modeling considerably. In addition, data presented in 
Chapter 2 suggest that this simple model describes the experimental results well. 
Appendix 2. Development of Simplified Equations to Describe Microdialysis Flux 
A.2.1 Flux From a Cylinder 
This appendix derives the relationships that can be used to gain an approximate 
understanding of the relative 
importance of the resistance from 
the extracellular fluid (ECF) 
space and the membrane to the 
microdialysis flux. These 
equations can then be used with 
varying approximations to 
determine the point at which 
kinetics and diffusion affect the 
microdialysis flux in the ECF 
space, and the combination of 
kinetic and diffusive values that 
allow the membrane to begin to play more of a role in the overall mass-transport 
resistance of a molecule. 
The approach used will first greatly simplify the microdialysis experiment so 
that an analytical solution for the flux away from the probe can be attained. The 
system to which equations will be developed is depicted in Figure 1. The dialysis 
membrane is a cylinder and therefore cylindrical coordinates will be used in the 
development of these equations. Step 1 assumes that the dialysis probe consists of 
a membrane cylinder that delivers a constant amount of material along the axial, z 
position. This would be analogous to a delivery (loss of analyte) experiment in 
microdialysis sampling terminology. This cylinder has an outer radius denoted as r„. 
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Figure 1.Dialysis membrane in a tissue space 
The analyte is assumed to diffuse from the cylinder (probe) with a diffusion 
coefficient, Dt and will react in the tissue space with a rate constant of k. Note that 
k could also be a generation constant, but here only consumption of material will be 
considered. The steady state (dC/dt = 0) equation for this process in cylindrical co-
ordinates is described as 
r dry dr) 
(A2.1) 
kC = 0 V 
Upon expansion of the derivative and multiplication by the square of r, Equation A2.2 
is obtained. 
2d2C A dC _ k , r _ (A2.2) r2—— + r— - — r2C = 0 
dr2 dr Dt 
Equation A2.2 is a form of Bessel's equation that can be found in many standard 
mathematics textbooks as shown in Equation A2.3. [Mickley et al., 1957] 
j & f l + Bx& + Cx'y = 0 ( A 2 J ) 
d x 2 d x 
Determination of the constants in Equation A2.3 leads to the generalized form of the 
solution given in Equation A2.4. 
'Jo 
\ 
—r + c~Kn 
/ \ 
±r 
D ' , 
2 0 > 
(A2.4) 
The specific solution can be determined by using the boundary conditions at the radius 
and infinity: at r = r0, C = Cmax and at r = r , C = 0, where Cmax is the 
concentration of the material that is being released by the probe (cylinder). 
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Argurent for the Bessel function 
The Bessel function I0 
approaches infinity with increasing 
values of r, and K0 approaches 
zero as shown in Figure 2. Using 
the second boundary condition 
forces the value of Cj to be zero. 
C2 is found by using the first 
boundary condition giving the final 
solution shown in Equation A2.5. 
Figure 2. Values for arguments using the Bessel 
functions I0, K0, and K, 
C = C K . max o I D t \ 
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(A2.5) 
The flux is defined as the amount of material removed per unit area and time and is 
described by Fick's law as: 
162 
(A2.6) 
The derivative of Equation A2.5 gives Equation A2.7 knowing that the derivative of 
the Bessel function K0 is the Bessel function -Kp 
The value Bessel functions K0 and Kj for the given values of the argument can be 
found by using tables found in handbooks [Abramowitz and Stegun], by writing a 
FORTRAN program [Press et al., 1986], or by using a common spreadsheet program 
such as Microsoft Excel, Version 4. Once the argument values are obtained the flux 
at the outer radius can be determined. Note that from Figure 2 that the quotient of 
Kj / K0 will approach one as the value of the argument increases, or for the same 
probe radius, for values of increasing rates of consumption or decreasing rates of 
diffusion as would be found with larger molecular weight substances. For these 
instances the flux reduces to the square root of the product of the tissue diffusion 
coefficient and the kinetic rate constant. 
A2.2 Flux from the Membrane with Membrane Diffusion Included 
The next step in the approximation of the factors that will affect the flux away 
from a microdialysis probe is to include the diffusion of substances through the 
membrane. By the inclusion of the membrane in the equations, it can be determined 
at what values of the diffusion coefficient in the tissue and the kinetic rate constants 
the membrane will play a limiting factor. 
(A2.7) 
Equations A2.5 and A2.7 describing the flux from a cylinder will be used and 
incorporated into the flux derivation that includes flux through the membrane. For the 
diffusion through the membrane the mass balance is simply the diffusive flux through 
the membrane as was described in Appendix 1 for the equations used in Chapter 2. 
0 =JA\rAt ~JA\r+XrAt -D 
dC 
m dr 
(A2.8) 
Dividing by ArAt , taking the limit yields: 
0 = U 
dr\ m{ dr ) 
2nrL 
(A2.9) 
The length of the membrane, L, will remain constant and it is assumed that the 
diffusion coefficient also remains constant, i.e. no changes in temperature or viscosity 
across the membrane, allowing Equation A2.9 to be reduced to A2.10. 
0 - ( A 2 ' 1 0 ) 
dr{ dr ) 
Integration two times yields, 
C' = cjnr + c2 (A2.ll) 
where ct and c2 are the constants of integration and C1 is the value of the 
concentration in the membrane. The boundary conditions are as follows: at r = rj9(the 
inner radius) C' = Ci and at r = r „ (the outer radius) ,Jm=Jt. In words, these 
boundary conditions state that at the inner radius of the membrane, the concentration 
will be equal to a constant denoted as Cf. This assumes that the dialysate is flowing 
fast enough to allow for minimal depletion of the substance through the dialysis fiber 
lumen. This could also be a well-stirred assumption that the concentration is constant 
across the fiber. An approximate value of this would be for flow rates greater than 
2 |il/min. The value of the recovery is of course length dependent so an 
approximation would be no more than 10 percent loss from the dialysate fiber lumen. 
From this approximation the value of the C' would only range from say 10 ^M at the 
beginning of the entrance of the dialysate to 9 ^M at the outlet collection side of the 
dialysis probe. This rate of course would be dependent upon the kinetics of the 
tissue and the length of the membrane. Boundary condition 2 (BC 2) is an equality 
of flux equation that indicates that flux at the outer radius is the same as the flux 
through the tissue at that point. BC 2 will be used to couple the membrane equation 
with the tissue equation previously derived. From BC 1 it is clear that 
, r , w
 (A2
'
12) 
c2 = Ct - clmrl 
By using the equation for c2 and the membrane concentration equation, A2.l l , the 
concentration at the membrane outer surface is shown in A2.13. 
Cm = C, + cjf ln ( r . / r , ) ) (A2.13) 
Cm will be substituted for the term Cmax from Equation A2.7. The flux at the 
membrane is described by using Fick's first law shown in Equation A2.8 and by 
taking the derivative of Equation A2.13. 
dC'/drl,,-^-
dC' J W ( J _ , _ €J_ (A2.14) 
For continuity the flux into the tissue must equal the flux leaving the probe 
membrane. Utilizing Equations A2.7, A2.13 and A2.14 allows the determination of 
the constant c,. To clean up the algebra the substitution K is made to hold the Bessel 
functions is suggested as shown in Equation A2.15 
(A2.15) 
• j b ? 
T V . ) 
After setting Equations A2.14 and A2.7 equal to each other and substituting Equation 
A2.7 for Cmax, the constant c, can be found. 
C, = 
-k C, (A2.16) 
1 (DJro + Kin ( r j r ) 
An expression for the concentration in the membrane at any radial point, r, is shown 
in Equation A2.17. 
C' = c , 
WJO + Kin(rjr)j 
In (r/r.) 
(A2.17) 
Now the flux through the membrane at any radial point is found by taking the 
derivative of Equation A2.17 and inserting it into the expression provided by equation 
A2.14. 
J = D. Cj 
[ W - Kln(r„/r()J 
(A2.18) 
Recall that K approaches the value of one at high kinetic rates and low diffusion 
coefficients as would be found for larger molecular weight substances such as the 
neuropeptide substance P. Additionally the geometry of the membrane plays a role 
since for thinner membranes such as cuprophan that has a outer radius, ra, of 222 pm 
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and an inner radius, r ; , of 200 nm the value of the natural logarithm will approach 
unity. 
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Appendix 3. Development of the Far-Field Boundaiy Condition in a Recovery 
Microdialysis Experiment 
The far-field boundary condition is described by the following differential equation: 
This equation states mathematically that the change in the far-field tissue 
concentration, Ce(oo) is related to the initial concentration in the plasma, C0» the local 
tissue concentration, Ce, the plasma elimination rate constant, A, the permeation rate 
constants between the tissue and the plasma compartments, k^, k^, and the local 
metabolism rate, k^. The equation is a linear differential equation and can be solved 
by using integrating factors which is described in most standard textbooks on 
differential equations [Potter, 1978]. By combining the rate constants associated with 
Ce to give a new rate constant ks, the solution can be obtained by the following 
general equation. 
dc; 
= kpeCQe'Xt - (km + k*p) C( (A3.1) dt 
Lpe o e 
The general form of the equation is described as: 
_ . . f k,dt 
F[x) = e} (A3J) 
By using the general solution the specific solution is then found to be: 
c ; ( t ) = I {kpeC0e'Xt) ek,t + C (A3.4) 
Integration of equation 4 yields: 
The constant of integration, C, can be solved for by using the initial condition of 
Coo=0, when t = 0. The final solution that is used in the mathematical model 
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k x r (kB-\) t 
C ; ( t ) = Z E ^ s l + (A3.5) 
becomes: 
C
e
"( t) = 
kpe CD e (-At) 
(k-A) 
kpeCp 
e ^ i k - X ) 
(A3.6) 
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Appendix 4. FORTRAN Code. 
1 c DIALYSIS.FOR 
2 
3 c J u l i e Ann S t e n k e n 
4 
5 c S u b m i t t e d w i t h t h e P h . D . d i s s e r t a t i o n i n p a r t i a l 
6 c r e q u i r e m e n t s o f t h e g r a d u a t e s c h o o l . 
7 
8 c T h i s FORTRAN p r o g r a m c a l c u l a t e s t h e c o n c e n t r a t i o n p r o f i l e 
9 c a n d t h e c o n c e n t r a t i o n o u t f l o w o f a m i c r o d i a l y s i s 
10 c e x p e r i m e n t g i v e n t h e p a r a m e t e r s i n t h e f i l e DATAFILE.DAT. 
11 
12 c The t h e o r e t i c a l d e v e l o p m e n t of t h i s m o d e l i s g i v e n 
13 c i n CHAPTER 3 of t h i s d i s s e r t a t i o n . A d d i t i o n a l i n f o r m a t i o n 
14 c c o n c e r n i n g t h e s t e p s t a k e n t o a c h i e v e a r e s u l t a r e 
15 c a l s o p r e s e n t e d i n C h a p t e r 3 . 
16 
17 
18 c The p r o g r a m c a n b e u s e d f o r t h e two t y p i c a l modes 
19 c o f o p e r a t i o n i n m i c r o d i a l y s i s — r e c o v e r y and d e l i v e r y . 
20 
2 1 c The p r o g r a m r u n s e a s i l y o n a n IBM c o m p a t i b l e c o m p u t e r 
22 c w i t h a 386 m a t h c o - p r o s s e s o r o r g r e a t e r . The l e n g t h o f t i m e 
23 c f o r t h e p r o g r a m t o c o m p l e t e t h e c a l c u l a t i o n s n e c e s s a r y i s 
24 c d e p e n d e n t o n t h e p a r a m e t e r s i n p u t t e d a n d t h e s p e e d o f t h e 
25 c c o m p u t e r , i . e . , a 66 MHz 486 r u n s f a s t e r t h a n a 33 MHz 4 8 6 . 
26 c W i t h t h e 4 8 6 - 6 6 MHz s y s t e m t h e a v e r a g e t i m e t o c o m p l e t i o n 
27 c i s a p p r o x i m a t e l y 3 m i n u t e s . T h i s t i m e t o c o m p l e t i o n i s a l s o 
28 c d e p e n d e n t on t h e t o l e r a n c e s u s e d i n t h e f i n a l c a l c u l a t i o n s . 
29 c The t o l e r a n c e s u s e d f o r e r r o r a r e s e t , b u t c o u l d be 
30 c c h a n g e d i f t h e u s e r o n l y w i s h e s f o r a r o u g h a n s w e r t o 
31 c a p a r t i c u l a r p r o b l e m . The p r o g r a m w o u l d o n l y n e e d t o 
32 c b e r e c o m p i l e d u s i n g a n y FORTRAN c o m p i l e r p r i o r t o u s e w i t h 
33 c t h e new t o l e r a n c e s . 
34 
35 c The p r o g r a m u t i l i z e s t h e f i n i t e d i f f e r e n c e a p p r o a c h t o 
3 6 c s o l v i n g t h e m a s s b a l a n c e e q u a t i o n s . T h i s p r o g r a m d o e s NOT 
37 c u s e a n y l i n k s t o FORTRAN l i b r a r i e s s u c h a s t h e IMSL l i b r a r y . 
38 c T h i s a l l o w s a n y i n d i v i d u a l t o r u n a n d u s e t h i s p r o g r a m a s 
39 c t h e IMSL l i b r a r y i s e x p e n s i v e a n d p r o p r i e t a r y . 
40 
4 1 c The p r o g r a m i s made u p o f t h e f o l l o w i n g s u b - r o u t i n e s 
42 c w h i c h a r e l i n k e d t o g e t h e r a n d s e r v e t h e f u n c t i o n s b r e i f l y 
43 c m e n t i o n e d h e r e , b u t d e s c r i b e d i n more d e t a i l i n t h e c o d e . 
44 
45 C T h e s e s u b r o u t i n e s a r e c a l l e d i n t h e f o l l o w i n g o r d e r . A 
46 c TOP-DOWN d e s i g n i n d i c a t e s w h i c h s u b r o u t i n e s c a l l o t h e r 
4*7 c s u b r o u t i n e s i n t h e c o d e . 
48 C 
49 C 1) I N I T — S u b r o u t i n e I N I T r e a d s t h e f i l e DATAFILE.DAT 
50 c a n d s e t s up a l l t h e i n i t i a l v a l u e s f o r t h e i n p u t s 
51 c n e e d e d f o r t h e p r o g r a m 
52 
53 c 2) BCOND — S u b r o u t i n e BCOND s e t s u p t h e i n i t i a l a r r a y s 
54 c o f c o e f f i c i e n t s n e c e s s a r y f o r t h e s o l v i n g o f 
55 c t h e d i a l y s i s o u t f l o w c o n c e n t r a t i o n and t h e 
56 c c o n c e n t r a t i o n p r o f i l e . 
57 
58 C 3) SOLVE — T h i s s u b r o u t i n e i s s e t s u p t h e a r r a y s 
5 9 c n e e d e d f o r t h e o t h e r s u b r o u t i n e s t o p e r f o r m t h e i r 
60 c j o b o f s o l v i n g t h e m a t r i c i e s w h i c h d e s c r i b e t h e 
61 c o u t f l o w c o n c e n t r a t i o n a n d t h e p r o f i l e away f r o m 
6 2 c t h e p r o b e . SOLVE c a l l s t h e f o l l o w i n g s u b r o u t i n e 
170 
63 c 3A) RAMP — S u b r o u t i n e RAMP i s u s e d a s t h e 
64 c f i n i t e d i f f e r e n c e m e t h o d s a r e s t e p m e t h o d s 
65 c i n t i m e a n d s p a c e . T h i s s u b r o u t i n e g e t s 
66 c v a l u e s i n t o t h e v a r i o u s a r r a y s s o t h a t 
67 c t h e c o m p u t a t i o n i n s o l v e c a n b e more 
68 c s t a b l e . RAMP c a l l s t h r e e o t h e r s u b r o u t i n e s 
69 c THOMEM and THOMECF b e f o r e c a l l i n g DATOUT 
7 0 c i n o r d e r t o o u t p u t t h e d a t a . 
7 1 c 3Ai ) THOMEM — C a l c u l a t e s t h e f l u x t h r o u g h t h e 
72 c d i a l y s i s m e m b r a n e . T h i s r o u t i n e u s e s t h e 
7 3 c THOMAS a l g o r i t h m f o u n d i n b a s i c n u m e r i c a l m e t h o d s 
74 c t e x t b o o k s t o s o l v e t h e t r i - d i a g o n a l m a t r i c e s . T h i s 
75 c r o u t i n e d i f f e r s f r o m THOMECF b e c a u s e t h e n u m b e r o f 
7 6 c e q u a t i o n s n e c e s s a r y t o s o l v e t h e membrane m a t r i c e s 
77 C i s f i x e d t o t h e v a l u e o f 1 0 , w h e r e a s t h e THOMECF 
78 c r o u t i n e u s e s t h e n u m b e r o f e q u a t i o n s c a l c u l a t e d 
79 c t h e b o d y of t h e p r o g r a m . 
80 c 3 A i i ) THOMECF — U s e s t h e same a l g o r i t h m a s a b o v e 
8 1 c e x c e p t t h a t t h e n u m b e r o f e q u a t i o n s i s d e t e r m i n e d 
82 c b y t h e m a i n p r o g r a m a n d t h e r a d i u s away f r o m t h e 
83 c d i a l y s i s m e m b r a n e . 
84 c 3 A i i i ) DATOUT — T h i s s u b r o u t i n e o u t p u t s t h e d a t a 
85 c i n t o ASCII f i l e s w h i c h t h e n c a n b e r e a d i n t o a n y 
86 c s p r e a d s h e e t p r o g r a m f o r f u t h e r d a t a a n a l y s i s o r 
87 c p l o t t i n g . 
88 c 
89 c 3B) THOMEM 
90 C 3C) THOMECF 
91 C 3D) DATOUT 
92 
93 c VARIABLES USED IN THE PROGRAM 
94 
95 c **************+**************+****+***++**+**+** 
96 
97 C ACOEFF (700) MATRIX OF COEFFICIENTS IN THE ECF IN "RAMP" 
98 C BCOEFF(700) " 
99 C CCOEFF(700) " 
100 c CHI (700 ) Same a s EPS e x c e p t u s e d i n SUBROUTINE RAMP 
101 C COEFFA(700) MATRIX OF COEFFICIENTS FOR THE ECF 
102 C COEFFB(700) MATRIX 
103 C COEFFC(700) MATRIX 
104 C CMAX = CONCENTRATION AT A FAR RADIAL POINT USER INPUT 
105 C DELCON = CONCENTRATION OF THE DIALYSATE 
106 C DDIAL = DIFFUSION COEFFICIENT IN THE DIALYSATE (cm A 2 /min ) 
107 C DECF = DIFFUSION COEFFICIENT IN ECF (CMA2/MIN) 
108 C DELT = D e l t a o f t i m e (min) 
109 C DELR = DELTA OF RADIAL DISTANCE (cm) 
110 C DMEM = DIFFUSION COEFFICIENT IN THE MEMBRANE (CMA2/MIN) 
111 C ECFLAM(700) = MODEL DIFFUSION COEFFICIENT USED IN SUBROUTINE 
112 C RAMP . . . D I F F E R E N T TIME DEPENDENCE 
113 C E C F T ( 7 0 0 ) = MATRIX OF NUMR VALUES AT TIME T 
114 C ECFTP1(700)=MATRIX OF NEW VALUES AT T PLUS 1 
115 C EPS ( 7 0 0 ) = A VALUE FOR THE COEFFICIENT OF C ( i , j + 1 ) 
116 C FLUXRI = FLUX IN THE MEMBRANE AT INNER SURFACE 
117 C GAMMA = APPROXIMATE DISTANCE OF THE CONCENTRATION PROFILE 
118 c AT HALF THE CONCENTRATION MAXIMUM. 
119 c See M o r r i s o n e t a l . Q u a n t i t a t i v e M i c r o d i a l y s i s . 
120 c TE R o b i n s o n a n d JB J u s t i c e J r e d s . i n 
121 c M i c r o d i a l y s i s i n t h e N e u r o s c i e n c e s 
122 C GICF = PRODUCTION (GENERATION) RATE IN THE I C F (min - 1 ) 
123 C GECF = GENERATION RATE IN THE ECF 
124 C LAMMEM = MODEL DIFFUSION COEFFICIENT IN THE MEMBRANE 
125 C LAMECF(700) = MODEL DIFFUSION COEFFICIENT (DECF*DELT/DELR*2 
126 C IN THE ECF 
127 C MEMLAM = MODEL DIFFUSION COEFFICIENT IN THE MEMBRANE 
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128 C DURING "RAMP" 
129 C PHI = VOLUME FRACTION OF SPACE IN THE ECF 
130 C PHIM = VOLUME FRACTION OF SPACE IN THE MEMBRANE 
131 C QDIAL = DIALYSIS FLOW RATE mL/MIN 
132 C m a x = USER INPUT OF MAX DISTANCE (Cm) 7*GAMMA 
133 C RIN = INNER RADIUS OF MEMBRANE (CM) 
134 C ROUT = OUTER RADIUS OF MEMBRANE (CM) 
135 C RMETAB = METABOLIC RATE IN ECF (min - 1 ) 
136 C RICF = METABOLIC RATE IN THE I C F (min - 1 ) 
137 c TAU = DELTA T / 1 0 . 0 USED IN SUBROUTINE 'RAMP' 
138 C VOLICF = VOLUME FRACTION IN THE ICF ( 1 - P H I ) 
139 C XKPI = PARTITION COEFFICIENT BETWEEN ICF AND ECF 
140 C XKPLEC = EXCHANGE RATE BETWEEN PLASMA TO ECF 
141 C XKECPL = EXCHANGE RATE BETWEEN ECF AND PLASMA 
142 C XLEN = LENGTH OF DIALYSIS FIBER IN CM 
143 
144 c * * 
145 
146 c B e g i n P r o g r a m 
147 
148 REAL C O E F F A ( 7 0 0 ) , C O E F F B ( 7 0 0 ) , C O E F F C ( 7 0 0 ) , E C F T ( 7 0 0 ) ,ACOEFF(700) , 
149 & BCOEFF(700) ,CCOEFF(700) ,LAMECF(700) , E C F L A M ( 7 0 0 ) , E P S ( 7 0 0 ) , 
150 & CHI ( 7 0 0 ) , DELR ( 7 0 0 ) , RMAX,DELT,DECF, TIME, DMEM,XKPLEC,XKECPL, 
1 5 1 & CMAX, RMETAB, SUMKS,LAMMEM, TAU,MEMLAM, QDIAL,XLEN, DDIAL 
152 
153 INTEGER NUMR,NUMT 
154 
155 c DATAFILE.DAT i s a f i l e w h i c h c o n t a i n s t h e n e c e s s a r y 
156 c m i c r o d i a l y s i s p a r a m e t e r s s u c h a s d i f f u s i o n ' c o e f f i c i e n t s , 
157 c r a t e c o n s t a n t s e t c . 
158 
159 c A l l *.ASC f i l e s m u s t b e d e l e t e d p r i o r t o t h e s t a r t 
160 c o f t h e p r o g r a m — o t h e r w i s e t h e p r o g r a m w i l l n o t 
1 6 1 c r u n a s t h e f i l e s c a n n o t b e o p e n e d a n d w r i t t e n o v e r . 
162 
1 6 3 
164 c CON PROF. ASC i s a c r e a t e d f i l e o f t h e c o n c e n t r a t i o n p r o f i l e 
165 c a w a y f r o m t h e d i a l y s i s p r o b e . 
166 c PLASMA.ASC i s a f i l e t h a t o u t p u t s w h a t t h e p l a s m a 
167 c c o n c e n t r a t i o n i s a s a f u n c t i o n o f t i m e . . i t c a n b e d e l e t e d 
168 c i f n e c e s s a r y . 
169 c OUTPUT.ASC i s t h e c o n c e n t r a t i o n o f t h e d i a l y s i s p e r f u s i o n 
170 c f l u i d a s a f u n c t i o n o f t i m e . 
1 7 1 
172 O P E N ( U N I T - 1 5 , F I L E - ' D A T A F I L E . D A T ' , S T A T U S - ' O L D ' ) 
1 7 3 OPEN (UNIT=60, F I L E - ' CONPROF. A S C ' , STATUS-'NEW') 
174 OPEN(UNIT-62 ,F ILE- 'PLASMA.ASC ' ,STATUS- 'NEW' ) 
1 7 5 OPEN(UNIT—65,FILE- 'OUTPUT.ASC' ,STATUS-"NEW') 
1 7 6 
1 7 7 
178 C THE PROGRAM FIRST I N I T I A L I Z E S THE PARAMETERS AMD READS 
1 7 9 C PARAMETERS FROM THE F I L E ' DATAFILE ..DAT' 
180 
1 8 1 CALL I N I T (LAMECF,ECFLAM,EPS, C H I , DELR, RIN, DELT, DECF, DMEM, 
1 8 2 & MEMLAM, TIME,RMAX,XKPLEC, XKECPL, RMET2SB,CMAX, LftMMEM, TAU, 
1 8 3 & ROUT, SUMKS, QDIAL, XLEN, DDIAL, EtMULT, RUNIT> G1CF, GBCF, NUMR, NUMT) 
184 C 
1 8 5 C The n e x t c a l l g o e s t o s u b r o u t i n e b c o n d Which w i l l s e t u p 
1 8 6 c t h e a r r a y f o r t h e b o u n d a r y c o n d i t i o n s . T h i s 
187 c a l s o i n c l u d e s t h e c o e f f i c i e n t s n e c e s s a r y t o s o l v e 
188 c t h e m a t r i x i m p l i c i t l y . 
1 8 9 
190 CALL BCOND (COEFFA, COEFFB, COEFFC, ACOEFF, BCOEFF, CCOEFF, 
1 9 1 & ECFT, LAMECF, ECFLAM, EPS, CHI, MEMLAM, LAMMEM, RMUMVNUMR) 
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193 C The n e x t c a l l g o e s t o s e t u p t h e m a t r i x f o r t h e Thomas 
194 c a l g o r i t h m . T h i s s o l v e s t h e m a t r i x a t e a c h t i m e s t e p . 
195 c T h i s r o u t i n e i n c l u d e s t h e c a l l t o t h e o u t p u t a l s o . 
196 
197 CALL SOLVE (ECFT, COEFFA, COEFFB, COEFFC, ACOEFF, BCOEFF, CCOEFF, 
198 & DELR, DELT, CMAX, SUMKS, ROUT, RIN,DMEM,DECF,QDIAL,XLEN,DDIAL, 
199 & TAU, XKPLEC, RUNIT, GICF, GECF, NUMR, NUMT) 
200 
2 0 1 CLOSE(UNIT=15,STATUS='KEEP') 
202 CLOSE(UNIT=60,STATUS=*KEEP') 
203 CLOSE(UNIT=62,STATUS='KEEP') 
204 CLOSE(UNIT=65,STATUS='KEEP') 
205 
206 p r i n t * , ' d o n e ' 
207 END 
208 
209 SUBROUTINE INIT (LAMECF, ECFLAM, EPS, CHI, DELR, RIN, DELT, DECF, DMEM, 
210 & MEMLAM, TIME, RMAX, XKPLEC, XKECPL, RMETAB, CMAX, LAMMEM, TAU, 
2 1 1 & ROUT, SUMKS, QDIAL, XLEN, DDIAL, RMULT, RUNIT, GICF, GECF,NUMR, NUMT) 
212 
2 1 3 REAL LAMECF (7 00) , ECFLAM ( 7 0 0 ) , EPS ( 7 0 0 ) , CHI (700) , DELR ( 7 0 0 ) , DELT, 
214 & DECF, TIME, RMAX, STEP, TMSTEP, RMETAB, XKPLEC, XKECPL, TAU, MEMLAM, 
2 1 5 & LAMMEM 
216 
217 INTEGER NUMR,NUMT 
218 
2ig c ************************************************** 
220 C PARAMETERS INTERNAL TO I N I T 
221 C ++++++++++++++++++++++++++++++++++++++++++++++++++ 
222 C RUNIT = SMALLEST POSSIBLE d e l t a r 
223 C RMULT = A NUMBER TO SET THE COEFFICIENTS CORRECTLY AS 
224 C RIN. NE. 0 . 0 . . .THEREFORE NEED TO SET SPACE 
225 C DIMENSION CORRECTLY 
226 C SUMKS = THE SUM OF ALL THE RATE CONSTANTS 
227 C STEP = SIZE OF d e l t a r 
228 C NSTEP = NUMBER OF POINTS IN THE MEMBRANE 
229 C SUMRAD = SUM OF THE RADIAL STEPS TO REACH RMAX (-COUNTER) 
230 c VOLICF = I S THE VOLUME IN THE ICF SPACE. 
231 C SMULT = THE EXPONENTIAL MULTIPLIER FOR THE SPACE STEP 
232 C * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * 
233 
234 c ****************************************** 
235 c 3 - 1 4 - 9 4 I n c l u d e d t h e v a r i a b l e s p a c e s t e p s i z e f r o m 
236 c F e l d b e r g , J . E l e c t r o a n a l . Chem . 1 2 7 ( 1 9 8 1 ) 1 - 1 0 . 
237 c d e l x = d e l x * e x p [ b e t a * ( i - 1 ) ] b e t a .LE . 0 . 5 
238 c The v a r i a b l e s t e p s i z e w i l l o n l y b e i n c l u d e d i n t h e 
239 c ECF 
240 C * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * 
241 
242 C P u r p o s e a n d f u n c t i o n o f s u b r o u t i n e INIT 
243 c 
244 c T h i s s u b r o u t i n e i n i t i a l i z e s a l l o f t h e v a l u e s t h a t 
245 c w i l l b e u s e d i n t h e p r o g r a m . I t a l s o s e t s u p t h e d e l t a r v a l u e s 
246 c a n d t h e d e l t a t v a l u e s u s e d i n t h e p r o g r a m . T h e r e a r e t w o 
247 c d i f f e r e n t v a l u e s t h a t a r e u s e d f o r d e l t a t . The f i r s t i s TAU 
248 c w h i c h i s u s e d f o r SUBROUTINE RAMP. TAU - DELT/10. 
249 c T h e n t h e p r o g r a m s e t s u p t h e v a r i a b l e s f o r t h e 
250 c m o d e l d i f f u s i o n c o e f f i c i e n t s t h a t i n c l u d e fit a n d fir d e p e n d e n c e 
251 c a n d t h e r e f o r e n e e d t o b e s t o r e d i n t h e a r r a y s LAMECF a n d 
252 c ECFLAM. 
253 c 
254 c +++++++++++++++++++++++++++++++++++++++++++++++++++++++++ 
255 
256 C Decf i s i n c m A 2 / s e c . I t w i l l n e e d t o b e c o n v e r t e d t o 
257 c CM A 2/min 
258 10 
259 
260 
261 
262 C 
263 
264 
265 
266 
267 
268 
269 
270 
271 
272 
273 c 
274 c 
275 
276 
277 
278 
279 
280 
281 
282 
283 
284 
285 
286 
287 
288 c 
289 c 
290 
291 
292 
293 
294 
295 
296 C 
297 c 
298 c 
299 c 
300 
301 
302 
303 
304 
305 
306 
307 
308 
309 
310 
311 
312 
313 
314 
315 
316 
317 
318 
319 
320 
321 
322 
173 
FORMAT(ElO.4) 
READ(15,10)ROUT 
R E A D ( 1 5 , 1 0 ) R I N 
The s m a l l e s t r a d i a l u n i t (RUNIT) i s d e f i n e d a s b e l o w : 
RUNIT=(ROUT-RIN)/10 
RMULT = RIN/RUNIT 
READ(15,10)DDIAL 
READ(15,10)DMEM 
READ(15,10)DECF 
R E A D ( 1 5 , 1 0 ) P H I 
READ(15,10)PHIM 
VOLICF = 1 . 0 - P H I 
C o r r e c t f o r t h e d i f f u s i o n c o e f f i c i e n t i n t e r m s o f m i n u t e s a n d 
i n t e r m s o f v o l u m e f r a c t i o n , 
DDIAL = DDIAL*60.0 
DECF = (DECF* 6 0 . 0 ) * PHI 
DMEM = PHIM*(DMEM*60.0) 
READ(15,10)RMETAB 
R E A D ( 1 5 , 1 0 ) R I C F 
READ(15,10)XKPLEC 
READ(15,10)XKECPL 
R E A D ( 1 5 , 1 0 ) G I C F 
READ(15,10)GECF 
READ(15 ,10)XKPI 
C h a n g e a l l t h e r a t e s t o r e f l e c t t h e d e p e n d e n c e on t h e ECF 
v o l u m e f r a c t i o n 
RMETAB = RMETAB*PHI 
XKPLEC = XKPLEC*PHI 
XKECPL = XKECPL*PHI 
R I C F = RICF*XKPI*VOLICF 
N o t e t h a t t h e g e n e r a t i o n t e r m s a r e c o n c e n t r a t i o n d e p e n d e n t . . . i f 
t h e s u b s t a n c e b e i n g m o d e l e d h a s z e r o o r d e r g e n e r a t i o n t h i s 
w i l l n e e d t o b e i n c l u d e d i n t h e m a t r i x f o r t h e Thomas 
a l g o r i t h m , . a s i s t h e c a s e f o r t h e p l a s m a t o ECF t e r m XKPLEC 
GECF = GECF*PHI 
GICF = GICF*VOLICF 
SUMKS= (XKECPL+RMETAB+RICF) 
RMAX = 0 . 5 
STEP=(RMAX-RIN)/RUNIT 
NSTEP = INT (STEP) + 1 
READ(15 ,10)TIME 
READ(15,10)TMSTEP 
DELT=TIME/TMSTEP 
TAU = D E L T / 1 0 . 0 
LAMMEM=(DMEM*DELT)/(RUNIT**2.0) 
MEMLAM=(DMEM*TAU)/(RUNIT**2.00) 
NUMT = INT (TIME/DELT)+1 
READ (15,10)CMAX 
READ (15 ,10 )XLEN 
R E A D ( 1 5 , 1 0 ) QDIAL 
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323 C 
324 
325 
326 
327 c 
328 c 
329 c 
330 c 
3 3 1 
332 
333 
334 c 
335 C 
336 c 
337 c 
338 c 
339 c 
340 c 
341 
342 
343 
344 
345 
346 
347 
348 
349 
350 
351 
352 15 
353 2 
354 
355 
356 1 6 3 
357 
358 
359 
360 
361 
362 
363 
364 
365 
366 
367 
368 
369 C 
370 c 
371 c 
372 c 
373 c 
374 c 
375 c 
376 C 
377 
378 
379 
380 10 
381 
382 C 
383 
384 c 
385 c 
386 
387 
C h a n g e QDIAL f r o m u l / m i n t o cmA3 
QDIAL=QDIAL/1000 .0 
SUMRAD = RIN+(10*RUNIT) 
SMULT i s t h e m u l t i p l i e r f o r t h e e x p o n e n t i a l s p a c e s t e p . 0 . 0 0 5 
was d e t e r m i n e d ' e x p e r i m e n t a l l y ' t o b e t h e b e s t w i t h o u t 
s a c r i f i c i n g d i s k s p a c e a n d c o m p u t a t i o n a l t i m e a s w e l l a s FLDX 
d e t e r m i n a t i o n e r r o r s . 
SMULT = 0 . 0 0 5 
The f o l l o w i n g l o o p i s n e c e s s a r y f o r t h e c o r r e c t ' m o d e l ' 
d i f f u s i o n c o e f f i c i e n t t o b e c a l c u l a t e d . T h i s c o e f f i c i e n t 
i s b a s e d u p o n t h e l e n g t h o f d e l t a r a n d h e n c e m u s t b e s t o r e d 
i n a n a r r a y t h a t k e e p s t h i s . When t h e RMAX h a s b e e n p a s s e d 
t h e n t h e LOGICAL I F s t a t e m e n t c a u s e s a jump o u t o f t h e l o o p . 
DO 15 1 = 1 1 , N S T E P 
D E L R ( I ) = R U N I T * E X P ( s m u l t * ( 1 - 1 1 ) ) 
L A M E C F ( 1 + 1 ) = ( D E C F * D E L T ) / ( D E L R ( I ) * * 2 . 0 0 ) 
E C F L A M ( I + 1 ) = ( D E C F * T A U ) / ( D E L R ( I ) * * 2 . 0 0 ) 
EPS (1+1) = - 1 . 0 - ( 2 . 0*LAMECF(1+1)) - (DELT* (SUMKS)) 
CHI (1+1) = - 1 . 0 - (2 .0*ECFLAM(I+1) ) - (TAU* (SUMKS) ) 
SUMRAD= SUMRAD+DELR(I) 
IF(SUMRAD.GE.RMAX) THEN 
GOTO 2 
ENDIF 
CONTINUE 
NUMR=I+1 
WRITE(60,163)NUMR 
FORMAT(IX, 'THE NUMBER OF STEPS = ' , I 4 ) 
RETURN 
END 
SUBROUTINE BCOND (COEFFA, COEFFB, COEFFC, ACOEFF, BCOEFF, CCOEFF, 
& ECFT, LAMECF, ECFLAM, EPS, CHI, MEMLAM, LAMMEM, RMULT, NUMR) 
REAL COEFFA ( 7 0 0 ) , COEFFB ( 7 0 0 ) , COEFFC ( 7 0 0 ) , ACOEFF(700) , 
& BCOEFF ( 7 0 0 ) , CCOEFF (700) , ECFT ( 7 0 0 ) , LAMECF ( 7 0 0 ) , 
& EPS ( 7 0 0 ) , CHI ( 7 0 0 ) ,ECFLAM(700) ,MEMLAM,LAMMEM 
INTEGER NUMR 
T h e p u r p o s e o f BCOND i s t o s e t u p t h e i n i t i a l a n d 
b o u n d a r y c o n d i t i o n s . I t s e t s u p a l l t h e c o e f f i c i e n t s 
f o r t h e s u b r o u t i n e SOLVE a n d RAMP. 
+++++++++++++++++++++++++++++++++++++++++-H++++++++++ 
S e t t h e i n i t i a l t i m e c o n d i t i o n s 
DO 10 J = l , NUMR 
E C F T ( J ) = 0 . 0 0 
CONTINUE 
SET UP THE COEFFICIENT MATRIX 
C O E F F ( l l ) i s t h e m e m b r a n e / E C F p o i n t a n d t h e 1 , - 1 a c c o u n t f o r 
t h e e q u a l i t y o f f l u x . 
COEFFB(11) = 1 . 0 
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388 BCOEFF(11) = COEFFB( l l ) 
389 COEFFA(11) = - 1 . 0 
390 ACOEFF (11) = COEFFA(l l ) 
391 
392 c P o i n t s n u m b e r 2 - 1 0 a r e a l l i n t h e membrane 
393 
394 DO 15 1 = 2 , 1 0 
395 ACOEFF(I)=MEMLAM-(MEMLAM/(2.0*(RMULT+(I-1) ) ) ) 
396 B C O E F F ( I ) = - 1 * ( 1 . 0 + (2.0*MEMLAM)) 
397 CCOEFF(I)=MEMLAM+(MEMLAM/(2.0*(RMULT+(I-1) ) ) ) 
398 COEFFA(I)=LAMMEM-(LAMMEM/(2.0*(RMULT+(1-1) ) ) ) 
399 C O E F F B ( I ) = - 1 * ( 1 . 0 + (2.0*LAMMEM)) 
400 COEFFC(I)=LAMMEM+(LAMMEM/(2.0*(RMULT+(1-1) ) ) ) 
401 15 CONTINUE 
402 
403 c P o i n t s 12 o n a r e a l l i n t h e ECF 
404 
405 DO 20 1=12,NUMR-1 
406 A C O E F F ( I ) = E C F L A M ( I ) - ( E C F L A M ( I ) / ( 2 . 0 * ( R M U L T + ( 1 - 1 ) ) ) ) 
407 B C O E F F ( I ) = C H I ( I ) 
408 C C O E F F ( I ) = ECFLAM(I) + ( E C F L A M ( I ) / ( 2 . 0 * ( R M U L T + ( 1 - 1 ) ) ) ) 
409 C O E F F A ( I ) = L A M E C F ( I ) - ( L A M E C F ( I ) / ( 2 . 0 * ( R M U L T + ( 1 - 1 ) ) ) ) 
410 C O E F F B ( I ) = E P S ( I ) 
411 C O E F F C ( I ) = LAMECF(I) + (LAMECF(I) / (2 . 0 * ( R M U L T + ( 1 - 1 ) ) ) ) 
412 20 CONTINUE 
413 
414 RETURN 
415 END 
416 
417 
418 SUBROUTINE SOLVE(ECFT, COEFFA,COEFFB, COEFFC, ACOEFF,BCOEFF,CCOEFF, 
419 & DELR,DELT,CMAX,SUMKS,ROUT,RIN,DMEM,DECF,QDIAL,XLEN,DDIAL, 
420 & TAU, XKPLEC, RUNIT, GICF, GECF, NUMR, NUMT) 
421 
422 REAL ECFT ( 7 0 0 ) , ECFTP1 ( 7 0 0 ) , COEFFA (700) ,COEFFB ( 7 0 0 ) , 
423 & C O E F F C ( 7 0 0 ) , A C O E F F ( 7 0 0 ) , B C O E F F ( 7 0 0 ) , C C O E F F ( 7 0 0 ) , 
424 & VALUE(700) ,DELR(700) ,DELT,CMAX,RIN,XKPLEC,sumks,TAU 
425 
426 INTEGER NUMR,NUMT,IPROG 
427 
428 c T h e f i l e 'ECFCON.DAT' i s n e c e s s a r y f o r t h e a u x i l i a r y 
429 c p r o g r a m s 'DEADDIAL.FOR' a n d "METAB.FOR% 
430 
431 OPEN(UNIT=85,FILE='ECFCON.DAT' , STATUS=1 NEW') 
432 
433 
434 c ***************************************************** 
435 C PARAMETERS INTERNAL TO SOLVE 
436 C 
437 C PERCEN = A GUESS OF WHAT THE PERCENTAGE OF THE FAR-FIELD 
438 C ECF VALUE WILL EQUAL THE OUTLET DIALYSATE CONC. 
439 C ARGUM = A VALUE THAT CHECKS THE PERCENTAGE OF DIFFERENCE 
440 C BETWEEN THE FLUX IN THE ECF TO THE MEMBRANE AND 
441 C THE FLUX IN THE MEMBRANE. 
442 C ADUM = A HOLDING VARIABLE TO CALCULATE CINFIN 
443 C CINFIN = CONCENTRATION VALUE AT THE FAR-FIELD ECF 
444 C PCNNEW = AN UPDATED VALUE OF PERCEN WHICH REFLECTS WHAT 
445 C THE CONCENTRATION OF THE DIALYSATE SHOULS BE. 
44 6 C VALUE = AN ARRAY THAT HOLDS THE VALUES NECESSARY FOR 
447 C THE THOMAS COMPUTATION 
448 
449 
450 c F o r e a c h t i m e i n c r e m e n t , a new m a t r i x of v a l u e s w i l l h a v e t o 
451 c b e c a l c u l a t e d . Once t h a t m a t r i x i s s e t u p t h e n t h e p r o g r a m 
452 C i s r e a d y t o c a l l t h e Thomas a l g o r i t h m . 
453 c 
454 C 
455 c 
456 
457 c 
458 c 
459 c 
460 c 
461 
462 
463 
464 
465 
466 C 
467 c 
468 c 
469 
470 c 
471 c 
472 
473 
474 c 
475 c 
476 c 
477 c 
478 c 
479 c 
480 c 
481 c 
4 82 
483 
484 C 
485 c 
486 c 
487 
488 
489 
4 90 
491 
492 
493 
494 
4 95 
496 
497 
498 
499 
500 c 
501 c 
502 c 
503 
504 
505 
506 
507 368 
508 
509 
510 
511 
512 
513 
514 
515 
516 367 
517 
S t a r t t i m e l o o p 
A p e r c e n t a g e o f t h e f a r - f i e l d c o n c e n t r a t i o n i s 
e n t e r e d t o g e t t h e p r o g r a m r o l l i n g . 
a********************************************************* 
F o r t h e d e l i v e r y c a s e w i l l u s e a p e r c e n t a g e l o s s a n d 
c o m p a r e i t w i t h t h e v a r i o u s f l u x v a l u e s . 
READ(15 ,*)CPERF 
READ(15,*)XLAM 
A s e t o f i n t e g e r f l a g s c a l l e d i p r o g t o d e t e r m i n e 
i n i t i a l l y i f t h e p r o g r a m n e e d s t o b e i n r e c o v e r y o r 
d e l i v e r y m o d e . 
IPROG = 1 d e n o t e s a r e c o v e r y e x p e r i m e n t 
IPROG = 2 d e n o t e s a d e l i v e r y e x p e r i m e n t 
The s u r o u t i n e r amp i s n e e d e d t o j u s t g e t v a l u e s i n t o t h e 
a r r a y s s o t h a t t h e r e i s n o l a g i n t h e c u r v e d u e 
t o t h e t i m e s t e p j u m p . RAMP r e d u c e s t h e t i m e s t e p 
t o a l l e v i a t e t h i s l a g p r o b l e m . T h i s was a r a t h e r 
s e v e r e p r o b l e m i n t h e f a r - f i e l d c o n c e n t r a t i o n p r o f i l e . 
. . . B u t d i d n o t seem t o a f f e c t t h e d i a l y s i s 
c o n c e n t r a t i o n . I n o r d e r t o make t h e p r o g r a m m o r e 
c o m p l e t e t h i s s u b - r o u t i n e was i n c l u d e d . 
PERCEN i s e i t h e r t h e p e r c e n t a g e l o s t o r t h e p e r c e n t a g e 
g a i n e d o f t h e f a r - f i e l d v a l u e C I N F . . U S E 1 . 0 % ( 9 - 1 5 - 9 4 ) . 
F o r m o s t a p p l i c a t i o n s t h i s w o r k s w e l l . 
PERCEN = 0 . 0 0 1 
CALL RAMP (ECFT, ACOEFF, BCOEFF, CCOEFF, DELR, CMAX, PERCEN, 
& RUNIT, SUMKS, ROUT, RIN, DMEM, DECF, QDIAL, XLEN, DDIAL, TAD, XKPLEC, 
& GICF,GECF,CPERF,XLAM,NUMR) 
ARGUM = 0 . 0 
DO 4 0 1=3,NUMT 
S i n c e t h e BC a t t h e w a l l w i l l b e z e r o , t h e n t h i s m o v e s 
t h e i n d e x i n g b a c k o n e . 
XLAM i n c l u d e s t h e d e c a y i n t h e b l o o d . 
CPLAS = CMAX*EXP(-XLAM*(REAL(i- l)*DELT)) 
TIME = REAL(1-1)*DELT 
WRITE(62 ,368 )TIME,CPLAS 
FORMAT ( IX , F 1 0 . 6 , 3X, F 1 0 . 6) 
DENDUM = SUMKS-XLAM 
ADUM=((CPLAS*XKPLEC+GICF+GECF)/DENDUM) 
BDUM = (XKPLEC*CMAX)/DENDUM 
CINFIN=ADUM-(BDUM*EXP(-SUMKS*DELT*REAL(i-l) ) ) 
CPLAS = CMAX*EXP(-XLAM*(REAL(i- l )*DELT)) 
W R I T E ( 6 0 , 3 6 7 ) C P L A S , c i n f i n 
FORMAT ( l x , F12 . 5 , 2 x , f l 2 . 5 ) 
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544 c 
545 C 
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549 c 
550 
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554 C 
555 c 
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557 c 
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565 
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578 
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580 
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I F (CPERF.GT.CINFIN) THEN 
IPROG = 2 
ELSE 
IPROG = 1 
ENDIF 
5 - 9 - 9 4 HAD PROBLEMS WITH DIVIDE BY ZERO ERROR CHANGED THIS 
TO A LOGICAL STATEMENT TO ALLEVIATE THE PROBLEM WITH 
A REAL DELIVERY 
ADDER = 1 . 0 E - 4 
PCNNEW = PERCEN 
C a l c u l a t e t h e a p p r o x . v a l u e f o r DELCON ( 0 . 0 5 * c i n f i n ) 
IARG = 1 
f o r m a t ( lx , 'DCNEW = \ f l 0 . 6 ) 
I F ( IPROG.EQ.1) THEN 
AMTGN = PCNNEW*CINFIN 
DCNEW = AMTGN + CPERF 
ELSE 
AMTLST = CPERF*PCNNEW 
DCNEW = CPERF-AMTLST 
ENDIF 
S e t u p g u e s s t o d e t e r m i n e t h e f l u x a t t h e i n n e r membrane 
s u r f a c e . S e e 3 - 5 - 9 4 d e v e l o p m e n t . 
Use c o n t i n u i t y e q u a t i o n t o o b t a i n g u e s s 
DELCON = DCNEW-CPERF 
FLUXRI = (DELCON*QDIAL) / ( 2 . 0 * 3 . 1 4 * R I N * X L E N ) 
d d i a l i n c l u d e s c o r r e c t i o n f o r f l o w ( 3 5 / 1 3 ) 
CMEMRI = ( ( F L U X R I * R I N ) / < ( 3 5 . 0 / 1 3 . 0 ) * D D I A L ) ) + D C N E W 
N o t e VALUE o n l y g o e s t o 10 b e c a u s e t h e BC i s 
i n c l u d e d . 
S t a r t w i t h s e t t i n g u p t h e v a l u e s t o b e s o l v e d f o r 
i n t h e m a t r i x f o r t h e m e m b r a n e . 
ECFT(1) = CMEMRI 
VALUE (1) =-ECFT (2) -COEFFA (2 ) * CMEMRI 
VALUE ( 1 0 ) = (FLUXRI* (RIN/ROUT) *RUNIT)/DMEM 
DO 4 5 K = 2 , 9 
VALUE(K)=-ECFT(K) 
CONTINUE 
C a l l THOMAS c a l l s t h e s u b r o u t i n e THOMAS t o s o l v e t h e 
m a t r i x of c o n c e n t r a t i o n s a t e a c h p o i n t . 
CALL THOMEM (ECFTP1, COEFFA, COEFFB, COEFFC, VALUE) 
F i n i s h t h e r e s t o f t h e ECF w h i c h i n c l u d e s t h e v a r i a b l e 
t i m e s t e p . V a l u e ( 1 2 ) i s t h e f i r s t p o i n t i n t h e 
ECF. V a l u e ( n u m r - 1 ) a n d V a l u e ( 1 2 ) i n c l u d e t h e b o u n d a r y 
c o n d i t i o n s . 
N o t e VALUE o n l y g o e s t o NUMR-1 b e c a u s e t h e BC i s 
i n c l u d e d . 
VALUE (NUMR-1) =-ECFT (NUMR-1) - (XKPLEC* CPLAS * DELT) 
& -COEFFC(NUMR-1)*CINFIN 
VALUE (12) = -ECFT ( 1 2 ) - (XKPLEC*CPLAS*DELT) 
& - ( (GICF+GECF) *DELT) - E C F T P 1 (10) *COEFFA(12) 
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DO 50 J=13,NUMR-2 
VALUE(J)=-ECFT ( J ) -(XKPLEC*CPLAS*DELT)-((GICF+GECF)*DELT) 
CONTINUE 
ITHOM = 12 
NUMEQ = NUMR-ITHOM 
C a l l THOMAS c a l l s t h e s u b r o u t i n e THOMAS t o s o l v e t h e 
m a t r i x o f c o n c e n t r a t i o n s a t e a c h p o i n t . 
CALL THOECF(ECFTPl, COEFFA, COEFFB, COEFFC, VALUE, NUMEQ, ITHOM, NUMR) 
Now c h e c k t h e d i f f e r e n c e i n t h e FLUXrout a n d FLUX e c f a n d 
s e t an i n i t i a l t o l e r a n c e o f 0 . 1 f o r t h e a b s o l u t e v a l u e 
o f t h e d i f f e r e n c e b e t w e e n t h e s e f l u x v a l u e s . , Onae t h e 
t h e i n i t i a l t o l e r a n c e o f 1 0 p e r c e n t i s e n c o u n t e r e d 
t h e n t h e p r o g r a m c h a n g e s t o s l o w l y i n c r e m e n t t h e v a l u e s 
i n t h e d i a l y s a t e so t h a t a t o l e r a n c e o f 1 p e r c e n t may be 
o b t a i n e d . 
FLUXEC = ( ( E C F T P 1 ( 1 2 ) - E C F T P 1 ( 1 0 ) ) / R U N I T ) * D E C F 
FLUXRO = FLUXRI*(RIN/ROUT) 
DIFFLX = ABS(FLUXEC-FLUXRO) 
ARGUM = ABS (DIFFLX/FLUXRO) 
TOLER1 = 0 . 0 0 5 
TOLER2 = 0 . 0 1 
I F ( I A R G . E Q . 7 0 0 0 ) THEN 
GOTO 38 
ENDIF 
The f o l l o w i n g s e t s o f IF-THEN-ELSE s t a t e m e n t s a r e d e s i g n e d 
t o s a v e a l i t t l e c o m p u t a t i o n a l t i m e . Once t h e s e t t o l e r a n c e 
o f 10% i s r e a c h e d t h e p r o g r a m s h i f t s t o a new s e t o f IF-THEN-
ELSE s t a t e m e n t s t o g e t t h e t o l e r a n c e down t o 1%. A p r o b l e m 
was e n c o u n t e r e d when t h e " t r u e " a n s w e r was p a s s e d a n d t h e 
c o n c e n t r a t i o n r e a l l y n e e d e d t o b e l o w e r e d . T h i s w a s o b s e r v e d 
by n o t i c i n g t h e i n c r e a s e i n t h e d i f f e r e n c e s b e t w e e n t h e o l d 
a r g u m e n t s . 
I F (ARGUM.GT.TOLER1) THEN 
IARG = IARG+1 
PCNNEW = PCNNEW + ADDER 
ILOOP = 1 
I FLAG = 1 
GOTO 18 
ENDIF 
U p d a t e v a l u e s i n t h e m e m b r a n e a n d i n t h e ECF 
DO 55 K = l , 1 0 
ECFT(K+l)=ECFTP1(K) 
CONTINUE 
DO 60 K=ITHOM,NUMR-1 
ECFT(K)=ECFTP1(K) 
CONTINUE 
CALL DATOUT (ECFT, DELR, RUNIT, DELT, RIN, CINFIN, DCNEW, NUMR, I ) 
CONTINUE 
p r i n t * , ' o v e r t o l e r a n c e l e v e l ' 
1 0 - 8 - 9 4 USED AS A TEST FOR EUTHANIZED ANIMALS NEED TO 
179 
648 C SAVE THE CONDITIONS AND USE AS b e CONDITIONS IN THE 
649 C n e x t p r o g r a m 
650 
651 DO 88 JJ=1,NUMR 
652 W R I T E ( 8 5 , 8 8 8 ) E C F T ( J J ) 
653 888 FORMAT(IX,F10.6) 
654 88 CONTINUE 
655 
656 CLOSE(UNIT=85,STATUS='KEEP' ) 
657 C 
658 RETURN 
659 END 
660 
661 SUBROUTINE RAMP (ECFT, ACOEFF, BCOEFF, CCOEFF, DELR, CMAX, PERCEN, 
662 4 RUNIT,SUMKS,ROUT,RIN,DMEM,DECF,QDIAL,XLEN,DDIAL,TAU,XKPLEC, 
663 4 GICF,GECF,CPERF,XLAM,NUMR) 
664 C 
665 c The p u r p o s e o f s u b r o u t i n e RAMP i s t o b r i n g t h e i n i t i a l v a l u e s 
666 c i n t h e m a t r i x u p . B e c a u s e t h e f i n i t e d i f f e r e n c e p r o g r a m i s a 
667 c s t e p c h a n g e a s e v e r e s t e p c h a n g e i n t h e t i m e doma in c a n c a u s e 
668 c i n s t a b i l i t y i n t h e r o u t i n e . 
669 c RAMP t a k e s t h e c h a n g e i n t h e t i m e d o m a i n a n d d i v i d e s i t by 
670 c 1 0 a n d t h e n s o l v e s t h e i m p l i c i t f i n i t e d i f f e r e n c e f o r a l l s p a c e 
671 c p o i n t s a t t h e s e e a r l y t i m e p o i n t s . The c o e f f i c i e n t s u s e d a r e 
672 c d e f i n e d f o r t h e s m a l l e r d e l t a t a b o v e i n t h e i n i t i a l i z i n g 
673 c s u b r o u t i n e 
674 c 
675 
676 
677 REAL ECFT ( 7 0 0 ) , ECFTP1 ( 7 0 0 ) , ACOEFF (700 ) ,BCOEFF(700) ,CCOEFF(700) , 
678 & VALUE(700) ,DELR(700) , CMAX, R I N , RUNIT, XKPLEC, SUMKS, TAU, 
679 & PERCEN,CPERF 
680 INTEGER NUMR,IPROG 
681 
682 OLDFLX = 0 . 0 
683 
684 DO 40 1 = 2 , 1 1 
685 
686 c S i n c e t h e BC a t t h e w a l l w i l l b e z e r o , t h e n t h ' I f moves 
687 c t h e i n d e x i n g b a c k o n e . 
688 
689 CPLAS= c m a x * e x p ( - x l a m * ( r e a l ( i - 1 ) * t a u ) ) 
690 DENDUM = SUMKS-XLAM 
691 ADUM=((CPLAS *XKPLEC+GICF+GECF)/DENDUM) 
692 BDUM = (XKPLEC*CMAX)/DENDUM 
693 CINFIN=ADUM- (BDUM*EXP ( -SUMKS*TAU*REAL(i -1) ) ) 
694 TIME = REAL ( 1 - 1 ) *TAU 
695 WRITE(62 , 568)TIME,CPLAS 
696 568 F O R M A T ( I X , F 1 0 . 6 , 3 X , F 1 0 . 6 ) 
697 
698 397 f o r m a t ( l x , ' c m a x = ' , f l O . 6 , 3 x , ' C a t f a r - f i e l d - 1 , f 1 0 . 6 ) 
699 
700 I F (CPERF.GT.CINFIN) THEN 
701 IPROG = 2 
702 ELSE 
703 IPROG = 1 
704 ENDIF 
705 
706 c 1 0 - 2 1 - 9 4 (Added s o m e t i m e i n 4 - 9 4 ) 
707 c The f o l l o w i n g I F THEN s t a t e m e n t was e m p i r i c a l l y a d d e d 
708 c f o r s i t u a t i o n i n w h i c h a L S n n r o t h o r n o n e t f l u x s i t u a t i o n 
709 c i s u s e d i n m i c r o d i a l y s i s . F o r some r e f t t f t t When t h e p e r f u s i o n 
710 c f l u i d c o n c e n t r a t i o n s t a r t e d t o g e t w i t h i n 30 p e r c e n t o f t h e 
711 c f a r - f i e l d c o n c e n t r a t i o n t h e n t h e f l u x g e t s s e n s i t i v e , . t h u s 
712 c r e a s o n f o r g o i n g u p i n p e r c e n t a g e u n i t s a t a s l o w e r r a t e . 
713 c 
714 c 
715 c 
716 c 
717 
718 
719 
720 
721 
722 
723 
724 
725 
726 
727 
728 
729 
730 
731 
732 c 
733 c 
734 
735 
736 369 
737 
738 19 
739 
740 
741 
742 
743 
744 
745 C 
746 c 
747 C 
748 
749 
750 
751 
752 
753 
754 
755 
756 
757 C 
758 c 
759 
760 
7 6 1 
762 
763 
764 45 
765 
766 C 
767 c 
768 
769 C 
770 
7 7 1 C 
772 c 
773 
774 
775 
7 7 6 
777 
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O t h e r w i s e t h e p r o g r a m w o u l d b y p a s s t h e s t a b l e v a l u e a n d 
w o u l d d i v e r g e f r o m t h e a n s w e r r a t h e r t h a n c o n v e r g e . I d o 
n o t know t h a t m a t h e m a t i c a l r e a s o n f o r t h i s . . . . b u t 3 0 p e r c e n t 
s e e m s t o w o r k t h e b e s t . 
I F ( C I N F I N . G T . 1 . O E - 6 ) THEN 
PERDUM = (ABS(CPERF-CINFIN)) /CINFIN 
I F (PERDUM.LE.0.3) THEN 
ADDER = 1E-4 
ELSE 
ADDER = 0 . 0 0 0 5 
ENDIF 
ELSE 
ADDER - 0 . 0 0 0 5 
ENDIF 
PCNNEW = PERCEN 
C a l c u l a t e t h e a p p r o x . v a l u e f o r DELCON ( 0 . 0 5 * o i n f i n ) 
IARG = 1 
ARGOLD = 1 . 0 E 6 
f o r m a t ( l x , ' D C N E W = ' , f l 0 . 6 ) 
I F ( IPROG.EQ. l ) THEN 
DCNEW = (PCNNEW* CINFIN)+CPERF 
ELSE 
AMTLST = CPERF*PCNNEW 
DCNEW = CPERF-AMTLST 
ENDIF 
S e t u p g u e s s t o d e t e r m i n e t h e f l u x a t t h e i n n e r m e m b r a n e 
s u r f a c e . 
Use c o n t i n u i t y e q u a t i o n t o o b t a i n g u e s s 
DELCON = DCNEW-CPERF FLUXRI = (DELCON*QDIAL)/(2 .0*3.14*RIN*XLEN) 
CMEMRI = ( (FLUXRI *RIN) / ( ( 3 5 . 0 / 1 3 . 0 ) * DDIAL))+DCNEW 
ECFT(1) = CMEMRI 
N o t e VALUE o n l y g o e s t o NUMR-1 b e c a u s e t h e BC i s 
i n c l u d e d . 
VALUE (1) =-ECFT (2) -ACOEFF (2) * CMEMRI 
VALUE(10)= (FLUXRI*(RIN/ROUT)*RUNIT)/DMEM 
DO 4 5 K = 2 , 9 
VALUE(K)=-ECFT(K) 
CONTINUE 
C a l l THOMAS c a l l s t h e s u b r o u t i n e THOMAS t o s o l v e t h e 
m a t r i x of c o n c e n t r a t i o n s a t e a c h p o i n t . 
CALL THOMEM (ECFTP1, ACOEFF, BCOEFF, CCOEFF, VALUE) 
N o t e VALUE o n l y g o e s t o NUMR-1 b e c a u s e t h e BC i s 
i n c l u d e d . 
VALUE (NUMR-1)=-ECFT (NUMR-1) - (XKPLEC*CPLAS*TAU) 
& - ( (GICF+GECF) *TAU) -CCOEFF(NUMR-1) *CINFIN 
VALUE ( 1 2 ) = -ECFT (12) - (XKPLEC*CPLAS*TAU) 
& - ( ( G I C F + G E C F ) * T A U ) - E C F T P 1 (10)*ACOEFF( 12) 
778 
779 
780 5 0 
7 8 1 
7 8 2 
7 8 3 
784 C 
7 8 5 c 
7 8 6 
7 8 7 
788 C 
7 8 9 
790 
791 C 
792 c 
793 c 
794 c 
795 c 
796 c 
797 
798 
799 
800 
801 
802 
803 
804 
805 
806 
807 
808 
809 
810 
811 
812 
813 
814 
815 
816 
817 
818 
819 
820 
821 
822 
823 
824 
825 
826 
827 
828 29 
829 
830 55 
831 
832 
833 60 
834 
835 
836 40 
837 39 
838 
839 
840 
841 
842 
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DO 50 J=13,NUMR-2 
VALUE ( J ) =-ECFT ( J ) - (XKPLEC*CPLAS*TAU) - ( (GICF+GECF) *TAU) 
CONTINUE 
ITHOM = 12 
NUMEQ = NUMR-ITHOM 
C a l l THOMAS c a l l s t h e s u b r o u t i n e THOMAS t o s o l v e t h e 
m a t r i x o f c o n c e n t r a t i o n s a t e a c h p o i n t . 
CALL THOECF(ECFTPl, ACOEFF, BCOEFF, CCOEFF, VALUE,NUMEQ, ITHOM, NUMR) 
Now c h e c k t h e d i f f e r e n c e i n t h e FLUXrout a n d FLUX e c f a n d 
s e t a t o l e r a n c e o f 0 . 1 f o r t h e a b s o l u t e v a l u e 
o f t h e d i f f e r e n c e . R e c a l l t h a t ECFTP1(12) i s t h e 
v a l u e i n t h e ECF a t p o i n t 12 a n d e c f t p l ( 1 0 ) i s 
t h e v a l u e o f t h e c o n c e n t r a t i o n a t t h e membrane o u t e r 
r a d i u s . DELR(11) i s t h e r a d i a l i n c r e m e n t i n t h e ECF 
FLUXEC = ( ( E C F T P 1 ( 1 2 ) - E C F T P 1 ( 1 0 ) ) / D E L R ( 1 1 ) ) * D E C F 
FLUXRO = FLUXRI*(RIN/ROUT) 
DIFFLX = (FLUXEC-FLUXRO) 
CHGFLX = OLDFLX-DIFFLX 
I F ( I PROG. EQ. 2 . AND. CHGFLX. LT. 0 . 0 . AND. DIFFLX .GWA.iWr7A) THEN 
IPROG = 1 
PCNNEW = PERCEN 
GOTO 19 
ENDIF 
OLDFLX = DIFFLX 
ARGUM = ABS(DIFFLX/FLUXRO) 
TOLER = 0 . 1 
I F ( I A R G . E Q . 2 0 0 0 ) THEN 
p r i n t * , ' o v e r t o l e r a n c e l e v e l IN RAMP' 
GOTO 39 
ENDIF 
I F (ARGUM.GT.TOLER) THEN 
IARG = IARG+1 
PCNNEW = PCNNEW+ADDER 
GOTO 19 
ELSE 
GOTO 2 9 
ENDIF 
DO 55 K = l , 1 0 
ECFT(K+l )=ECFTP1(K) 
CONTINUE 
DO 60 K=ITHOM,NUMR-1 
ECFT(K)=ECFTP1(K) 
CONTINUE 
CALL DATOUT (ECFT, DELR, RUNIT, TAU, RIN, CINFIN, DCNEW,NUMR, I ) 
CONTINUE 
RETURN 
END 
SUBROUTINE THOMEM (ECFTP1, THOMA, THOMB, THOMC, VALUE) 
REAL ECFTP1 (700) ,THOMA(700) , THOMB ( 7 0 0 ) , 
843 
844 
845 C 
846 C 
847 C 
848 C 
849 C 
850 C 
851 C 
852 c 
853 c 
854 
855 c 
856 
857 
858 c 
859 c 
860 c 
861 
862 c 
863 c 
864 c 
865 c 
866 c 
867 c 
868 c 
869 c 
870 
871 
872 
873 
874 
875 
876 c 
877 c 
878 
879 
880 
881 
882 35 
883 
884 
885 
886 
887 
888 
889 
890 45 
891 
892 
893 
894 
895 
896 
897 
898 
899 
900 
901 
902 
903 C 
904 C 
905 c 
906 c 
907 c 
& THOMC(700) ,VALUE(700) ,THBETA(700) , THGAMM(700) 
INTEGER IT,NEQU 
n e q u = n u m b e r o f e q u a t i o n s = n u m r - 1 
SOLVE A SET OF ALGEBRAIC EQUATIONS USING THE THOMAS 
TECHNIQUE FOR TRIDIAGONAL EQUATIONS 
THE THOMAS TECHNIQUE INVOLVES THREE DIFFERENT 
SECTIONS: 
1) DECOMPOSITION 
2) FORWARD SUBSTITUTION 
3) BACK SUBSTITUTION 
CHANGED USED CARNAHAN EXAMPLE PG. 442 
DO THE DECOMPOSITION 
NEQU=10 
1 - 2 0 - 9 4 Need t o c h e c k a n d m a k e s u r e t h a t t h e i n d e x i n g i n 
Thomas i s c o r r e c t . N e e d t o move e v e r y t h i n g u p by 
o n e s o t h a t t h e c o e f f i c i e n t s m a t c h t h e v a l u e s g i v e n 
PARAMETERS INTERNAL TO THOMEM 
A************************************************************ 
THBETA = AN ARRAY TO HOLD THE "B" COEFFICIENTS BECAUSE 
THE B COEFFICIENTS PASS THROUGH THIS ROUTINE MORE 
THAN O N C E . . . THEREFORE THEY NEED TO BE PRESERVED. 
THGAMMA = AN ARRAY NECESSARY FOR THE SOLVING OF THE 
MATRIX 
THBETA(l)=THOMB (2) 
THGAMM(1)=VALUE(1)/THBETA(1) 
DO 35 IT=2,NEQU 
THBETA ( I T ) =THOMB ( I T ) - ( (THOMA ( I T ) * THOMC ( I T - 1 ) ) /THBETA ( I T - 1 ) ) 
THGAMM ( I T ) = (VALUE ( I T ) - (THOMA ( I T ) * THGAMM ( I T - 1 ) ) ) /THBETA ( I T ) 
THBETA ( IT) =THOMB ( I T + 1 ) - ( (THOMA ( I T + 1 ) * THOMC (IT) ) /THBETA ( I T - 1 ) ) 
THGAMM ( IT) = (VALUE ( I T ) - (THOMA ( I T + 1 ) * THGAMM ( I T - 1 ) ) ) /THBETA ( I T ) 
CONTINUE 
ECFTPI(NEQU)=THGAMM(NEQU) 
DO 45 K T = N E Q U - 1 , 1 , - 1 
ECFTP1 (KT)=THGAMM (KT) - ( (THOMC (KT+1) *ECFTP1 (KT+1)) 
& /THBETA(KT)) 
CONTINUE 
RETURN 
END 
SUBROUTINE THOECF (ECFTP1, THOMA, THOMB, THOMC, VALUE, NUMEQ, ITHOM, 
& NUMR) 
REAL ECFTP1 (700 ) , THOMA ( 7 0 0 ) , THOMB ( 7 0 0 ) , 
& THOMC (7 0 0 ) , VALUE ( 7 0 0 ) , THBETA ( 7 0 0 ) , THGAMM (700) 
INTEGER NUMEQ,ITHOM, IT,NEQU 
n e q u = n u m b e r o f e q u a t i o n s = n u m r - 1 
SOLVE A SET OF ALGEBRAIC EQUATIONS USING THE THOMAS 
TECHNIQUE FOR TRI DIAGONAL EQUATIONS 
THE THOMAS TECHNIQUE INVOLVES THREE DIFFERENT 
SECTIONS: 
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908 C 1) DECOMPOSITION 
909 C 2) FORWARD SUBSTITUTION 
910 C 3) BACK SUBSTITUTION 
911 C CHANGED USED CARNAHAN EXAMPLE PG. 4 42 
912 
913 C p r i n t * , ' s u b r o u t i n e t h o m a s ' 
914 
915 C DO THE DECOMPOSITION 
916 NEQU=NUMEQ 
917 
918 C 1 - 2 0 - 9 4 Need t o c h e c k a n d make s u r e t h a t t h e i n d e x i n g i n 
919 c Thomas i s c o r r e c t . Need t o maove e v e r y t h i n g up by 
920 c one s o t h a t t h e c o e f f i c i e n t s m a t c h t h e v a l u e s g iven 
921 c 3 - 6 - 9 4 . . c h a n g e d i n d e x i n g 
922 
923 THBETA(ITHOM)«THOMB(ITHOM) 
924 THGAMM (ITHOM) VALUE (ITHOM) /THBETA (ITHOM) 
925 
926 DO 35 IT=ITHOM+l,NUMR-1 
927 c 1 - 2 0 - 9 4 . . . N o t e t h i s i s w h e r e t h e c h a n g e i s i n i n d e x i n g . 
928 c 3 - 6 - 9 4 . . . c h a n g e d i t b a c k , . o l d i n d e x i n g s a v e d i n comments 
929 
930 THBETA(IT)=THOMB(IT)-( (THOMA(IT) *THOMC ( I T - 1 ) ) /THBETA(IT-1)) 
931 THGAMM (IT) = (VALUE (IT)-(THOMA ( IT) *THGAMM( I T - 1 ) ))/THBETA (IT) 
932 
933 C THBETA (IT) =TH0MB ( IT+1) - ( (THOMA ( IT+1) *TH0MC ( I T ) ) /THBETA ( IT-1) ) 
934 C THGAMM (IT) = (VALUE ( IT ) - (THOMA(IT+1) *THGAMM ( I T - 1 ) ) ) /THBETA(IT) 
935 
936 35 CONTINUE 
939 ECFTP1 (NUMR-1) =THGAMM(NEQU) 
940 DO 45 KT=NUMR-1,ITHOM,-1 
941 c c h a n g e d i n d e x i n g i s a f f e c t e d h e r e t o o a d d 1 t o c o e f f c . 
942 c 3 - 6 - 9 4 . . u n d i d c h a n g e 
943 ECFTP1 (KT) =THGAMM (KT) - ( (THOMC (KT) *ECFTP1 (KT+1) ) 
94 4 & /THBETA(KT)) 
945 45 CONTINUE 
946 
947 c p r i n t * , ' j u m p i n g o u t o f t h o m a s ' 
948 RETURN 
949 END 
950 
951 
952 SUBROUTINE DATOUT (ECFT, DELR, RUNIT, DELT, RIN, CINFIN, DCNEW, NUMR, I) 
953 REAL E C F T ( 7 0 0 ) , DELR(700) ,DELT,SIMTIM,RADIAL,RIN 
954 INTEGER NUMR,I 
955 
956 c 4 - 5 - 9 4 C o u n t i n g i n d a t a o u t was i n c o r r e c t . . . d i d not 
957 c t a k e i n t o a c c o u n t t h e r a d i a l i n c r e m e n t 
958 
959 
960 c RECOV = (DCNEW/ECFT(11))*100 
961 c WRITE(60,279)RECOV 
962 c 2 7 9 FORMAT (IX,'RECOVERY(%) = \ F 1 0 . 6 ) 
963 C EXFRAC = DELCON/CINFIN 
964 C WRITE(60,277)EXFRAC 
965 C277 FORMAT(IX,'EXTRACTION FRACTION = ' , E 1 5 . 5 ) 
966 SIMTIM=(1-1)*DELT 
967 WRITE(6, 578)SIMTIM 
968 578 FORMAT(IX,'TIME UNIT = ' , F 1 0 . 6 ) 
969 
970 WRITE(65, 289)SIMTIM,DCNEW 
971 WRITE(60, 289)SIMTIM,DCNEW 
972 289 FORMAT ( I X , F12 . 5 , 2 x , f l 2 . 5) 
184 
973 c T h i s s u b r o u t i n e w i l l o u t p u t t h e f i l e so t h a t i t can be 
974 c i m p o r t e d i n t o E x c e l . From E x c e l t h e u s e r c a n d e t e r m i n e 
975 c w h i c h t i m e p o i n t s o f t h e s i m u l a t i o n w i l l b e saved 
976 c o r d i s c a r d e d . 
977 
978 
979 w r i t e ( 6 0 , 2 9 8 ) R I N , e c f t (1) 
980 298 FORMAT (IX, f 1 2 . 5 , 2 x , f 12 . 5 , ) 
981 c o u t p u t m e m b r a n e 
982 DO 70 J = 2 , 1 1 
983 c C a l c u l a t e t h e r a d i a l d i s t a n c e f o r e a c h c o n c e n t r a t i o n 
984 RADIAL=RIN+((J - l )*RUNIT) 
985 c x n o r m = e c f t ( j ) / c i n f i n 
986 c WRITE(60, 2 9 9 ) R A D I A L , E C F T ( J ) , x n o r m 
987 C299 FORMAT ( IX, f 12 . 5 , 2 x , f 12 . 5 , 2 x , f 1 2 . 5 ) 
988 WRITE (60, 2 9 9) RADIAL, ECFT ( J ) 
989 299 FORMAT(IX, f 1 2 . 5 , 2 x , f l 2 . 5 ) 
990 
991 70 CONTINUE 
992 
993 c o u t p u t r e s t i n s t e p s o f t e n 
994 c B e c a u s e o f v a r i a b l e o u t p u t n e e d a l o g i c a l s t a t e m e n t 
995 c i c o u n t = 0 
996 
997 DO 75 J = 1 2 , 2 5 
998 RADIAL=RADIAL+DELR ( J - l ) 
999 WRITE (60 , 2 9 9 ) RADIAL, ECFT ( J ) 
1000 75 CONTINUE 
1 0 0 1 
1002 
1003 DO 80 J=26,NUMR-1 
1004 i c o u n t = i c o u n t + 1 
1005 RADIAL=RADIAL+DELR(J-l) 
1006 C x n o r m = e c f t ( j ) / c i n f i n 
1007 i f ( i c o u n t . e q . 1 0 ) t h e n 
1008 C WRITE ( 6 0 , 899) RADIAL, ECFT (J) ,xnorm 
1009 C899 FORMAT ( IX, f 12 . 5 , 2 x , f l 2 . 5 , 2 x , f 12.5) 
1010 WRITE ( 6 0 , 8 99) RADIAL, ECFT (J) 
1 0 1 1 899 FORMAT ( I X , f 1 2 . 5 , 2 x , f 1 2 . 5 ) 
1012 i c o u n t = 0 
1013 e n d i f 
1014 80 CONTINUE 
1015 RADIAL=RADIAL+DELR (NUMR-1) 
1016 w r i t e ( 6 0 , 3 0 1 ) r a d i a l , c i n f i n 
1017 301 FORMAT(IX, f 1 2 . 5 , 2 x , f 1 2 . 5 ) 
1018 
1019 
1020 RETURN 
1 0 2 1 END 
1022 
